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ENGINEERING	AND	CHARACTERIZING	RNA	GENETIC	REGULATORS	Sarai	Itagaki	Meyer,	Ph.D.	Cornell	University	2017		 The	 ability	 to	 predictably	 and	 accurately	 control	 gene	 expression	 is	 a	fundamental	requirement	for	synthetic	biologists	as	they	seek	to	harness	the	power	of	 cellular	machinery	 for	 real-world	applications.	 	To	do	so	 requires	well-behaved	genetic	 regulators	 that	 can	 be	 assembled	 to	 create	 the	 desired	 pattern	 of	 gene	expression—be	 it	 the	 conditional	 translation	 of	 a	 reporter	 gene	 for	 molecular	sensing	 or	 the	 phased	 production	 of	 pathway	 enzymes	 for	 the	 synthesis	 of	 a	biopharmaceutical.	 	 I	 sought	 to	 engineer	 and	 characterize	 genetic	 regulators	 to	address	 this	 need,	 focusing	 on	 regulators	 constructed	 of	 RNA	 because	 of	 its	functional	versatility,	predictable	folding,	and	ease	of	characterization.		The	research	presented	here	 covers	 the	 construction	of	RNA	 regulators	designed	 to	 respond	 to	external	 signals	 in	 the	 form	 of	 small	 molecules	 or	 light	 exposure,	 as	 well	 as	 the	characterization	of	a	naturally	occurring	RNA	responsive	to	changes	in	temperature.		In	addition,	I	also	report	on	the	successful	engineering	and	optimization	of	a	series	of	synthetic	small	RNA	transcriptional	activators.	 	Together,	 these	projects	expand	the	 toolkit	of	genetic	regulators	available	 to	synthetic	biologists	and	 inform	future	RNA	 engineering	 by	 improving	 our	 understanding	 of	 the	 RNA	 structure-function	relationship.	
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CHAPTER	1	
INTRODUCTION	
	
1.1 The	promise	of	engineering	gene	expression		Synthetic	 biology	 holds	 great	 promise	 for	 generating	 sophisticated	 solutions	 to	address	complex	problems	in	human	health,	sustainability	and	biochemical	production,	but	at	 its	most	 fundamental	 level	 it	 depends	 largely	 on	 the	 successful	manipulation	 of	 gene	expression.	 	 For	 instance,	 microbes	 used	 to	 produce	 fuels	 and	 pharmaceuticals	 on	 an	industrial	scale	require	genetic	engineering	 to	express	 the	appropriate	pathway	enzymes	to	 generate	 the	 desired	 chemical	 product.	 Similarly,	 certain	 medical	 diagnostics	 depend	upon	the	conditional	gene	expression	of	a	reporter	gene	with	a	colored	product	in	response	to	 the	 presence	 of	 a	 pathogen	 RNA.	 To	 reliably	 control	 gene	 expression	 in	 this	 fashion,	synthetic	 biologist	 rely	 on	 a	 variety	 of	 biological	 building	 blocks—some	 harvested	 from	nature,	others	designed	de	novo—in	order	to	assemble	genetic	networks	that	behave	in	a	predictable	 fashion.	 	 However,	 the	 creation	 of	 increasingly	 complex	 circuitry	 requires	 a	large	toolbox	of	well-behaved	biological	parts	with	which	to	build	these	biological	devices.		My	 work	 seeks	 to	 tackle	 this	 growing	 need	 by	 generating	 RNA	 regulators	 for	 use	 in	synthetic	biology	applications.		While	others	within	the	synthetic	biology	community	have	focused	on	engineering	protein	regulators,	we	chose	to	work	with	RNA	for	its	versatility	of	function,	 ease	 of	 design,	 and	 amenability	 to	 structural	 characterization	 (Chappell	 et	 al.,	2013).			
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1.2 Why	RNA?		Once	viewed	as	simply	an	intermediary	between	DNA	and	protein,	RNA	has	come	to	be	 recognized	 for	 its	 diverse	 roles	 in	 myriad	 cellular	 processes,	 particularly	 within	 the	context	of	regulating	gene	expression	(Chappell	et	al.,	2013).		Not	only	is	RNA	an	incredibly	versatile	molecule,	its	simple	four-letter	alphabet	and	defined	base-pairing	rules	make	it	a	manageable	 target	 for	 rational	 design—allowing	 scientists	 to	 design	 RNAs	 that	 adopt	desired	 conformations	 (Zadeh	 et	 al.,	 2011).	 	 Moreover,	 the	 pairing	 of	 RNA-structural	characterization	 with	 next-generation	 sequencing	 (Loughrey	 et	 al.,	 2014;	 Lucks	 et	 al.,	2011a)	has	enabled	increasingly	facile	and	accurate	determination	of	RNA	structure	when	combined	with	computational	structure	prediction.	For	these	reasons	we	turned	to	RNA	in	our	efforts	to	engineer	gene	expression	for	synthetic	biology.	The	research	reported	here	reflects	 my	 efforts	 to	 engineer	 various	 RNA	 regulators	 and	 to	 characterize	 a	 naturally	occurring	 temperature-sensitive	RNA	regulator	 in	order	 to	better	design	 future	synthetic	regulators.	 	 In	 order	 to	 give	 proper	 background	 for	 these	 results,	 I	 will	 first	 overview	naturally	occurring	modes	of	genetic	regulation,	experimental	methods	of	RNA	structural	determination,	and	recent	advances	in	RNA	synthetic	biology	before	delving	into	the	details	of	my	research.		
1.3 RNA	genetic	regulation	in	bacteria	Naturally	occurring	RNAs	exhibit	 a	vast	array	of	 functions	 that	have	only	 recently	begun	to	be	uncovered.		Bacterial	regulatory	RNAs	have	been	found	to	govern	nearly	every	aspect	 of	 gene	 expression,	 from	 transcription	 to	 mRNA	 degradation	 to	 translation	
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(Chappell	et	al.,	2013)	(Figure	1.1),	through	mechanisms	that	will	be	briefly	reviewed	here,	giving	special	attention	to	the	regulators	whose	functions	are	relevant	for	later	chapters.		
	
Figure	 1.1	 RNA	 regulation	 of	 gene	 expression.	 	 A	 schematic	 showing	 how	 naturally-occurring	 bacterial	 RNAs	 govern	 gene	 expression	 by	 regulating	 transcription,	 mRNA	degradation,	and	translation.	Figure	adapted	from	works	by	Chappell	et	al.	(2013,	2015).	
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1.3.1 Transcriptional	control	of	gene	expression	Since	 RNA	 folding	 occurs	 co-transcriptionally,	 RNA	 transcriptional	 regulation	 can	act	 in	 cis,	 with	 the	 nascent	 RNA	 regulating	 its	 own	 elongation,	 or	 in	 trans,	 via	 the	interaction	of	a	separate	sRNA	with	RNA	being	transcribed.		RNA	transcriptional	regulation	depends	 on	 the	 potential	 formation	 of	 intrinsic	 terminator	 hairpins	 within	 the	 5’	untranslated	region	(5’	UTR)	of	the	regulated	gene.		These	hairpin	sequences	are	followed	by	poly-uridine	stretches	that	encourage	polymerase	pausing,	allowing	the	hairpin	to	fold,	thus	causing	the	polymerase	to	abort	transcription	(Farnham	and	Platt,	1981;	Larson	et	al.,	2008).	 	 In	 some	 transcriptional	 riboswitches,	 like	 the	 Bacillus	 subtilis	 thiamine	pyrophosphate	(TPP)	of	 flavin	mononucleotide	(FMN)	riboswitches,	 the	 formation	of	 this	intrinsic	terminator	depends	on	the	binding	of	a	small	 ligand	to	an	RNA	aptamer	domain	(Mironov	 et	 al.,	 2002),	 while	 other	 riboswitches,	 like	 the	 glycine	 riboswitch,	 depend	 on	ligand	binding	to	disrupt	terminator	hairpin	formation	(Winkler	et	al.,	2002).		Another	regulatory	mechanism	of	particular	interest	is	transcriptional	attenuation,	a	 form	 of	 regulation	 that	 depends	 on	 the	 repressive	 action	 of	 a	 small	 RNA	 (sRNA)	 that	targets	an	attenuator	sequence	in	the	5’	UTR	of	the	regulated	mRNA.		In	the	presence	of	the	sRNA,	 the	 attenuator	 forms	 an	 intrinsic	 terminator	 hairpin,	 prematurely	 aborting	transcription,	but	in	the	absence	of	the	sRNA,	the	attenuator	folds	into	an	interfered	form,	allowing	 transcription	of	 the	downstream	gene	 (Brantl,	2007).	 	Figure	1.2	 illustrates	 this	attenuation	mechanism	for	 the	pT181	plasmid	copy	control	element	 from	Staphylococcus	
aureus	(Brantl	and	Wagner,	2002).		
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Figure	 1.2	 Mechanism	 of	 transcriptional	 repression	 of	 the	 pT181	 attenuator.	 	 In	 the	absence	 of	 the	 antisense	 sRNA,	 the	 anti-terminator	 region	 pairs	 with	 the	 5’	 half	 of	 the	terminator	 stem,	 allowing	 transcription	 (ON),	but	 in	 the	presence	of	 antisense	 sRNA,	 the	target	forms	the	attenuator	structure,	causing	intrinsic	termination	of	transcription	(OFF).		
1.3.2 mRNA	degradation	control	of	gene	expression	RNAs	can	also	govern	gene	expression	by	regulating	mRNA	stability	in	a	number	of	ways,	either	by	directly	causing	RNA	cleavage	(in	 the	case	of	ribozymes)	or	by	triggering	structural	changes	that	allow	or	inhibit	cleavage	by	RNase	E,	which	initiates	the	main	mode	of	mRNA	degradation	in	bacteria	(Carpousis,	2007).		For	ribozymes,	direct	RNA	cleavage	in	response	to	a	target	ligand,	as	occurs	in	the	glmS	ribozyme	upon	glucosamine-6-phosphate	binding,	is	followed	by	rapid	breakdown	of	the	cleaved	fragments	(Collins	et	al.,	2007).		In	certain	 riboswitches	 like	 the	 E.	 coli	 lysC	 riboswitch,	 ligand-dependent	 structural	rearrangements	expose	an	RNase	E	cut	site,	allowing	for	mRNA	degradation	(Caron	et	al.,	
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2012).	 	 Other	 degradation	 control	 mechanisms	 rely	 on	 a	 trans-acting	 sRNAs	 to	 seed	refolding	events	that	prevent	RNase	cleavage	(Opdyke	et	al.,	2004),	thereby	stabilizing	the	mRNA,	or	encourage	RNase	E	degradation,	resulting	in	irreversible	repression	(Pfeiffer	et	al.,	2009).			
1.3.3 Translational	control	of	gene	expression	Lastly,	RNAs	can	regulate	gene	expression	by	controlling	the	process	of	translation	by	 influencing	 ribosome	 binding	 site	 (RBS)	 accessibility	 through	 a	 wide	 variety	 of	mechanisms.	 	Many	sRNAs,	function	by	directly	binding	to	and	blocking	either	the	RBS	or	the	 start	 codon	 (Desnoyers	 et	 al.,	 2013),	 although	 others,	 like	 the	DsrA	 sRNA	 in	 E.	 coli,	activate	translation	by	causing	refolding	events	that	expose	the	RBS	(Majdalani	et	al.,	1998)	
Cis-acting	 modes	 of	 RNA	 translational	 regulation	 include	 both	 activating	 and	 repressive	riboswitches:	for	instance,	the	S-adenosylhomocysteine	(SAH)	riboswitch	refolds	to	expose	the	RBS	upon	 ligand	binding	 (Wang	et	al.,	2008),	while	 the	 thiamine	riboswitch	occludes	the	 RBS	 in	 response	 to	 binding	 of	 thiamine	 or	 thiamine	 pyrophosphate	 (Winkler	 et	 al.,	2002).		Another	mechanism	of	interest	relies	on	temperature-sensitive	RNA	structures	that	prevent	RBS	access	at	low	temperatures	while	allowing	translation	at	higher	temperatures	(Kortmann	 and	 Narberhaus,	 2012)—these	 “RNA	 thermometers”	 will	 be	 discussed	 in	Chapter	5	as	one	of	the	regulators	I	have	chosen	to	study	in	greater	detail.		
1.4 RNA	structural	probing	and	prediction	Our	ability	to	elucidate	the	mechanisms	behind	this	vast	array	of	RNA	regulators	is	greatly	 aided	 by	 the	 existence	 of	 a	 broad	 suite	 of	 chemical	 and	 enzymatic	 probes	 to	
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determine	RNA	structure,	combined	with	ever-improving	methods	for	computational	RNA	structure	 prediction.	 	 Together,	 these	 two	 technologies	 enable	 increasingly	 accurate	 and	high-thoughput	determination	of	the	structural	features	that	underlie	RNA’s	broad	range	of	capabilities.	
	
1.4.1 Experimental	determination	of	RNA	structures	There	exist	a	wide	range	of	methods	for	experimentally	determining	RNA	structure,	offering	 varying	 degrees	 of	 structural	 detail	 all	 the	 way	 down	 to	 the	 angstrom-level	structural	 accuracy	 offered	 by	 X-ray	 crystallography.	 	 However,	 the	 highest	 resolution	methods	 for	determining	RNA	structure,	namely	X-ray	crystallography	and	NMR	(nuclear	magnetic	resonance)	(Rinnenthal	et	al.,	2010),	require	a	high	degree	of	specialization	and	are	 particularly	 low	 through-put,	 severely	 limiting	 the	 number	 of	 structures	 that	 can	 be	determined	via	these	strategies.			Other	 commonly	 used	 methods	 for	 determining	 RNA	 structure	 rely	 on	 either	chemical	or	enzymatic	probes	to	cleave	or	modify	RNA	in	a	structurally-dependent	fashion	(Knapp,	 1989;	 Weeks,	 2010).	 	 	 The	 locations	 of	 modification	 or	 cleavage	 can	 then	 be	determined	 by	 either	 reverse	 transcription	 (halting	 at	 the	 site	 of	 modification)	 and	sequencing	or	visualized	via	gel	electrophoresis	(Krol	and	Carbon,	1989).		Combined	with	a	knowledge	 of	 probe	 specificity—for	 instance,	 that	 RNase	 VI	 cleaves	 double-stranded	regions,	while	RNase	A	cleaves	at	single-stranded	pyrimidines—the	read-outs	of	cleavage	location	 can	 be	 used	 to	 infer	 aspects	 of	 the	 underlying	 structure	 (Knapp,	 1989).	 	 Of	particular	utility	are	the	family	of	chemical	probes	known	as	SHAPE	(selective	2’-hydroxyl	acylation	 analyzed	 by	 primer	 extension)	 reagents,	 including	 the	 widely	 used	 1M7	 (1-
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methyl-7-nitroisatoic	 anhydride),	 which	 modify	 the	 2’-hydroxyl	 of	 single-stranded	nucleotides,	 allowing	 for	 sequence-agnostic	 probing	 of	 RNA	 structures	 at	 nucleotide	resolution	(Weeks	and	Mauger,	2011)	with	read-out	via	capillary	electrophoresis	through	SHAPE-CE	 (Figure	 1.3A).	 	 	 Not	 only	 have	 SHAPE	 probes	 been	 deployed	 in	 living	 cells	(Spitale	 et	 al.,	 2013;	Watters	 et	 al.,	 2015a),	 the	method	 has	 also	 been	 paired	with	 next-generation	 Illumina	sequencing	 in	SHAPE-Seq	(Loughrey	et	al.,	2014;	Lucks	et	al.,	2011a;	Watters	 et	 al.,	 2015b)	 to	 allow	 for	 high-throughput	 structure	 determination	 of	 multiple	RNAs	simultaneously	(Figure	1.3B),	including	monitoring	the	complete	folding	pathways	of	RNAs	during	 in	vitro	 transcription	(unpublished	data).	 	 	Whether	performed	 in	vitro	or	 in	vivo,	 the	 output	 of	 each	 SHAPE-Seq	 experiment	 is	 a	 series	 of	 reactivities	 indicating	 the	susceptibility	of	 individual	nucleotides	 to	modification	by	SHAPE	reagent	 (and	 thus	 their	likelihood	of	being	single-stranded	within	the	RNA	structural	ensemble).		This	information	can	then	be	coupled	with	computational	RNA	structural	prediction	in	order	to	arrive	at	a	proposed	RNA	structure	or	structures	(Hajdin	et	al.,	2013;	Leonard	et	al.,	2013).		
1.4.2 Computational	prediction	of	RNA	structures	RNA’s	 logical	 base-pairing	 rules	 and	 limited	 alphabet	 have	 made	 it	 an	 attractive	target	 for	computational	attempts	at	 structural	prediction.	 	A	number	of	algorithms	have	found	 reasonable	 success	 at	 predicting	 RNA	 secondary	 structures	 by	 calculating	 the	structural	 partition	 function	 using	 it	 to	 determine	 the	 minimum	 free	 energy	 (MFE)	structure,	 ViennaRNA	 (Hofacker,	 2003)	 and	 RNAStructure	 (Reuter	 and	 Mathews,	 2010)	being	 two	widely-used	 examples.	 Although	 algorithms	of	 this	 type	neglect	 non-canonical	base-pairing	and	generally	ignore	tertiary	structure,	they	can	be	made	markedly	more	acc-	
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Figure	 1.3	 RNA	 structural	 probing	 via	 SHAPE.	 (A)	 Schematic	 outlining	 the	 key	 steps	 in	SHAPE-CE	probing	of	RNA	structures.	 	The	RNA	of	 interest	 is	 folded	 in	vitro,	 subjected	to	chemical	 modification	 via	 SHAPE-reagent	 or	 a	 solvent	 control	 of	 DMSO	 (dimethyl	sulfoxide),	 and	 then	 reverse	 transcribed	 using	 fluorescently	 labeled	 primers.	 	 The	 DNA	fragments	of	different	lengths	are	separated	by	capillary	electrophoresis,	and	the	resulting	electropherogram	 peaks	 are	 analyzed	 to	 give	 the	 underlying	 nucleotide	 reactivities.	 (B)	Schematic	outlining	RNA	structure	probing	using	SHAPE-Seq.	SHAPE-Seq	follows	the	same	general	strategy	as	SHAPE-CE,	only	the	RNAs	can	be	probed	either	 in	vivo	or	 in	vitro,	and	the	 DNA	 fragments	 are	 prepared	 for	 Illumina	 sequencing	 rather	 than	 capillary	electrophoresis,	 requiring	 additional	 ligation	 and	 PCR	 steps	 to	 add	 flanking	 adapter	sequences	required	by	the	Illumina	sequencing	platform.	*Figure	adapted	from	Watters	et	al.	(2015b).							
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-urate	 in	 by	 incorporating	 structural-probing	 data	 as	 a	 folding	 constraint	 (Hajdin	 et	 al.,	2013;	 Leonard	 et	 al.,	 2013).	 	 In	 fact,	 using	 structural-probing	 data	 combined	 with	computational	 prediction	 in	 this	 manner	 has	 proved	 useful	 for	 characterizing	 and	designing	engineered	RNA	regulators	(Qi	et	al.,	2012;	Takahashi	et	al.,	2016),	making	 it	a	valuable	tool	for	RNA	synthetic	biologists	seeking	to	detailed	structural	information	about	their	designed	RNA	constructs.		Moreover,	the	need	for	such	tools	is	increasing	along	with	the	recent	growth	of	RNA	synthetic	biology—overviewed	in	the	following	section.		
1.5 RNA	synthetic	biology—an	overview	RNA	synthetic	biology	has	made	great	advances	in	recent	years,	with	research	in	the	last	 decade	 reporting	 the	 development	 of	 a	 variety	 of	 new	 RNA	 regulators	 as	 well	 as	increasingly	 complex	 applications	 for	 synthetic	 RNAs,	 ranging	 from	 logic	 circuits	 and	metabolic	 engineering	 to	 biosensors	 and	 molecular	 diagnostics	 (Chappell	 et	 al.,	 2015a).		Many	 synthetic	 RNA	 regulators	 build	 off	 of	 pre-existing	 natural	 systems	 or	 use	 them	 as	inspiration	 for	 their	 design:	 for	 instance,	 the	 naturally-occurring	 pT181	 transcription	regulator	discussed	previously	(section	1.4.1)	has	proved	a	particularly	 fruitful	 launching	point	 for	 RNA	 engineering—as	 part	 of	 a	 synthetic	 theophylline-responsive	 ncRNA	 (non-coding	RNA)	 regulator	 (Qi	 et	 al.,	 2012),	 as	 a	 scaffold	 for	 building	 a	 library	 of	 orthogonal	chimeric	 transcriptional	 attenuators	 (Takahashi	 and	 Lucks,	 2013),	 or	 as	 a	 re-engineered	regulator	to	activate	transcription	(Chappell	et	al.,	2015b),	as	will	be	discussed	in	greater	detail	 in	 Chapter	 3.	 	 Other	 naturally-occurring	 RNA	 regulators	 have	 inspired	 synthetic	variants	 as	well,	 from	 synthetic	 riboswitches	 created	by	 fusing	 aptamer	domains	 to	 pre-existing	riboswitch	expression	platforms	(Ceres	et	al.,	2013a,	2013b)	to	synthetic	sRNAs	to	
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regulate	 mRNA	 stability	 and	 degradation	 (Man	 et	 al.,	 2011)	 and	 synthetic	 RNA	thermosensors	 that	 expose	 RNase	 E	 sites	 for	 degradation	 in	 response	 to	 changes	 in	temperature	 (Hoynes-O’Connor	et	al.,	2015).	 	Other	synthetic	RNA	regulators	 include	 the	riboregulator	developed	by	Isaacs	et	al.	(2004),	which	represses	translation	in	cis	through	an	RNA	hairpin	designed	to	block	access	to	the	RBS	unless	a	trans-acting	sRNA	binds	and	prevents	hairpin	formation.	 	This	design	strategy	has	been	simplified	with	the	creation	of	toehold	 switches	 (Green	 et	 al.,	 2014)	 (Figure	 1.4),	 which	 allow	 for	 efficient	 translation	activation	and	computational	design	via	the	NUPACK	design	algorithm	(Zadeh	et	al.,	2010).		
		
Figure	1.4	Mechanism	of	the	RNA	toehold	switch.		In	the	OFF	state,	the	RBS	is	inaccessible	in	 a	 hairpin	 loop,	 but	 the	 binding	 of	 the	 designed	 trigger	 RNA	 to	 the	 toehold	 sequence	unzips	the	adjacent	hairpin,	allowing	for	ribosome	access	and	translation.		*Figure	adapted	from	Chappell	et	al.	(2015a).			 Many	of	these	synthetic	regulators	have	been	used	to	build	RNA	circuits,	 including	RNA	 logic	 gates	 (networks	 which	 perform	 basic	 digital	 computations)	 using	 toehold	switches	 (Green	 et	 al.,	 2014),	 	 an	 AND	 gate	 constructed	 using	 small	 transcriptional	activating	RNAs	(Chappell	et	al.,	2015b),	and	a	NOR	gate	constructed	from	ligand-sensing	
Coding RegionToehold
Switch RNA
Ribosome
OFF ONTrigger RNARBS
Start Codon
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transcriptional	 regulators	 (Qi	 et	 al.,	 2012).	 	NOR	 gates	 have	 also	 been	 constructed	 using	CRISPR	 interference	 (CRISPRi),	 in	 which	 a	 catalytically	 dead	 version	 of	 Cas9	 (dCas9)	 is	paired	 with	 a	 small	 guide	 RNA	 (sgRNA)	 that	 targets	 a	 particular	 mRNA	 to	 repress	transcription	 (Nielsen	 and	 Voigt,	 2014).	 	 Extending	 their	 application	 beyond	 basic	 logic	gates,	 catalytically	 dead	 CRISPRs	 have	 also	 been	 fused	with	 light-responsive	 proteins	 to	create	 optogenetic	 regulators	 targeted	 using	 engineered	 sgRNAs	 (Nihongaki	 et	 al.,	 2015;	Polstein	 and	 Gersbach,	 2015).	 	 In	 other	 applications	 of	 note	 for	 RNA	 synthetic	 biology,	ribosome	binding	site	engineering	based	on	the	RBS	Library	Calculator	has	been	used	for	metabolic	 engineering,	 optimizing	 flux	 through	 a	 biosynthetic	 pathway	 (Farasat	 et	 al.,	2014),	 and	 toehold	 switches	 have	 been	 applied	 to	 create	 paper-based	 molecular	diagnostics	 capable	 of	 detecting	mRNAs	 and	 distinguishing	 between	 sequences	 from	 the	Zaire	and	Sudan	strains	of	 the	Ebola	virus	 (Pardee	et	al.,	2014).	 	Rather	 than	using	cells,	these	 impressive	 paper-based	 biosensors	 rely	 on	 freeze-dried	 cell-free	 transcription-translation	 systems	 to	 generate	 a	 colorimetric	 output.	 	As	outlined	below,	 these	 cell-free	systems	have	broad	utility	for	synthetic	biology.		
1.6 The	TX-TL	cell	extract	system	and	its	utility		 Cell-free	transcription-translation	systems	have	long	been	used	as	a	way	to	express	proteins	outside	of	the	cellular	environment	(Hoagland	et	al.,	1958;	Wood	and	Berg,	1962).		Recent	 refinements	 in	 the	 preparation	 of	 these	 cell	 extracts	 have	 improved	 their	performance	(Kigawa	et	al.,	2004;	Sun	et	al.,	2013),	and	the	development	of	transcription-translation	 systems	 built	 from	 carefully	 assembled	 purified	 components	 (Shimizu	 et	 al.,	2001)	 has	 allowed	 for	 the	 introduction	 of	 non-canonical	 amino	 acids	 and	 the	 careful	
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dissection	of	 	 transcriptional	mechanisms	(Mishler	and	Gallivan,	2014).	 	 In	 transcription-translation	 (TX-TL)	 systems,	 any	 nucleic	 acid	 sequence	 or	 molecule	 of	 interest	 can	 be	added,	without	regard	to	cell	uptake	or	membrane	permeability,	and	these	components	can	be	added	at	any	point	during	the	reaction,	allowing	for	the	easy	monitoring	of	the	system’s	response.	 	 Moreover,	 cell-free	 TX-TL	 systems	 shorten	 the	 design-build-test	 cycle	 for	developing	genetic	circuit	elements	by	eliminating	the	need	to	transform	cells	with	the	new	genetic	 constructs	 of	 interest,	 reducing	 the	 time	 required	 for	 testing	 from	 3	 days	 to	 2-3	hours	and	making	TX-TL	an	especially	attractive	technology	for	synthetic	biologists.		In	broad	strokes,	the	production	of	TX-TL	cell	extract	requires	the	preparation	of	a	crude	 E.	 coli	 cell	 lysate	 that	 goes	 through	 a	 series	 of	 treatment	 steps—centrifugation,	digestion,	 and	 dialysis—in	 order	 to	 remove	 unwanted	 components	 from	 the	 lysate.	 	 For	experimental	 use,	 the	 cell	 lysate	 is	 combined	 with	 a	 buffer	 solution	 of	 amino	 acids,	nucleotides,	 co-factors,	 and	 batch-specific	 optimized	 levels	 of	 magnesium-glutamate,	potassium-glutamate,	 and	 dithiothreitol	 (Sun	 et	 al.,	 2013).	 	 DNA	 templates	 (plasmid	 or	linear),	RNAs,	and	small	molecules	can	be	added	directly	to	the	TX-TL	reactions,	which	are	generally	carried	out	in	384-well	plates	and	monitored	via	plate	reader.	Early	work	establishing	the	viability	of	genetic	circuit	assembly	in	cell-free	systems	demonstrated	the	use	of	both	EGFP	and	firefly	 luciferase	as	reporter	genes	and	validated	the	 function	 of	 a	 multi-level	 cascades	 and	 genetic	 circuits	 containing	 both	 positive	 and	negative	regulatory	elements	(Noireaux	et	al.,	2003).	 	Since	 then,	TX-TL	cell-free	systems	have	been	used	to	prototype	artificial	cells	(Noireaux	and	Libchaber,	2004),	to	pattern	gene	expression	to	emulate	Drosophila	developmental	gene	networks	(Isalan	et	al.,	2005),	and	to	completely	 synthesize	 the	 T7	 bacteriophage	 (Shin	 et	 al.,	 2012).	 	 However,	 from	 the	
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standpoint	 of	 synthetic	 biology,	 a	 key	 strength	 of	 the	 TX-TL	 cell-free	 system	 remains	 its	efficiency	 for	 quickly	 testing	 genetic	 constructs	 without	 the	 need	 to	 undergo	 bacterial	transformation,	 allowing	 TX-TL	 to	 function	 as	 a	 cell-free	 breadboard	 for	 prototyping	genetic	regulators	and	circuits	(Siegal-Gaskins	et	al.,	2014;	Sun	et	al.,	2014).		In	particular,	recent	work	by	Takahashi	et	al.	(2015)	used	TX-TL	to	measure	the	response	time	of	an	RNA	transcriptional	 cascade	 and	 test	 an	 RNA	 single	 input	 module	 shown	 to	 function	 in	 vivo,	demonstrating	 the	 clear	 utility	 of	 the	 cell-free	 TX-TL	 system	 for	 testing	 RNA	 genetic	regulators.		
1.7 Engineering	and	understanding	RNA	regulators	Motivated	by	the	need	for	novel	genetic	regulators	to	expand	the	synthetic	biology	toolkit	 and	 the	 clear	 benefits	 of	working	with	RNA,	 I	 set	 out	 to	 build	 and	 characterize	 a	series	of	RNA	genetic	regulators.		
1.7.1 Chapter	2:	Toward	a	light-activated	RNA	regulator	One	of	the	key	goals	of	synthetic	biology	is	to	engineer	biological	systems	capable	of	sensing	 and	 responding	 to	 their	 environment	 in	 predictable	 fashion.	 	 In	 particular,	 light	offers	interesting	opportunities	for	facile	temporal	and	spatial	control	of	external	signaling,	making	 it	 an	 attractive	 potential	 input	 for	 genetic	 circuits.	 	 Most	 previous	 optogenetic	synthetic	biology	applications	to	date	have	relied	upon	light-sensing	proteins	(Gardner	and	Deiters,	2012),	but	I	sought	to	build	off	previous	research	on	light-sensitive	RNA	aptamers	(Hayashi	et	al.,	2009;	Lee	et	al.,	2007;	Young	and	Deiters,	2008)	in	order	to	create	a	novel,	light-sensitive	 RNA	 transcriptional	 regulator.	 	My	 attempts	 relied	 on	 RNA	 aptamers	 that	
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selectively	bound	one	form	of	a	small	molecule	or	peptide	that	underwent	light-catalyzed	structural	isomerization,	with	the	goal	that	this	binding	signal	would	then	be	transduced	to	a	fused	pre-existing	regulator,	either	the	pT181	attenuator	system	(Lucks	et	al.,	2011b)	or	a	riboswitch	 expression	 platform	 (Ceres	 et	 al.,	 2013a).	 	 This	 strategy	 for	 generating	 light-sensing	 RNA	 regulators	 ultimately	 proved	 unsuccessful,	 but	 the	 attendant	 study	 of	aptamer-ligand	binding	reaffirmed	the	utility	of	SHAPE	probing	 for	 identifying	regions	of	ligand	binding	in	RNA	aptamers.		
1.7.2 Chapter	3:	Improving	fold	activation	of	small	RNAs	with	rational	engineering	
strategies	The	 recent	advent	of	 small	 transcription	activating	RNAs	 (STARs)	 (Chappell	 et	 al.,	2015b)	 (mentioned	 in	 section	 1.2)	 filled	 an	 important	 gap	 in	 RNA	 regulation,	 giving	synthetic	 biologists	 the	 ability	 to	 activate	 as	 well	 as	 repress	 gene	 expression	 on	 the	transcriptional	 level	 using	 small	 RNAs.	 	 These	 newly	 developed	 regulators	 allowed	 for	novel	RNA	circuit	architectures;	however,	their	utility	was	limited	by	the	small	number	of	highly	 functional	 STARs	 available	 for	 construction	 of	 complex	 circuits.	 	 	 Our	 research	addressed	this	limitation	by	generating	additional	highly	functional	STARs	through	a	series	of	rational	RNA	engineering	strategies	(Meyer	et	al.,	2016).		We	found	that	the	addition	of	5’	stability	hairpins	and	3’	sRNA	scaffolds	to	STARs,	combined	with	increasing	the	ratio	of	STAR	antisense	to	target	sense,	resulted	in	large	increases	in	fold-activation	for	a	number	of	low-performing	STARs.		Moreover,	the	newly	optimized	STARs	were	largely	orthogonal	to	 each	other	 and	 to	pre-existing	 regulators,	making	 them	broadly	useful	 for	 future	RNA	circuitry.	
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1.7.3 Chapter	4:	Engineering	ligand-responsive	RNA	activators	Building	off	of	the	invention	of	STARs,	I	sought	to	generate	a	new	mechanism	of	RNA	regulation:	ligand-activated	transcriptional	activation	in	trans	via	aptamer-STAR	fusions	or	“aptaSTARs.”		Using	a	combination	of	rational	design	and	random-screening	approaches,	I	was	able	to	generate	a	few	ligand-sensitive	aptaSTARs	for	the	small-molecule	theophylline.		However,	the	aptaSTARs	lacked	the	dynamic	range	of	their	original	parent	STARs,	making	them	less	useful	as	potential	circuit	elements,	and	hinting	at	remaining	gaps	in	our	ability	to	design	switchable	RNA	structures.	
	
1.7.4 Chapter	 5:	 Characterizing	 the	 structure-function	 relationship	 of	 a	 naturally	
occurring	RNA	thermometer	An	 intriguing	 example	 of	 RNA-based	 gene	 regulation,	 the	agsA	 RNA	 thermometer	from	Salmonella	enterica	allows	the	bacterium	to	sense	the	temperature	change	associated	with	 entering	 the	 human	 gut	 and	 up-regulate	 the	 AgsA	 heat-shock	 protein	 in	 response.		Using	 a	 combination	 of	 in	 vivo	 and	 in	 vitro	 methods,	 I	 characterized	 the	 structure	 and	function	of	the	agsA	regulator,	establishing	that	its	mechanism	is	based	on	an	equilibrium-based	melting	of	the	helix	containing	the	ribosome	binding	site.		Moreover,	I	demonstrated	the	ability	of	SHAPE-Seq	to	detect	reactivity	changes	within	the	agsA	thermometer	caused	by	ribosome	binding	and	the	resultant	structural	changes.				
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1.7.5 Chapter	6:	Conclusions	and	perspectives	As	demonstrated	in	the	presented	work,	RNA	regulators	provide	broad	potential	for	genetic	 regulation	 and	 synthetic	 biology.	 	 I	 have	 succeeded	 in	 engineering	 new	 and	improved	RNA	regulators	and	in	uncovering	the	mechanism	behind	those	found	in	nature.		Through	 improving	 our	 understanding	 between	 the	 relationship	 between	RNA	 structure	and	function,	this	work	will	better	our	ability	to	design	new	regulators	for	diverse	synthetic	biology	 applications.	 	 It	 is	 my	 hope	 that	 future	 research	 will	 further	 enhance	 our	understanding	of	RNA	engineering	and	enable	the	design	of	increasingly	sophisticated	RNA	circuitry	able	to	properly	address	complex	problems.		
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CHAPTER	2		
TOWARD	A	LIGHT-ACTIVATED	RNA	REGULATOR		
2.1	 Abstract	Making	 devices	 that	 sense	 and	 respond	 to	 signals	 in	 their	 environments	 is	 a	 key	 goal	 of	synthetic	 biology.	 	 In	 particular,	 light	 represents	 an	 attractive	 and	 easy	way	 to	 interface	with	biological	machinery—enabling	exquisite	spatial	and	temporal	control	and	essentially	instantaneous	sensing,	 thus	avoiding	 the	delays	 for	diffusion	and	uptake	often	associated	with	molecular	signals.		This	work	details	a	series	of	attempts	to	engineer	a	light-sensitive	RNA	switch	in	order	to	expand	the	synthetic	biology	toolbox	and	allow	for	light-based	gene	control	at	the	transcriptional	level.	While	it	did	not	succeed	in	generating	a	light-activated	switch,	 the	 reported	 research	 did	 help	 establish	 the	 utility	 of	 the	 SHAPE	 technique	 for	identifying	the	location	of	ligand-binding	in	an	RNA	aptamer.		
2.2	 Introduction	Realizing	 the	 full	 potential	 of	 synthetic	 biology	 will	 involve	 creating	 biological	 devices	capable	of	sensing	and	responding	to	environmental	cues,	and	including	light	in	the	suite	of	detectable	signals	offers	a	number	of	obvious	advantages.	 	Not	only	do	light	signals	allow	for	accurate	spatial	and	temporal	control,	they	can	also	be	sensed	virtually	instantaneously	and	are	incredibly	cost-effective	in	comparison	to	expensive	molecular	inducers.	The	 dependence	 of	 nearly	 all	 earthly	 life	 on	 harnessing	 energy	 from	 sunlight	 has	resulted	 in	a	vast	array	of	naturally	occurring	protein-based	mechanisms	for	sensing	and	responding	to	light.	 	Scientists	have	co-opted	many	of	these	proteins	for	a	wide	variety	of	applications,	 ranging	 from	neuronal	 control	 and	monitoring	 (Song	and	Knöpfel,	 2015)	 to	
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the	 creation	 of	 light-controlled	 synthetic	 gene	 circuits	 (Gardner	 and	 Deiters,	 2012).	 	 In	particular,	 the	 opsin	protein	 family	has	 found	widespread	use	 as	 a	 neuronal	 optogenetic	tool	 (Zhang	 et	 al.,	 2011),	 allowing	 researchers	 to	 directly	 photostimulate	 mammalian	neurons	(Boyden	et	al.,	2005),	drive	movement	preference	in	mice	through	in	vivo	control	of	 intracellular	 signaling	 (Airan	 et	 al.,	 2009),	 and	 detect	 individual	 action	 potentials	 in	cultured	rat	brain	cells	(Kralj	et	al.,	2012).			Within	the	field	of	synthetic	biology,	naturally	occurring	light-sensing	proteins	have	been	employed	and	engineered	for	a	broad	range	of	uses	from	basic	genetic	regulation	to	the	creation	of	complex	devices.		Various	light-activated	gene	regulation	mechanisms	have	been	developed	to	act	at	the	transcriptional	and	translational	levels.		In	one	instance,	Cao	et	al.	(2013)	engineered	a	platform	for	light-induced	mRNA	translation	by	fusing	a	eukaryotic	translation	initiation	factor	to	the	photo-sensitive	Arabodopsis	cryptochrome	protein	CRY2	and	 an	 RNA	 binding	 domain	 to	 its	 illumination-dependent	 binding	 partner,	 CIB1.		Following	 a	 different	 strategy,	 Ryu	 and	 Gomelsky	 (2014)	 used	 an	 engineered	 light-activated	 bacteriophytochrome	 diguanylate	 cyclase	 to	 regulate	 production	 of	 a	 signaling	molecule	 c-di-GMP,	 thereby	 controlling	 a	 c-di-GMP-dependent	 transcription	 factor	 and	target	gene.		Research	by	Tabor	and	co-workers	took	this	idea	of	light-controlled	gene	expression	one	 step	 further	 in	 order	 to	 generate	 networks	 capable	 of	 edge-detection	 and	 bacterial	photography.		By	generating	a	chimeric	light	receptor	(Cph8)	composed	of	a	photoreceptor	fused	to	the	EnvZ-OmpR	histidine	kinase	and	response-regulator,	they	created	a	system	in	which	 gene	 expression	 from	 the	 OmpC	 promoter	 was	 prevented	 in	 the	 presence	 of	 red	light.	 	Then,	by	placing	the	LacZ	reporter	gene	under	the	OmpC	promoter,	they	generated	
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bacterial	“film”	capable	of	recording	a	pattern	of	red	light	projected	onto	S-gal	containing	media	(Levskaya	et	al.,	2005).		When	this	same	chimeric	light	receptor	was	used	to	regulate	the	intercellular	signal	AHL	(3-oxohexanoyl-homoserine	lactone)	and	combined	with	clever	circuit	architecture	for	expression	of	LacZ	upon	AHL	detection	in	the	absence	of	light,	the	result	 was	 a	 bacterial	 edge-detection	 system,	 capable	 of	 printing	 in	 cleaved	 S-gal	 the	outline	of	a	projected	photomask	(Tabor	et	al.,	2009).		Other	light-sensitive	applications	of	note	include	the	use	of	light-induced	protein	interactions	to	trigger	membrane-localization	of	a	desired	target,	allowing	for	 light-directed	lamellipodial	extension	in	mammalian	cells	(Levskaya	 et	 al.,	 2005),	 and	 the	 use	 of	 light-induced	 transgene	 expression	 to	 regulate	insulin	levels	in	diabetic	mice	(Ye	et	al.,	2011).	Because	 of	 the	 inherent	 difficulty	 of	 generating	 novel	 light-sensitive	 proteins	(Levskaya	 et	 al.,	 2009),	 all	 of	 the	 work	 discussed	 so	 far	 relied	 on	 pre-existing	 light-responsive	proteins	and	chromophores,	generally	fused	to	another	domain	or	protein	with	the	desired	activity.		However,	a	few	groups	have	investigated	ways	to	use	photo-caging	to	introduce	 light-sensitivity	 to	 new	 proteins	 or	 interactions.	 	 Recent	 research	 has	demonstrated	the	generation	of	newly	photo-sensitive	proteins	through	the	incorporation	of	amino	acids	modified	with	photo-labile	protecting	groups.		Photo-caged	serine	was	used	to	 create	 a	 light-sensitive	 variant	 of	 the	 transcription	 factor	 Pho4	 by	 blocking	phosphorylation	of	key	 residues	whose	phosphorylation	 state	determines	Pho4’s	nuclear	export	 kinetics	 (Lemke	 et	 al.,	 2007).	 	 Similar	work	by	Gautier	 et	 al.	 (2011)	 introduced	 a	photo-caged	lysine	into	a	MAP	kinase	to	sterically	block	ATP-binding	in	a	light-dependent	fashion.		Photo-caging	has	also	been	applied	to	small-molecule	targets	like	IPTG	(Young	and	
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Deiters,	 2007)	 and	 doxycycline	 (Cambridge	 et	 al.,	 2006)	 as	 an	 alternate	 strategy	 for	introducing	light-sensitivity	to	a	pre-existing	system.	Although	RNA-based	regulators	offer	 relative	ease	of	engineering	and	selection,	 in	comparison	to	the	explosion	of	research	on	protein-based	optogenetics,	little	research	has	focused	 on	 building	 light-sensitive	RNA	devices,	 largely	 because	 of	 the	 lack	 of	 naturally-occurring	light-sensitive	RNAs	(Jäschke,	2012).		However,	a	few	key	papers	have	explored	the	possibility	of	generating	light-responsive	RNAs	by	taking	advantage	of	RNA’s	ability	to	bind	 a	wide	 variety	 of	 targets	with	 high	 specificity.	 	 Here	 I	 give	 a	 brief	 overview	 of	 the	relevant	work	to	date	before	launching	into	a	discussion	of	our	attempts	to	generate	a	light-activated	RNA	regulator	by	building	off	of	previous	research.	Just	 as	 photo-responsive	 proteins	 use	 bound	 chromophores	 to	 sense	 light,	 photo-responsive	 RNAs	 depend	 on	 small	molecules	 that	 undergo	 defined	 structural	 changes	 in	response	 to	 light.	 	 For	 instance,	 a	 dihydropyrene	 compound	 known	 as	BDHP-COOH	 (10-carboxy-2,7-di-t-butyl-trans-12c,12d-dimethyl-12c,12d-dihy-drobenzo[e]pyrene)	 that	isomerizes	into	its	“open”	form	(BCPD-COOH)	in	response	to	visible	light	(Figure	2.1A)	was	used	 to	 generate	 a	 photo-responsive	 hammerhead	 ribozyme	 (Lee	 et	 al.,	 2007a).	 	 Using	systematic	 evolution	 of	 ligands	 by	 exponential	 enrichment	 (SELEX,	 see	 section	 A.2	 for	background)	(Ellington	and	Szostak,	1990;	Tuerk	and	Gold,	1990),	they	isolated	an	aptamer	with	 high	 specificity	 for	 the	 closed	 BDHP	 form	 of	 the	 target	 dihyropyrene.	 	 Next,	 they	identified	the	minimal	aptamer	necessary	for	BDHP	binding	by	assaying	the	binding	affinity	of	 a	 series	 of	 truncated	 aptamers.	 	 This	 minimal	 BDHP	 aptamer	 was	 then	 fused	 to	 the	hammerhead	 ribozyme	 via	 a	 handful	 of	 potential	 communication	 modules,	 and	 the	resulting	 suite	 of	 ribozymes	 were	 tested	 for	 light	 and	 ligand-dependent	 cleavage.	 	 A	
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construct	dubbed	the	UGLOOP	hammerhead	ribozyme	(Figure	2.1B)	showed	clear	BDHP-dependent	 cleavage	 and	 irradiation-dependent	 activity,	 demonstrating	 the	 successful	creation	of	a	light-dependent	ribozyme	mediated	by	ligand	interaction.	
	
		
	
Figure	 2.1	 A	 light-responsive	 dihydropyrene-binding	 ribozyme.*	 (A)	 Isomerization	between	the	closed	BDHP-COOH	form	and	open	BCPD-COOH	form	of	10-carboxy-2,7-di-t-butyl-trans-12c,12d-dimethyl-12c,12d-dihy-drobenzo[e]pyrene.	 (B)	 Putative	 structure	 of	the	 UGLOOP	 hammerhead	 ribozyme	 construct	 whose	 cleavage	 activity	 showed	 clear	dependence	on	the	dihydropyrene’s	BDHP	form.	*Figures	reprinted	from	Lee	et	al.	(2007).	
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The	 small	 molecule	 spiropyran	 also	 undergoes	 a	 photocatalyzed	 isomerization,	transitioning	 between	 its	 normal	 colorless	 state	 and	 its	 purple	 merocyanine	 form	 in	response	to	visible	or	UV	light	(Figure	2.2).		Research	by	Asanuma	et	al.	(2001)	had	taken	advantage	of	 this	structural	change	to	generate	a	spiropyran-tethered	DNA	strand	with	a	light-modulated	 duplex	 melting	 temperature.	 	 More	 recent	 work	 by	 Young	 and	 Deiters	(2008)	 used	 SELEX	 to	 isolate	 an	 aptamer	 specific	 to	 the	 spiropyran	 form	 via	 carefully	alternated	positive	and	negative	selection.	 	The	aptamer	pool	was	 incubated	with	a	resin	containing	 bound	 spiropyran,	 and	 non-binding	 aptamers	were	washed	 away.	 	 The	 resin	was	then	exposed	to	UV	light	to	catalyze	the	formation	of	the	merocyanine	form,	and	the	
	
Figure	 2.2	 The	 structural	 transitions	 of	 the	 light-sensitive	 spiropyran	 molecule.*	 	 The	colorless	spiropyran	form	(1)	 transitions	between	its	purple	merocyanine	form	(2a)	and	yellow	 merocyanine	 form	 (2b)	 in	 response	 to	 exposure	 to	 UV	 light	 or	 changes	 in	 pH.	*Reprinted	from	Young	and	Deiters	(2008)	with	permission	from	John	Wiley	and	Sons.	
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	aptamers	 that	 did	 not	 bind	 were	 eluted	 and	 collected.	 	 After	 ten	 rounds	 of	 SELEX,	 an	aptamer	 variant	 with	 good	 specificity	 for	 spiropyran	 was	 identified,	 and	 its	 reversible	binding	to	immobilized	spiropyran	was	confirmed	using	surface	plasmon	resonance	(SPR).		 	
	
Figure	 2.3	 Aptamer	 binding	 to	 the	 light-responsive	 KRAzR	 peptide.*	 (A)	 The	 KRAzR	peptide	 (Lysine-Arginine-Azobenzene-Arginine)	 in	 its	 E	 and	 Z-isomeric	 forms,	 with	 the	azobenzene	 highlighted	 in	 blue	 and	 the	 guanidinium	 groups	 that	 undergo	 spatial	rearrangement	highlighted	 in	 yellow.	 (B)	 A	 schematic	 of	RNA	aptamer	 (red)	binding	 the	KRAzR	E-isomer	and	releasing	upon	UV-light	catalyzed	isomerization	to	Z-KRAzR.	*Figure	reprinted	 with	 permission	 from	 Hayashi,	 G.,	 Hagihara,	 M.,	 Dohno,	 C.,	 and	 Nakatani,	 K.	(2007).	Photoregulation	of	a	Peptide-RNA	Interaction	on	a	Gold	Surface.	J.	Am.	Chem.	Soc.	
129,	8678–8679.	Copyright	(2007)	American	Chemical	Society.	
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Following	 a	 similar	 principle,	 Hayashi	 and	 coworkers	 developed	 a	 series	 of	 RNA	aptamers	for	KRAzR,	a	short	peptide	containing	a	photosensitive	azobenzene	molecule	that	reversibly	switches	between	its	E	and	Z-isomers	(Hayashi	et	al.,	2007,	2009)	(Figure	2.3A).	After	 using	 SELEX	 to	 isolate	 aptamers	 that	 preferentially	 bound	 KRAzR	 in	 its	 E-isomer	(Figure	 2.3B),	 they	 established	 the	 reversibility	 of	 the	 interaction	 using	 SPR	 to	 detect	aptamer	 binding	 to	 light-switched	 KRAzR	 immobilized	 on	 a	 gold	 surface	 (Hayashi	 et	 al.,	2007).	 	 Later,	 they	 continued	with	additional	 cycles	of	 SELEX	 to	 identify	more	aptamers,	followed	 by	 a	 doped	 re-selection	 of	 mutants	 of	 the	 best	 variant.	 	 By	 examining	 the	distribution	of	sequences	in	the	re-selected	pool	of	mutants,	they	were	able	to	identify	the	conserved	 regions	 necessary	 for	 binding	 and	 established	 a	 probable	 structure	 for	 the	KRAzR	aptamer	 (Hayashi	 et	 al.,	 2009).	 	Their	work	underlines	 the	 flexibility	of	 SELEX	 to	identify	RNA	aptamers	for	photo-responsive	peptides	as	well	as	small	molecules.	However,	 not	 all	 photo-sensitive	 RNAs	 depend	 on	 an	 aptamer	 domain:	 	 in	 fact,	 a	photoswitchable	 hammerhead	 ribozyme	 developed	 by	 Liang	 et	 al.	 (2013)	 owes	 its	 light-sensitivity	to	azobenzene-containing	oligonucleotides	fused	to	either	end	of	the	ribozyme.		When	 the	 azobenzenes	 are	 in	 their	 trans-form,	 the	 oligonucleotides	 form	 a	 duplex	 that	inhibits	ribozyme	cleavage,	but	irradiation	with	UV	light	triggers	azobenzene	isomerization	to	 the	 cis-form,	 allowing	 the	 ribozyme	 to	 cleave	 its	 target.	 	 Moreover,	 the	 authors	demonstrated	that	visible	 light	could	be	used	to	re-set	 the	switch,	allowing	for	reversible	photoregulation	of	ribozyme	activity.			Although	 the	use	of	azobenzene	modified	nucleotides	offered	an	 intriguing	way	 to	incorporate	 photosensitivity	 into	 RNAs,	 I	 chose	 to	 pursue	 a	 strategy	 based	 on	 RNA	aptamers	that	bind	light-responsive	targets.		Avoiding	the	need	for	artificially	synthesized		
	 34	
	
	
	
	
	
	
Figure	 2.4	 Schematic	 for	 proposed	 light-sensitive	 RNA	 transcriptional	 regulator.	 (A)	Rearrangement	of	the	chimeric	antisense	RNA	composed	of	an	aptamer	for	a	light-sensitive	chromophore	fused	to	the	pT181	antisense.		The	target	chromophore	isomerizes	between	two	states	 (red	circle	and	red	 triangle)	 in	response	 to	 light.	When	 the	aptamer	binds	 the	chromophore	 in	 its	binding-competent	 isomer	 (red	circle),	 the	antisense	hairpin	 (dashed	rectangle)	 forms,	 but	 the	 antisense	 hairpin	 is	 interfered	 in	 the	 absence	 of	 chomophore	binding.	 	(B)	Mechanism	of	action	of	the	pT181	antisense	hairpin,	whose	interaction	with	the	pT181	attenuator	causes	formation	of	a	terminator	hairpin,	preventing	transcription	of	the	downstream	reporter	gene	(SFGFP)	(OFF).		In	the	absence	of	antisense	hairpin	RNA,	the	terminator	hairpin	does	not	form,	allowing	expression	of	the	reporter	gene	(ON).				
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nucleotides	 left	 open	 the	 possibility	 of	 generating	 light-activated	 circuitry	 that	 could	eventually	be	usable	in	vivo.		Our	goal	was	to	generate	a	photosensitive	RNA	transcriptional	regulator	and	characterize	 its	 function	and	 structure	using	TX-TL	assays	 (see	 section	1.6	for	 background)	 and	 SHAPE-CE	 (covered	 in	 section	 1.4.1).	 	 	 The	 regulator	 was	 to	 be	generated	by	fusing	an	RNA	aptamer	for	a	light-sensitive	ligand	to	the	prototypical	pT181	transcriptional	 attenuator	 (discussed	 in	 Chapter	 1.3.1)	 upstream	 of	 the	 reporter	 gene	super-folder	green	fluorescent	protein	(SFGFP)	(Figure	2.4).		In	this	chapter,	I	will	outline	my	attempts	toward	this	goal	and	summarize	my	findings	along	the	way.		
2.3	 Results	
2.3.1	 Exploring	KRAzR-Based	RNA	Switches	As	 a	 potential	 strategy	 for	 generating	 light-sensitive	 RNA	 switches,	 I	 explored	 the	possibility	of	building	off	previous	work	(Hayashi	et	al.,	2008)	by	using	the	KRAzR	aptamer	and	 its	 azobenzene	 peptide	 ligand.	 While	 the	 KRAzR	 aptamer	 proved	 amenable	 to	structural	study	and	was	successfully	characterized	via	SHAPE-CE	(Figure	2.5)	after	in	vitro	transcription	and	purification,	acquiring	the	peptide	ligand	proved	unfeasible,	making	any	approach	based	on	the	KRAZr	aptamer	unviable.		
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Figure	 2.5	 Structure	 of	 the	 KRAzR	 aptamer	 58.	 	 The	 folding	 of	 the	 previously	 reported	KRAzR	 aptamer	 (Hayashi	 et	 al.,	 2008)	 is	 predicted	 using	 SHAPE-CE	 reactivities	 as	constraints	 in	 RNAStructure.	 	 Highly	 reactive	 nucleotides	 are	 colored	 in	 red,	 low	reactivities	nucleotides	in	blue,	and	the	nucleotides	without	any	data	(largely	the	structure	cassettes)	in	grey.		
2.3.2	 Dihydropyrene	As	 an	 alternate	mode	of	 encoding	 light-sensitivity,	 I	 investigated	using	 the	dihyropyrene	aptamer	 (Clone	 8)	 developed	 by	 Lee	 et	 al.	 (2007).	 	 The	 aptamer	 proved	 amenable	 to	SHAPE-CE,	so	I	ran	probing	experiments	with	and	without	the	target	dihydropyrene	
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Figure	2.6	Structure	and	reactivity	of	dihydropyrene	aptamers.	(A)	Predicted	structure	of	dihydropyrene	 atpamer	 from	 RNAStructure	 (Reuter	 and	 Mathews,	 2010)	 prediction	constrained	by	SHAPE	reactivity	data	in	the	absence	of	ligand.		The	color	map	displays	the	reactivity	difference	after	the	addition	of	ligand,	with	blue	indicating	a	reactivity	drop,	red	indicating	 a	 reactivity	 increase,	white	 indicating	 no	 change,	 and	 grey	 indicating	 no	 data.		The	reactivity	pattern	suggests	 ligand-binding	at	 the	 top	stem-loop	and	possibly	 the	 left-hand	stem-loop	as	well.	 	(B)	SHAPE	reactivity	and	reactivity	difference	plots	showing	the	reactivity	data	for	the	BDHP	aptamer.	 	The	groupings	of	reactivity	decreases	between	25-30	 and	 65-70	 nucleotides	 correspond	 to	 the	 possible	 ligand	 binding	 stem-loop	 regions.
	 39	 	
G
G
C
C
U
U
C
G G
G
C
C
A
A
G
G
U
GU
G
C
G
U
AC
G
A
G U
A
U
A
U
G G
U
C
A
U
C
C U
A
C
A
U
C
U
G
C
U
U
U
G
A
G
C
A
U
C
U
C
G
A
C
G A
A
G
A
G
U
U
U
G
U
C
U
C
A
A
U
C
G
G
U
C
U
G
U
A
U
C
C
C
G A U C C G C U
U
C
GG
CGG
AUC
C
A
A
A
U
C
G
G
G
C
U
UC
G
G
U
C
C
G
G
U
UC
1
10
20
30
40
50
60
70
80
90
100
110
120
130
136
Reactivity
Difference
A
B
-1.44 0.80
	 40	
	 	ligand	 (the	 PEG-attached	 variant	 in	 its	 BDHP	 confirmation).	 Localized	 decreases	 in	reactivity	 confirmed	 the	 putative	 ligand	 binding	 site	 from	 the	 original	 research	 and	suggested	the	possible	 involvement	of	additional	distal	residues	in	 ligand	binding	(Figure	2.6).		Moreover,	absorbance	spectra	of	the	dihydropyrene-PEG	before	and	after	visible	light	exposure	 matched	 the	 spectra	 reported	 by	 Lee	 et	 al.	 (2007),	 confirming	 the	 transition	between	the	BDHP	(closed)	and	BCPD	(open)	forms	of	the	ligand	(Figure	A.1).	Based	 on	 this	 structural	 data,	 I	 designed	 and	 generated	 a	 series	 of	 minimal	dihydropyrene	 aptamers	 (Figure	 2.7)	 and	 established	 their	 ability	 to	 bind	 the	
	
Figure	2.7	Structure	of	dihydropyrene	minimal	aptamers.	Designed	minimal	truncations	of	the	dihydropyrene	aptamer.	
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dihydropyrene	 target	 using	 changes	 in	 SHAPE	 reactivity.	 	 These	minimal	 aptamers	were	then	 fused	 to	 the	 antisense	 RNA	 of	 the	 pT181	 transcriptional	 regulator	 following	 the	scheme	outlined	 in	Figure	2.4.	While	 functional	 testing	of	 these	 fusions	 in	 the	TX-TL	cell-	extract	 system	 initially	gave	promising	 results	 for	 the	 fusion	based	on	minimal	hairpin	1	(Figure	A.2),	appearing	to	show	repression	of	fluorescence	in	response	to	dihydropyrene,	multiple	 further	 experiments	 failed	 to	 replicate	 these	 results.	 	More	pT181	 fusions	were	constructed,	and	while	the	addition	of	the	aptamer	domain	did	prevent	repression	just	as	designed,	the	addition	of	ligand	failed	to	restore	antisense	repression	(Figure	2.8).			As	an	alternate	strategy,	 I	 followed	the	riboswitch	engineering	method	 laid	out	by	Ceres	et	al.	(2013),	in	which	a	variety	of	aptamer	domains	were	fused	to	naturally-derived	riboswitch	 expression	 platforms	 in	 order	 to	 generate	 new	 riboswitches	 in	 a	 modular	fashion	(see	section	1.5).		While	initial	tests	verified	the	function	of	the	constructs	reported	by	Ceres	et	al.,	multiple	attempts	to	generate	dihydropyrene	riboswitches	using	the	same	expression	platforms	proved	unsuccessful	 (Figure	A.3),	 leading	 to	eventual	abandonment	of	this	avenue.											
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Figure	 2.8	 TX-TL	 testing	 of	 fusions	 of	 the	pT181	 antisense	 and	dihydropyrene	 aptamer.		Kinetic	 fluorescence	 traces	 were	 measured	 in	 the	 TX-TL	 extract	 system	 for	 various	antisense	plasmid	and	 ligand	combinations	 (BDHP-target	 ligand,	DMSO-no-ligand	solvent	control)	 all	 paired	 with	 a	 pT181	 sense	 plasmid	 in	 which	 the	 regulator	 controlled	transcription	 of	 SFGFP.	 	 Functional	 antisense	 fusions	 would	 be	 expected	 to	 show	significantly	lower	fluorescence	in	the	presence	of	BDHP	(open	circles)	than	DMSO	(closed	circles).					
2.3.3	 Testing	a	spiropyran-sensitive	transcriptional	switch	Looking	to	expand	off	Young	and	Dieters’s	success	in	developing	a	light-sensitive	aptamer	(Young	 and	 Deiters,	 2008),	 I	 sought	 to	 use	 their	 spiropyran-binding	 aptamer	 to	make	 a	
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light-responsive	transcriptional	regulator.		As	a	starting	point,	I	synthesized	the	spiropyran	aptamer	and	first	established	its	ability	to	be	characterized	via	SHAPE-CE.	Characterization	of	 spiropyran	alone	 showed	 that	 it	 appeared	 to	 transition	between	 its	 two	 colorful	 open	forms	(see	Figure	2.2)	in	response	to	changes	in	pH,	and	prolonged	heat	exposure	caused	the	transition	between	the	purple	merocyanine	form	and	colorless	closed	form	as	reported	previously	(Young	and	Deiters,	2008).			As	our	next	step,	I	cloned	a	pair	of	regulators	linking	the	spiropyran	aptamer	to	the	pT181	 antisense	 targeting	 the	 pT181	 transcriptional	 attenuator	 upstream	 of	 SFGFP	 (see	Figure	 2.4).	 I	 tested	 their	 ON	 functionality	 in	vivo,	measuring	 bulk	 fluorescence	 levels	 in	response	to	the	addition	of	an	empty	antisense	plasmid	and	the	spiropyran	aptamer-pT181	fusions.	 	These	tests	confirmed	that	the	aptamer	fusions	did	not	cause	termination	 in	the	absence	of	spiropyran	(Figure	2.9A),	an	important	checkpoint	before	embarking	on	in	vitro	testing	 using	 spiropyran.	 	 (The	 costliness	 of	 the	 spiropyran	 molecule	 made	 large-scale	culture	testing	of	the	with-ligand	case	impractical.)	Moreover,	the	fusions	proved	amenable	to	SHAPE-CE,	giving	cleanly	resolved	capillary	electropherograms.	However,	analysis	of	the	reactivity	data	indicated	that	the	5’	structure	cassette	was	interfering	with	proper	folding	of	the	aptamer	(Figure	2.9B),	requiring	the	synthesis	of	the	fusion	without	the	interfering	structure	cassette.			
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Figure	2.9	Spiropyran	aptamer-pT181	fusions.	(A)	In	vivo	functional	data	showing	the	normalized	fluorescence	from	the	pT181	attenuator-controlled	SFGFP	output	in	response	to	the	presence	of	the	spiropyran	aptamer-pT181	antisense	fusions	without	spiropyran	as	compared	to	an	empty	control	plasmid.		As	expected,	the	fusions	fail	to	repress	SFGFP	fluorescence	in	the	absence	of	spiropyran.	(B)	Example	predicted	structure	of	spiropyran	aptamer-pT181	antisense	fusion	from	RNAStructure	(Reuter	and	Mathews,	2010)	with	prediction	constrained	by	SHAPE	reactivity	data	in	the	absence	of	ligand.		The	structure	cassettes	(green)	appear	to	be	interfering	with	the	folding	of	the	aptamer	and	antisense	rather	than	folding	into	self-contained	hair-pins	as	desired.		 Attempts	 to	 probe	 the	 structure	 of	 the	 spiropyran	 aptamer	 and	 fusions	 in	 the	presence	of	spiropyran	were	impeded	by	an	inability	to	dissolve	the	spiropyran	in	the	RNA	folding	 buffer	 at	 high	 concentrations.	 	 After	 consulting	 with	 the	 authors	 of	 the	 original	research	 (Young	 and	 Deiters,	 2008),	 I	 addressed	 this	 problem	 by	 adding	 10%	 DMSO	 to	
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solution	in	order	to	increase	spiropyran	solubility.		I	also	used	proton	NMR	to	confirm	that	the	 spiropyran	was	adopting	 the	colorless,	 closed	 form	 in	 solution,	 although	a	 remaining	purple	tint	hinted	at	the	continued	presence	of	open	form.	Although,	initial	attempts	to	reverse-transcribe	the	spiropyran	fusions	failed	to	give	good	 extension,	 optimization	 of	 reverse-transcription	 conditions	 (temperature	 and	extension	 time)	 eventually	 gave	 analyzable	 results.	 However,	 SHAPE	 characterization	 of	the	spiropyran	aptamer	and	fusions	with	and	without	spiropyran	failed	to	distinguish	any	reactivity	 differences	 associated	 with	 ligand	 binding	 regardless	 of	 the	 form	 of	 the	spiropyran	(Figure	A.6).		Contacting	Douglas	Young	helped	explain	this	surprising	result—his	own	experiences	 indicated	that	spiropyran	behaved	differently	when	 immobilized	(as	in	the	original	selection	and	SPR	binding	experiments)	as	opposed	to	when	free	in	solution,	where	it	would	quickly	revert	to	the	closed	form.			Based	on	this	knowledge	and	our	failure	to	 demonstrate	 ligand-binding	 via	 SHAPE-CE,	 we	 chose	 to	 discontinue	 work	 with	 the	spiropyran	aptamer.		
2.3.4	 Biliverdin	aptamer	characterization		 	As	an	alternate	approach	to	developing	a	light-sensing	RNA	activator,	I	investigated	using	biliverdin	as	the	relevant	 ligand.	 	Biliverdin	(Figure	2.10)	 is	a	green	tetrapyrrole	pigment	that	arises	naturally	in	the	breakdown	of	heme	(José	et	al.,	2001)	and	which	can	undergo	changes	in	conformation	in	response	to	light	(Bois-Choussy	and	Barbier,	1980).	Moreover,	biliverdin	has	been	previously	synthesized	in	E.	coli	at	rates	reaching	3.3	mg/L	(Chen	et	al.,	2012),	 indicating	 that	 E.	 coli	 can	 tolerate	 biliverdin	 as	 a	 possible	 signaling	 molecule.		Fortuitously,	our	collaborators	in	Matthew	Levy’s	lab	at	Albert	Einstein	College	of	Medicine,	had	 already	 performed	 ten	 rounds	 of	 SELEX	 on	 a	 randomized	RNA	 library,	 generating	 a	
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pool	of	sequences	enriched	for	biliverdin-binding	RNA	aptamers.		
	
	
Figure	 2.10	 The	 structure	 of	 the	 heme-derived,	 green	 tetrapyrrole	 pigment	 biliverdin.	Reprinted	from	Kirkby	and	Adin	(2006).		 After	 sequencing	 this	 pool	 of	 SELEX-generated	 potential	 aptamers	 (Figure	 A.4),	 I	synthesized	a	handful	of	 the	highest-frequency	aptamers	via	 in	vitro	 transcription	 to	 test	for	 changes	 in	 structure	 in	 the	 presence	 of	 biliverdin.	 	When	 the	 SHAPE-CE	 reactivities	between	 the	 ligand	 and	 no	 ligand	 cases	 were	 compared,	 one	 of	 the	 aptamers	 tested	(aptamer	 70),	 showed	 particularly	 striking	 changes	 in	 reactivity	 patterns,	 indicating	 a	probable	location	of	biliverdin	binding	(Figure	2.11A).	Based	on	this	data,	I	designed	three	different	potential	minimal	aptamers	(Figure	2.11B)	in	order	to	establish	the	smallest	motif	sufficient	for	ligand	binding	out	of	the	original	121	nucleotide	aptamer.		My	hope	was	that	
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working	with	a	minimal	version	of	the	aptamer	would	make	for	simpler	engineering	of	our	eventual	 synthetic	 riboswitch.	 Of	 the	 minimal	 aptamers	 tested,	 the	 one	 of	 intermediate	length	(minimal	aptamer	2,	Figure	2.11B)	gave	the	best	results:	it	folded	into	its	intended	structure	(based	on	structure	prediction	constrained	by	SHAPE	reactivities)	and	exhibited	the	expected	reactivity	changes	in	response	to	ligand	binding.	However,	further	exploration	at	 this	point	 indicated	 that	 the	conformational	switching	and	relaxation	of	biliverdin	was	too	 fast	 to	 be	 of	 utility	 for	 light-activated	 riboswitch,	 making	 continued	 in	 work	 this	direction	impractical.																
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Figure	 2.11	 Structure	 and	 reactivity	 of	 biliverdin	 aptamers.	 (A)	 Predicted	 structure	 of	biliverdin	 aptamer	 70	 from	 RNAStructure	 (Reuter	 and	 Mathews,	 2010)	 prediction	constrained	by	SHAPE	reactivity	data	in	the	absence	of	ligand.		The	color	map	displays	the	reactivity	difference	after	the	addition	of	ligand,	with	blue	indicating	a	reactivity	drop,	red	indicating	 a	 reactivity	 increase,	white	 indicating	 no	 change,	 and	 grey	 indicating	 no	 data.		The	 reactivity	pattern	 suggests	 ligand-binding	 at	 the	 top	 stem-loop.	 	 (B)	Reactivity	plots	showing	 the	 SHAPE-CE	 reactivities	 with	 and	 without	 ligand,	 as	 well	 as	 the	 reactivity	differences.	 (C)	 Designed	 structures	 for	 three	 minimal	 truncations	 of	 the	 biliverdin	aptamer	70.		
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2.4	 Discussion	and	conclusions	While	 the	work	 failed	 to	develop	a	 light-activated	RNA	switch,	 the	 reported	research	did	reaffirm	 the	 utility	 of	 SHAPE	 probing	 for	 identifying	 the	 location	 of	 ligand-binding	 in	 an	RNA	aptamer	in	the	case	of	both	the	dihydropyrene	and	biliverdin	aptamers.	 	There	is	no	doubt	 that	 creating	 a	 light-sensitive	 RNA	 regulator	 remains	 entirely	 feasible,	 given	 that	work	 by	 Lee	 et	 al.	 (2007)	 in	 creating	 a	 light-responsive	 ribozyme	 has	 shown	 that	 light-sensitive	ligand	binding	can	indeed	be	linked	to	RNA	functionality.	 	However,	to	engineer	such	 a	 regulator	may	 require	 the	 isolation	of	 new	RNA	aptamers	 for	 a	 carefully	 selected	target—ideally	one	with	 stable,	 light-switchable	 conformations,	 as	well	 as	high	 solubility	and	bio-compatibility.	 	 	Regardless,	 the	challenge	remains	 to	engineer	an	RNA	 that	 ties	a	light-based	 input	 to	 an	 output	 in	 gene	 expression,	 and	 it	 is	 my	 hope	 that	 this	 goal	 is	someday	achieved.		
2.5	 Materials	and	methods	
Gene	synthesis	and	plasmid	cloning	The	 KRAZr	 aptamer	 templates	were	 synthesized	 by	 PCR	 to	 create	 DNA	 templates	 for	 in	
vitro	transcription.			The	spiropyran	aptamer	and	minimal	aptamers	were	cloned	into	a	pUC57	backbone	via	 Gibson	 assembly	 (Gibson	 et	 al.,	 2009)	 and	 fused	 to	 the	 pT181	 regulator	 using	 the	inverse	 polymerase	 chain	 reaction	 (iPCR)	 (Hemsley	 et	 al.,	 1989)	method	 of	 site-directed	mutagenesis.	The	 dihydropyrene	 aptamer	 was	 cloned	 into	 a	 colE1	 backbone	 and	 fused	 to	 the	pT181	regulator	using	Gibson	assembly.	
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The	 biliverdin	 aptamers	 were	 synthesized	 via	 PCR	 and	 cloned	 into	 a	 Genscript	pUC57	backbone	provided	by	Matthew	Levy	of	Albert	Einstein	College	of	Medicine	using	Gibson	assembly	such	that	 the	aptamer	sequence	was	preceded	by	a	T7	promoter	and	 in	certain	cases	followed	hepD	ribozyme	to	improve	the	accuracy	of	the	3’	end.			
RNA	preparation	via	in	vitro	transcription	RNA	 for	 structural	 characterization	 was	 transcribed	 via	 in	 vitro	 transcription	 from	 its	synthetic	DNA	template	 including	a	T7	promoter	and	flanking	structural	cassette	regions.		
In	vitro	transcription	reactions	were	generally	performed	at	the	1	mL	scale,	requiring	20	μL	of	 the	 resuspended	 PCR	 product	 generated	 as	 outlined	 above.	 	 In	 addition,	 each	transcription	 reaction	 contained	40	mM	Tris	 (pH	8.0),	20	mM	MgCl2,	 10	mM	DTT,	2	mM	spermidine,	0.01%	Triton,	5	mM	mixed	NTPs,	3	μL	RNAse	Inhibitor	(Promega),	and	10	μL	of	 an	 in-house	 His-tagged	 T7	 RNA	 polymerase	 preparation.	 	 After	 careful	 mixing,	 the	reaction	 was	 incubated	 at	 37°C	 for	 at	 least	 6	 hours,	 until	 a	 white	 organic	 phosphate	precipitate	was	clearly	visible	at	the	bottom	of	the	reaction	tube.		
RNA	purification	The	RNA	from	the	 in	vitro	transcription	was	purified	by	ethanol	precipitation	followed	by	polyacrylamide	gel	extraction.		To	a	given	volume	of	supernatant	were	added	0.1	volumes	of	3	M	NaOAc	(pH	5.2)	and	3	volumes	of	ice-cold	100%	EtOH,	and	the	resulting	mixture	was	chilled	for	at	least	30	minutes	at	-80	°C	before	centrifugation	at	15,000	rpm	at	4	°C	for	30	minutes.		The	supernatant	was	removed,	and	the	RNA	pellet	was	dissolved	in	a	solution	of	85%	deionized	 formamide,	 0.5X	TBE	 (Tris/Borate/EDTA)	buffer,	 50	mM	EDTA	 (pH	8.0),	
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and	0.01%	(w/v)	xylene	cyanol	and	bromophenol	blue	by	heating	the	sample	tubes	at	95	°C	and	carefully	pipetting	up	and	down	to	encourage	pellet	dissolution.	The	RNA	was	run	on	a	large,	pre-warmed	8%	denaturing	polyacrylamide	gel	for	2.5-3	 hrs	 at	 35	W.	 Bands	 were	 visualized	 using	 UV	 shadowing,	 then	 cut	 and	 transferred	 to	microcentrifuge	 tubes,	 crushed	 with	 a	 pipette	 tip,	 and	 passive-eluted	 into	 nuclease	 free	water	while	rotating	overnight	on	a	tube	rotisserie	at	4	°C.		The	resulting	eluted	RNA	was	once	 again	 ethanol	precipitated	by	 adding	0.1	 volumes	4	M	NaCl	 and	3	 volumes	 ice-cold	100%	EtOH,	followed	by	15	minutes’	chilling	at	-80	°C	and	centrifugation	at	15,000	rpm	at	4	°C	 for	30	minutes.	 	Afterwards,	 the	supernatant	was	removed,	 the	pellet	re-centrifuged	for	2	minutes,	and	any	remaining	supernatant	was	carefully	aspirated	away.		The	RNA	was	resuspended	 in	TE	 (Tris/EDTA)	buffer	 and	 its	 concentration	determined	using	 the	Qubit	fluorometric	 quantitation	 assay.	 	 Finally,	 150	 ng	 were	 run	 on	 a	 small	 denaturing	polyacrylamide	gel	 alongside	RNA	Century	Ladder	 (Ambion)	 in	order	 to	 check	 for	purity	and	correct	RNA	length.		The	gel	was	stained	using	SYBR	Gold	and	imaged	on	a	ChemiDoc	XRS+	(Bio-Rad).			
Selective	2’-Hydroxyl	acylation	Analyzed	by	Primer	Extension-Capillary	Electrophoresis	
(SHAPE-CE)	and	SHAPE-Seq	SHAPE-Seq	 experiments	 were	 performed	 following	 the	 protocol	 previously	 published	(Loughrey	et	al.,	2014),	and	SHAPE-CE	experiments	were	executed	as	follows:	
	
RNA	modification	The	modification	protocol	was	based	on	the	original	method	published	by	Merino	et	al.	 (	
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(2005),	 altered	 to	use	 the	SHAPE	reagent	1M7	 instead	of	NMIA	and	 to	accommodate	 the	addition	of	ligand	during	folding:	Ten	picomoles	of	the	RNA	to	be	modified	were	brought	up	to	a	total	volume	of	12	μL	in	nuclease-free	water	and	heated	for	2	minutes	at	95	°C,	then	removed	to	ice	for	1	minute,	followed	by	 the	 addition	of	6	uL	of	3.3x	 folding	buffer	 composed	of	333	mM	HEPES	 (pH	8.0),	333	mM	NaCl,	and	33	mM	MgCl2.		The	RNA	was	refolded	for	20	minutes	at	37	°C.	(In	experiments	 involving	 the	 addition	 of	 ligand,	 the	 RNA	 volume	 was	 decreased	 to	accommodate	the	ligand	volume,	and	the	ligand	was	added	before	RNA	refolding.)		Next,	9	μL	 of	 the	 refolded	 RNA	 were	 added	 to	 two	 pre-prepared	 tubes	 containing	 either	 1	 μL	anhydrous	DMSO	(unmodified	(-)	reaction)	or	1	μL	65	mM	of	SHAPE	reagent	1M7	dissolved	in	anhydrous	DMSO	(modified	(+)	reaction),	and	the	tubes	were	both	incubated	at	37	°C	for	1	minute.	To	precipitate	 the	RNA,	90	μL	of	nuclease-free	water,	 5	μL	of	3	M	NaOAc,	1	μL	of	glycogen	(to	aid	in	visualizing	RNA	pellet),	and	400	μL	ice-cold	100%	EtOH	were	added	to	each	tube,	and	the	tubes	were	then	incubated	at	-80	°C	for	at	 least	30	minutes.	 	Next,	the	tubes	were	centrifuged	at	15,000	rpm	at	4	°C	 for	30	minutes,	 followed	by	removal	of	 the	supernatant	 and	 2	 additional	minutes	 of	 centrifugation.	 	 Any	 final	 traces	 of	 supernatant	were	aspirated,	and	the	RNA	pellets	were	dissolved	in	10	μL	0.5x	TE	buffer	and	stored	at	-20	°C.		
Reverse	transcription	For	each	RNA	to	be	characterized,	20	pmol	were	dissolved	in	18	μL	of	nuclease-free	water	and	 split	 into	 two	 tubes	with	 9	 μL	 each,	 corresponding	 to	 the	 ddA	 and	 ddT	 sequencing	
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reactions.	 	 To	 each	 of	 these	 sequencing	 tubes	 and	 the	 (+)	 and	 (-)	 reactions	 from	 the	modification	step	were	added	3	μL	of	a	fluorescently	labeled	reverse	transcription	primer	complementary	 to	 its	 target,	 with	 fluorescent	 labeling	 corresponding	 to	 the	 particular	reaction:	0.3	μM	of	primers	labeled	with	FAM	(ddT	sequencing	reaction),	VIC	((+)	modified	RNA	 reaction),	 or	NED	 ((-)	un-modified	RNA	 reaction),	 or	0.6	μM	of	primer	 labeled	with	PET	(ddA	sequencing	reaction).		The	reactions	were	heated	on	a	thermal	cycler	at	95	°C	for	two	minutes	and	then	65	°C	for	5	minutes	before	removal	to	ice.	 	Next,	1	μL	ddA	and	ddT	was	added	to	the	appropriate	tubes,	and	1	μL	0.5x	SSIII	(Invitrogen)	and	6	μL	Master	Mix*	were	added	to	every	tube.		The	tubes	were	then	heated	at	45	°C	for	1	minute,	52	°C	for	25	minute,	65	°C	for	5	minutes,	and	finally	cooled	to	4	°C.			*Master	Mix	composition:	4	volumes	of	5x	SSIII	First	Strand	Buffer	(Invitrogen),	1	volume	0.1	M	DTT,	and	1	volume	10	mM	mixed	dNTPs	(10	mM	each	dATP,	dCTP,	dTTP,	and	dITP).	The	reverse-transcribed	DNA	from	each	sample	was	precipitated	together,	with	the	sequencing	and	(+)	and	(-)	reactions	for	each	sample	combined	along	with	240	μL	ice-cold	100%	EtOH	into	a	non-stick	2	mL	micro-centrifuge	tube.		The	tubes	were	chilled	at	-80	°C	for	at	least	15	minutes	before	centrifugation	at	4	°C	and	15,000	rpm.		The	supernatant	was	removed,	and	 the	precipitated	DNA	pellets	were	washed	with	800	μL	 ice-cold	70%	EtOH	and	centrifuged	for	a	further	2	minutes.		The	supernatant	was	pipetted	off	again,	the	pellets	re-spun	 for	 a	 final	 2	 minutes,	 and	 any	 remaining	 supernatant	 was	 aspirated	 before	 the	pellets	were	 dried	 for	 10	minutes	 on	 a	 rotary	 evaporator	 set	 on	 its	 lowest	 setting.	 	 The	dried	 pellets	 were	 resuspended	 in	 10	 μL	 deionized	 formamide	 before	 submission	 for	fragment	analysis	on	an	ABI	3730xl	capillary	electrophoresis	machine.	Data	were	aligned	and	 analyzed	 using	 SHAPEFinder	 (Vasa	 et	 al.,	 2008),	 and	 reactivities	 were	 normalized	
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using	the	2%/8%	rule	(Lucks	et	al.,	2011).		
TX-TL	testing	TX-TL	extract	was	prepared	following	the	previously	reported	protocol	(Shin	and	Noireaux,	2010;	Sun	et	al.,	2013).			Plasmids	to	be	tested	were	grown	in	NEB	Turbo	cells	overnight	and	purified	following	the	manufacturer	protocol	for	the	QIAfilter	Plasmid	Midi	Kit	(Qiagen),	deviating	from	the	protocol	only	in	that	the	plasmid	pellets	were	dissolved	in	MilliQ-purified	water	in	place	of	buffer.		The	TX-TL	experiments	were	performed	following	the	methods	laid	out	by	Takahashi	et	al.	(2014)	with	temperature	set	at	either	30	°	C	or	37	°	C	and	fluorescent	readings	taking	place	every	5	minutes.		
In	vivo	functional	testing	All	in	vivo	bulk	fluorescence	experiments	were	performed	in	Escherichia	coli	(E.	coli)	strain	TG1	(F'traD36	lacIq	Delta(lacZ)	M15	pro	A+B+/supE	Delta(hsdM-mcrB)5	(rk-	mk-	McrB-)	thi	
Delta(lac-proAB)).	For	each	experiment,	pairs	of	sense	target	plasmid	and	antisense	plasmid	(or	a	no-antisense	control	plasmid)	were	transformed	into	chemically	competent	
E.	coli	TG1	cells,	plated	on	Difco	LB	+	Agar	plates	with	100	mg/mL	carbenicillin	and	34	mg/ml	chloramphenicol,	and	incubated	overnight	at	37	°C	for	approximately	17	hours.		For	every	experiment,	the	same	procedure	was	repeated	for	the	pair	of	empty	autofluorescence	control	plasmids,	JBL001	and	JBL002,	which	did	not	express	either	antisense	or	sense	target	RNAs	and	were	used	to	determine	background	cellular	autofluorescence.		After	overnight	incubation,	the	plates	were	removed	from	the	incubator	and	kept	at	room	temperature	for	approximately	7	hours.		Three	separate	colonies	were	picked	for	each	
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condition	or	control,	and	each	was	used	to	inoculate	300	µL	of	LB	(Luria-Bertani)	media	containing	100	mg/mL	carbenicillin	and	34	mg/mL	chloramphenicol	in	a	2	mL	96-well	block	(Costar	3960).		The	block	was	covered	with	a	breathable	seal	(Aeraseal	BS-25)	and	incubated	at	37	°C	while	shaking	at	a	speed	of	1,000	rpm	in	a	Labnet	Vortemp	56	bench-top	shaker	for	18-19	hours	overnight.		From	this	overnight	culture	4	µL	were	taken	and	used	to	inoculate	196	µL	of	M9	minimal	media	(1	x	M9	minimal	salts,	1	mM	thiamine	hydrochloride,	0.4	%	glycerol,	0.2	%	casamino	acids,	2	mM	MgSO4,	0.1	mM	CaCl2)	containing	100	mg/mL	carbenicillin	and	34	mg/ml	chloramphenicol.		The	cultures,	alongside	three	wells	of	an	M9	only	control,	were	grown	in	a	2	mL	96-well	block	under	the	same	conditions	as	the	overnight	culture	for	~4	hours.	Fifty	µL	of	this	culture	were	diluted	1:1	with	phosphate	buffered	saline	(PBS)	in	a	black-welled	clear-bottomed	96-well	plate	(Costar	3231).	The	diluted	cultures’	optical	density	(OD)	at	600	nm	and	fluorescence	(485	nm	excitation,	520	nm	emission)	were	then	measured	with	a	Biotek	Synergy	H1	plate	reader.		
Data	analysis	After	subtracting	the	average	absorbance	and	fluorescence	of	the	three	wells	containing	the	media	blank	from	the	measured	sample	values,	the	ratio	of	fluorescence	to	OD	was	calculated	for	each	well,	and	the	triplicate	values	were	averaged	for	each	set	of	samples	after	subtraction	of	the	average	fluorescence	to	OD	ratio	for	the	background	cellular	autofluorescence	control.			
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CHAPTER	3	
IMPROVING	FOLD	ACTIVATION	OF	SMALL	TRANSCRIPTION	ACTIVATING	RNAS	
(STARS)	WITH	RATIONAL	RNA	ENGINEERING	STRATEGIES.1	
	
3.1	 Abstract	Regulatory	 RNAs	 have	 become	 integral	 components	 of	 the	 synthetic	 biology	 and	bioengineering	toolbox	for	controlling	gene	expression.	We	recently	expanded	this	toolbox	by	 creating	 small	 transcription	 activating	 RNAs	 (STARs)	 that	 act	 by	 disrupting	 the	formation	of	a	target	transcriptional	terminator	hairpin	placed	upstream	of	a	gene.	While	STARs	are	a	promising	addition	to	the	repertoire	of	RNA	regulators,	much	work	remains	to	be	 done	 to	 optimize	 the	 fold	 activation	 of	 these	 systems.	 Here	 we	 apply	 rational	 RNA	engineering	 strategies	 to	 improve	 the	 fold	 activation	 of	 two	 STAR	 regulators.	 We	demonstrate	 that	 a	 combination	 of	 promoter	 strength	 tuning	 and	 multiple	 RNA	engineering	 strategies	 can	 improve	 fold	 activation	 from	 5.4-fold	 to	 13.4-fold	 for	 a	 STAR	regulator	derived	from	the	pbuE	riboswitch	terminator.	We	then	validate	the	generality	of	our	approach	and	show	that	these	same	strategies	improve	fold	activation	from	2.1-fold	to	14.6-fold	 for	 an	 unrelated	 STAR	 regulator,	 opening	 the	 door	 to	 creating	 a	 range	 of	additional	 STARs	 to	 use	 in	 a	 broad	 array	 of	 biotechnologies.	We	 also	 establish	 that	 the	optimizations	preserve	the	orthogonality	of	these	STARs	between	themselves	and	a	set	of	RNA	 transcriptional	 repressors,	 enabling	 these	 optimized	 STARs	 to	 be	 used	 in	sophisticated	circuits.																																																										1	This	work	was	originally	published	in	Biotechnology	and	Bioengineering	and	has	been	reproduced	here	under	the	author	use	and	publication	permission	policy	of	Wiley.	Meyer,	S.,	Chappell,	J.,	Sankar,	S.,	Chew,	R.,	Lucks,	J.	B.	(2016).	Improving	fold	activation	of	small	transcription	activating	RNAs	(STARs)	with	rational	RNA	engineering	strategies.	Biotechnology	and	Bioengineering	113,	216-225.	
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3.2	 Introduction	Natural	and	engineered	RNA	regulators	have	become	powerful	components	of	our	toolbox	for	precisely	regulating	gene	expression	(Chappell	et	al.,	2013).	This	is	in	large	part	due	to	advances	 in	 our	 understanding	 of	 RNA	 biology	 that	 have	 uncovered	 a	 vast	 range	 of	regulatory	 functions	 performed	 by	 naturally	 occurring	 RNAs	 (Cech	 and	 Steitz,	 2014;	Chappell	 et	 al.,	 2013).	Many	of	 these	 functions	 involve	 the	 regulation	of	 the	 fundamental	processes	of	gene	expression,	including	mRNA	degradation	(Collins	et	al.,	2007;	Filipowicz	et	al.,	2008;	Storz	et	al.,	2011),	 translation	(Gottesman	and	Storz,	2011;	Nou	and	Kadner,	2000;	 Winkler	 et	 al.,	 2002),	 and	 transcription	 elongation	 (Brantl	 and	 Wagner,	 2000).	Recent	 work	 has	 further	 revealed	 how	 these	 functions	 are	 intimately	 linked	 to	 the	structure	of	 the	 regulatory	RNAs	 and	 the	 structural	 rearrangements	 they	 induce	 in	 their	targets	 (DebRoy	 et	 al.,	 2014).	 This	 in	 turn	 has	 enabled	 significant	 advances	 in	 design	approaches	 that	 use	 computational	 RNA	 structure	 prediction	 algorithms	 to	 design	synthetic	 RNAs	 that	 adopt	 specific	 conformations	 to	 perform	 their	 regulatory	 function	(Green	 et	 al.,	 2014;	 Rodrigo	 et	 al.,	 2012).	 RNA	 regulators	 thus	 represent	 a	 versatile	 and	designable	 platform	 for	 controlling	 gene	 expression	 and	 have	 been	 used	 in	 a	 number	 of	recent	 applications,	 including	 the	 creation	 of	 synthetic	 RNA	 regulatory	 gene	 expression	switches	(Ceres	et	al.,	2013a;	Lynch	et	al.,	2007;	Wachsmuth	et	al.,	2013),	RNA–only	logic	gates	 and	 circuits	 (Chappell	 et	 al.,	 2015;	 Lucks	 et	 al.,	 2011;	 Xie	 et	 al.,	 2011),	 RNA	transcriptional	networks	(Bhadra	and	Ellington,	2014;	Lucks	et	al.,	2011;	Takahashi	et	al.,	2014),	and	RNA-based	diagnostics	(Pardee	et	al.,	2014).	For	 bacterial	 systems,	 small	 RNAs	 (sRNAs)	 have	 proven	 to	 be	 particularly	 well	suited	 to	 engineering	 approaches	 that	 optimize	 and	 alter	 their	 function.	Although	 sRNAs	
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can	 act	 through	 a	wide	 variety	 of	mechanisms	 (Gottesman	 and	 Storz,	 2011),	 a	 common	mode	of	sRNA	regulation	relies	on	Watson-Crick	base	pairing	between	a	sense	target	RNA,	usually	 located	upstream	of	 the	gene	to	be	controlled,	and	a	trans-acting	antisense	sRNA.	By	itself,	the	sense	target	RNA	can	fold	into	structures	that	block	or	allow	gene	expression	–	for	example,	by	occluding	a	ribosome	binding	site,	in	the	case	of	translation	regulation,	or	forming	an	intrinsic	terminator	hairpin,	in	the	case	of	transcription	regulation.	Interaction	between	 the	 sense	 target	 RNA	 and	 antisense	 sRNA	 can	 then	 cause	 structural	rearrangement,	 ultimately	 controlling	 the	 expression	of	 the	 gene.	 Years	 of	 research	have	uncovered	 design	 principles	 for	 these	mechanisms,	 enabling	 engineers	 to	 create	 a	 wide	array	of	sRNA	regulators,	including	translational	repressors	(Mutalik	et	al.,	2012;	Na	et	al.,	2013)	translational	activators	(Green	et	al.,	2014;	Isaacs	et	al.,	2004;	Rodrigo	et	al.,	2012),	and	 transcriptional	 repressors	 (Lucks	 et	 al.,	 2011;	Qi	 et	 al.,	 2012a;	Takahashi	 and	Lucks,	2013).	Despite	the	versatility	of	engineered	sRNA	regulators,	until	recently	there	were	no	known	natural	or	synthetic	examples	of	sRNAs	that	could	activate	transcription	(Chappell	et	al.,	2013).	To	address	this	gap,	we	created	small	transcription	activating	RNAs	(STARs)	(Chappell	 et	 al.,	 2015)	 (Figure	 3.1A).	 In	 the	 STAR	 mechanism,	 the	 sense	 target	 region	contains	an	 intrinsic	 terminator	hairpin,	which	 terminates	 transcription	 in	 the	OFF	state,	preventing	read-through	of	the	downstream	gene.	The	STAR	antisense	contains	a	specific	anti-terminator	sequence	that	is	designed	to	bind	to	the	5’	stem	of	the	terminator	in	trans	to	 prevent	 terminator	 formation	 and	 allow	 transcriptional	 read-through	 in	 the	ON	 state.	This	 mechanistic	 design	 strategy	 was	 applied	 to	 target	 a	 range	 of	 intrinsic	 terminators	derived	from	natural	sources,	from	the	pbuE	riboswitch	to	the	pT181	plasmid	copy	control	
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element,	ultimately	creating	five	different	STARs	that	displayed	a	range	of	transcriptional	activation	from	3-fold	to	94-fold	(Chappell	et	al.,	2015).	In	addition,	orthogonality	between	these	 STARs	 and	 a	 preexisting	 library	 of	 RNA	 transcriptional	 repressors	 (Takahashi	 and	Lucks,	2013)	allowed	the	construction	of	two	previously	unattainable	RNA-only	logic	gates	(Chappell	et	al.,	2015),	demonstrating	the	potential	of	STARs	for	engineering	sophisticated	RNA	genetic	circuitry.	STARs	 thus	 represent	 a	 powerful	 expansion	 of	 the	 RNA	 engineering	 toolbox	 for	precisely	 regulating	 gene	 expression	 and	 creating	 synthetic	 genetic	 networks.	 However,	much	 work	 remains	 to	 be	 done	 to	 broadly	 optimize	 the	 fold	 activation	 of	 these	 new	regulators.	 In	 particular,	 only	 two	 of	 the	 originally	 designed	 STARs	 showed	 levels	 of	activation	greater	than	10-fold,	thereby	limiting	the	number	of	STARs	useful	in	applications	that	require	large	differences	between	ON	and	OFF	expression	states.	Here	we	remedy	this	by	 applying	 several	 sRNA	 engineering	methods	 (Carrier	 and	Keasling,	 1997;	 Sakai	 et	 al.,	2013)	and	gene	expression	optimization	strategies	to	optimize	the	overall	fold	activation	of	weak	STAR	regulators.	Specifically,	we	used	a	combination	of	promoter	strength	tuning	and	STAR	 antisense	 RNA	 stabilization	 and	 engineering	 strategies	 to	 improve	 fold	 activation	from	5.4-fold	(±2.2)	 to	13.4-fold	(±3.8)	 for	 the	pbuE	STAR	regulator.	To	confirm	that	our	approach	 could	 be	 generalized,	 we	 then	 applied	 these	 strategies	 to	 the	 unrelated	 prgX	STAR	(derived	from	a	conjugation	control	system	terminator)	to	improve	its	fold	activation	from	2.1-fold	 (±0.4)	 to	14.6-fold	 (±3.7).	This	process	also	yielded	multiple	STAR	variants	for	both	systems	with	intermediate	fold	activation	levels,	showing	that	this	strategy	can	be	used	to	fine-tune	STAR	performance.	Finally,	although	the	optimization	strategies	required	the	addition	of	a	significant	amount	of	extra	RNA	sequence	and	structure,	we	demonstrated	
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that	 orthogonality	 was	 preserved	 between	 the	 optimized	 STARs	 and	 a	 set	 of	 RNA	transcriptional	 repressors.	 These	 optimization	 strategies	 open	 the	 door	 for	 creating	 a	range	of	additional	STARs	for	use	in	a	broad	array	of	biotechnologies.	
	
3.3	 Materials	and	Methods	
3.3.1	 Plasmid	construction	and	cloning	STAR-mediated	 gene	 expression	 was	 tested	 with	 a	 two-plasmid	 system.	 Plasmids	 were	constructed	so	that	the	sequence	encoding	each	sense	target	RNA	was	placed	downstream	of	a	constitutive	promoter	and	upstream	of	the	coding	sequence	for	the	superfolder	green	fluorescent	 protein	 (SFGFP)	 reporter	 (Pédelacq	 et	 al.,	 2006),	 complete	 with	 its	 own	ribosome	binding	site	(Figure	B.1).	Separate	plasmids	were	constructed	for	STAR	antisense	expression,	with	the	sequence	encoding	the	STAR	preceded	by	a	constitutive	promoter	and	followed	by	the	t500	transcriptional	terminator	(Yarnell	and	Roberts,	1999)	(Figure	B.1).	For	 experiments	 in	 which	 the	 STAR	 antisense	 was	 absent,	 a	 control	 plasmid	 was	constructed	 containing	 the	 constitutive	 promoter	 followed	 directly	 by	 a	 transcriptional	terminator	(rrnB	terminator	‘TrrnB’)	(Figure	B.1).	All	plasmids	and	sequences	used	in	this	study	are	enumerated	in	Table	B.1.	All	sense	target	plasmids	included	the	p15A	origin	and	a	gene	for	chloramphenicol	resistance,	while	all	 STAR	 antisense	 plasmids	 contained	 the	 ColE1	 origin	 and	 encoded	 a	 gene	 for	carbenicillin	resistance.	All	plasmids	were	either	previously	reported	or	constructed	from	previously	 reported	 plasmids	 (Chappell	 et	 al.,	 2015;	 Lucks	 et	 al.,	 2011;	 Takahashi	 and	Lucks,	2013)	using	inverse	polymerase	chain	reaction	(iPCR)	to	make	substitutions	and/or	insertions.	The	 inserted	sRNA	scaffold	and	stability	hairpin	sequences	were	derived	from	
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previous	 work	 by	 Sakai	 et	 al.	 (2013)	 and	 Carrier	 et	 al.	 (1999),	 respectively.	 Sequence-verified	stocks	of	the	plasmids	were	used	for	all	experiments.		
	
3.3.2	 Strains,	media,	and	in	vivo	bulk	fluorescence	experiments	All	bulk	fluorescence	experiments	were	performed	in	Escherichia	coli	(E.	coli)	strain	TG1	
(F'traD36	lacIq	Delta(lacZ)	M15	pro	A+B+/supE	Delta(hsdM-mcrB)5	(rk-	mk-	McrB-)	thi	
Delta(lac-proAB))	with	three	independent	replicates,	except	for	the	hfq	knockout	experiments	(Figure	3.3D),	which	were	performed	in	E.	coli	strain	BW25113	(F-,	DE(araD-
araB)567,	lacZ4787(del)::rrnB-3,	LAM-,	rph-1,	DE(rhaD-rhaB)568,	hsdR514)	and	the	BW25113	Δhfq	variant	from	the	Keio	collection	(Baba	et	al.,	2006).	For	each	independent	replicate,	pairs	of	sense	target	plasmid	and	STAR	antisense	plasmid	(or	no-antisense	control	plasmid	JBL002)	were	transformed	into	chemically	competent	E.	coli	TG1	cells,	plated	on	Difco	LB	+	Agar	plates	with	100	mg/mL	carbenicillin	and	34	mg/ml	chloramphenicol,	and	incubated	overnight	at	37	°C	for	approximately	17	hours.	For	every	experiment,	the	same	procedure	was	repeated	for	the	pair	of	empty	autofluorescence	control	plasmids,	JBL001	and	JBL002,	which	did	not	express	either	STAR	or	sense	target	RNAs	and	were	used	to	determine	background	cellular	autofluorescence.	After	overnight	incubation,	the	plates	were	removed	from	the	incubator	and	kept	at	room	temperature	for	approximately	7	hours.	Three	separate	colonies	were	picked	for	each	condition/control,	and	each	was	used	to	inoculate	300	µL	of	LB	media	with	100	mg/mL	carbenicillin	and	34	mg/mL	chloramphenicol	in	a	2	mL	96-well	block	(Costar	3960).	In	the	case	of	the	pbuE	variants	in	Figure	3.4A,	9	colonies	were	picked	in	order	to	guarantee	enough	passed	the	growth	requirements	described	below.	The	block	was	covered	with	a	breathable	seal	
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(Aeraseal	BS-25)	and	incubated	at	37	°C	while	shaking	at	a	speed	of	1,000	rpm	in	a	Labnet	Vortemp	56	bench-top	shaker	for	18-19	hours	overnight.	From	this	overnight	culture	4	µL	were	taken	and	used	to	inoculate	196	µL	of	M9	minimal	media	(1	x	M9	minimal	salts,	1	mM	thiamine	hydrochloride,	0.4	%	glycerol,	0.2	%	casamino	acids,	2	mM	MgSO4,	0.1	mM	CaCl2)	containing	100	mg/mL	carbenicillin	and	34	mg/mL	chloramphenicol.	The	cultures,	alongside	three	wells	of	an	M9	only	control,	were	grown	in	a	2	mL	96-well	block	under	the	same	conditions	as	the	overnight	culture,	until	the	majority	of	the	OD	values	exceeded	0.07,	which	took	5	to	7	hours.	Fifty	µLs	of	this	culture	were	diluted	1:1	with	phosphate	buffered	saline	(PBS)	in	a	black-welled	clear-bottomed	96-well	plate	(Costar	3231).	The	diluted	cultures’	optical	density	(OD)	at	600	nm	and	fluorescence	(485	nm	excitation,	520	nm	emission)	were	then	measured	with	a	Biotek	Synergy	H1	plate	reader.	
	
3.3.3	 Data	analysis	for	bulk	fluorescence	experiments	Each	experiment	included	two	sets	of	controls:	three	wells	of	a	media	blank	(M9)	and	three	wells	inoculated	from	separate	colonies	of	the	autofluorescence	control	E.	coli	cells	lacking	SFGFP	but	harboring	plasmids	with	the	same	backbones	and	resistances	as	all	sense	target	and	STAR	antisense	plasmids	(transformed	control	JBL001	and	JBL002).	All	fluorescence	and	OD	values	for	each	colony	were	initially	corrected	by	subtracting	the	corresponding	values	from	the	average	of	the	three	media	blanks.	The	ratio	of	fluorescence	units	over	OD	(Fluorescence/OD)	was	then	calculated	for	each	well	and	corrected	for	background	fluorescence	by	subtracting	the	average	Fluorescence/OD	for	the	autofluorescence	control	cells	without	SFGFP.	For	each	STAR-target	pair,	three	independent	colonies	were	characterized	from	three	independent	transformations	(9	colonies	total).	Data	were	
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discarded	for	colonies	that	showed	low	growth	(OD<0.07),	although	this	requirement	was	relaxed	for	the	orthogonality	grid	in	Figure	3.5	in	order	to	account	for	the	different	growth	rates	of	the	tested	variants.	Averages	and	standard	deviations	(depicted	by	error	bars)	of	Fluorescence/OD	were	calculated	over	the	repeat	experiments.	Fold	activation	was	calculated	by	dividing	the	average	corrected	Fluorescence/OD	for	a	STAR-target	pair	(ON)	by	the	average	corrected	Fluorescence/OD	for	the	same	sense	target	plasmid	paired	with	the	control	no	STAR	antisense	plasmid	(JBL002)	(OFF).	Fold	activation	error	was	calculated	using	standard	error	propagation	formulas	based	on	the	standard	deviations	of	the	average	corrected	Fluorescence/OD	values.		In	calculating	fold	repression	(Figure	3.5),	the	negative	reciprocal	was	taken	to	give	the	fold	repression,	i.e.,	0.20	became	−5-fold	repression	(Chappell	et	al.,	2015).	Statistical	significance	calculations	(two-sided	T-tests)	were	performed	on	the	individual	colony	Fluorescence/OD	ON	levels	normalized	by	the	average	Fluorescence/OD	OFF	levels.	
	
3.4	 Results	and	Discussion	
3.4.1	 The	pbuE	STAR	as	a	case	study	for	optimization	of	fold	activation	As	a	starting	point	for	exploring	strategies	to	increase	fold	activation,	we	chose	to	focus	on	a	STAR-target	 system	(Chappell	et	al.,	2015)	derived	 from	the	 intrinsic	 terminator	of	 the	pbuE	 riboswitch	 (Ceres	 et	 al.,	 2013b).	 As	 illustrated	 in	 Figure	 3.1A,	 the	 pbuE	 STAR	 is	designed	to	be	fully	complementary	to	the	5’	half	of	the	pbuE	intrinsic	terminator	present	in	the	target	RNA.	Interaction	of	the	STAR	with	its	target	RNA	thus	prevents	the	formation	of	the	terminator	hairpin,	enabling	transcription	elongation	into	the	downstream	reporter	gene,	 superfolder	 green	 fluorescent	 protein	 (SFGFP).	 To	 determine	 fold	 activation,	 gene	
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expression	 was	 characterized	 by	 measuring	 fluorescence	 normalized	 by	 optical	 density	(Fluorescence/OD)	 for	 cultures	 of	 E.	 coli	 cells	 co-transformed	 with	 two	 plasmids:	 one	plasmid	encoding	the	pbuE	sense	target	fused	to	the	downstream	SFGFP	coding	sequence	and	 the	 other	 plasmid	 encoding	 either	 the	 STAR	 antisense	 (ON	 state)	 or	 an	 empty	backbone	 control	 (OFF	 state)	 (absence	 of	 STAR	 antisense	 case).	 Activation	 was	 then	calculated	as	a	ratio	of	the	ON/OFF	Fluorescence/OD	values	(see	Materials	and	Methods).	Characterization	 of	 the	 pbuE	 STAR	 in	 this	 study	 reconfirmed	 its	 low	 fold	 activation,	previously	reported	by	Chappell	et	al.	(2015),	with	an	observed	activation	of	5.4-fold	(±2.2)	in	 the	 presence	 of	 the	 STAR	 antisense	 compared	 to	 when	 only	 the	 target	 RNA	 was	expressed	(Figure	3.1B).	This	result	indicated	that	there	was	ample	room	for	improvement	in	 fold	 activation	 compared	 to	 the	 94-fold	 (±26)	 activation	 shown	 by	 the	 best	 STAR	activator	 reported	 previously	 (Chappell	 et	 al.,	 2015).	 Furthermore,	 previous	 work	 on	applying	RNA	sequence	optimization	strategies	did	not	improve	the	low	fold	activation	of	the	pbuE	STAR	system	(Chappell	et	al.,	2015),	motivating	us	to	pursue	a	suite	of	alternative	strategies	discussed	below.										
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Figure	3.1	Design	and	function	of	a	model	Small	Transcription	Activating	RNA	(STAR).	(A)	Schematic	of	 the	mechanism	following	Chappell	et	al.	 (2015).	 In	 the	absence	of	 the	STAR	antisense,	the	nascent	sense	target	RNA	upstream	of	the	reporter	gene	forms	a	terminator	hairpin	that	stops	transcription	by	RNA	polymerase	(RNAP)	before	the	gene	is	transcribed	(OFF).	 The	 STAR	 antisense	 is	 designed	 to	 contain	 an	 anti-terminator	 sequence	complementary	 to	 the	 5’	 side	 of	 the	 terminator	 hairpin.	 When	 the	 STAR	 antisense	 is	present,	 it	 binds	 to	 the	 terminator	 sequence,	 preventing	 formation	 of	 the	 terminator	hairpin	 and	 allowing	 transcription	 of	 the	 downstream	 gene	 (ON).	 (B)	 In	 vivo	characterization	of	the	pbuE	STAR	regulator	performed	in	this	study	using	superfolder	GFP	(SFGFP)	 fluorescence	 to	measure	 gene	 expression	 from	 a	 sense	 target	 plasmid	with	 and	without	 a	 STAR	 antisense	 (AS)	 plasmid.	 	 Normalized	 fluorescence	was	 divided	 by	 OD600	(Optical	density	at	600	nm)	to	give	Fluorescence/OD,	and	fold	activation	was	calculated	as	Fluorescence/OD	 ON	 divided	 by	 Fluorescence/OD	 OFF.	 Error	 bars	 represent	 sample	standard	deviation	over	3	independent	replicates	with	3	colonies	each	(n=9).	The	*	symbol	indicates	a	 statistically	 significant	 (p<0.05)	 increase	 in	Fluorescence/OD	 in	 the	 case	with	STAR	antisense	as	determined	by	a	two-sided	T-test.	
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3.4.2	 Improving	 fold	 activation	 of	 STARs	 by	 manipulating	 STAR/target	 expression	
ratios	To	 begin,	 we	 chose	 to	 investigate	 improving	 fold	 activation	 by	 increasing	 the	 relative	concentration	 ratio	 of	 STAR	 antisense	 to	 its	 complementary	 sense	 target.	 A	 previously	developed	 model	 of	 the	 STAR	 mechanism	 hypothesized	 that	 transcription	 activation	 is	directly	 related	 to	 the	 rate	 of	 binding	 between	 STAR	 and	 target	 (Chappell	 et	 al.,	 2015).	Therefore,	 increasing	 the	 expression	 level	 of	 the	 STAR	 antisense	 relative	 to	 its	 target	should	naturally	increase	the	number	of	binding	events,	and	thus	increase	the	likelihood	of	any	 given	 target	 RNA	 being	 transcriptionally	 activated.	 To	 test	 this,	we	manipulated	 the	STAR/target	expression	ratio	in	vivo	in	E.	coli	cells	by	altering	the	relative	strengths	of	the	constitutive	promoters	that	drive	the	expression	of	the	STAR	antisense	and	sense	target	in	our	two-plasmid	system	(see	Materials	and	Methods).	Given	that	both	the	STAR	and	target	RNAs	 were	 originally	 under	 the	 control	 of	 the	 same	 strong	 constitutive	 σ70	 promoter,	decreasing	the	strength	of	the	sense	target	RNA	promoter	provided	a	straightforward	way	to	 titrate	down	 the	 steady-state	 levels	of	 sense	 target	RNA	by	 reducing	 the	 transcription	rate.	 Following	 this	 strategy,	 we	 cloned	 a	 series	 of	 successively	 weaker	 constitutive	promoters	 upstream	 of	 the	 pbuE	 sense	 target	 RNA	 and	 examined	 their	 effects	 on	 fold	activation	 in	vivo	 (Figure	3.2).	We	 chose	promoters	 from	 the	Anderson	promoter	 library	from	 the	 Registry	 of	 Standard	 Biological	 Parts	 (partsregistry.org),	 whose	 strengths	 have	been	well-characterized	in	previous	work	(Kelly	et	al.,	2009)	(Table	B.2).	The	in	vivo	testing	of	 these	 target	 promoter	 variants	 indicated	 that	weakening	 the	 sense	 plasmid	 promoter	strength	did	 indeed	result	 in	greater	 fold	activation,	and	we	observed	a	 clear	 correlation	between	decreased	 sense	 promoter	 strength	 and	 increased	 fold	 activation	 (Figure	 3.2B),	
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with	 the	majority	 of	 changes	 in	 fold	 activation	 being	 statistically	 significant	 (Table	 B.3).	Although	 the	 overall	 ON	 level	 of	 fluorescence	 decreased	 as	 expected	 with	 a	 weaker	promoter	on	the	sense	target	reporter	plasmid,	we	observed	an	even	greater	decrease	 in	the	 OFF	 level	 that	 followed	 the	 same	 relative	 order	 as	 promoter	 strength	 (Kelly	 et	 al.,	2009).	This	greater	decrease	in	OFF	level	led	to	an	overall	increase	in	fold	activation.	When	compared	 to	 the	 original	 promoter	 configuration,	 the	 weakest	 promoter	 tested,	 J23150,	more	than	doubled	the	fold	activation	of	the	pbuE	STAR	regulator	from	4.1-fold	(±1.2)	to	11.1-fold	(±3.2).	To	further	confirm	that	fold	activation	was	directly	related	to	the	relative	ratio	of	STAR	 to	 the	sense	 target	RNA,	we	characterized	 fold	activation	 from	the	original	pbuE	sense	target	RNA	as	a	function	of	decreased	expression	of	the	STAR	using	the	same	promoter	series	(Figure	B.2).	As	expected,	lowering	the	STAR	expression	resulted	in	lower	fold	activation,	confirming	the	importance	of	a	high	relative	ratio	of	STAR	antisense	RNA	to	sense	 target	 RNA	 for	 high	 fold	 activation.	 	 Overall,	 our	 results	 demonstrate	 that	we	 can	increase	 the	 fold	 activation	 of	 STAR	 regulators	 through	 manipulating	 STAR/target	expression	ratios.	
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Figure	3.2	Optimization	of	the	STAR/target	expression	ratio	yields	higher	fold	activation.	
(A)	 Schematic	 of	 the	 design	 strategy	 for	 improved	 activation.	 A	 number	 of	 weaker	promoters	were	substituted	for	the	strong	wild-type	(WT)	promoter	(J23119	SpeI)	on	the	sense	target	plasmid	 in	order	to	decrease	the	expression	 level	of	 the	sense	RNA.	 In	these	experiments,	 the	STAR	was	expressed	 from	a	high-copy	plasmid	using	 the	strong	 J23119	SpeI	promoter.	This	promoter	series	was	designed	to	increase	the	relative	expression	ratio	of	 STAR	 to	 target.	 (B)	 In	 vivo	 fluorescence	 characterization	 demonstrates	 an	 increase	 in	fold	activation	when	a	weaker	target	promoter	 is	used,	with	a	 fold	activation	of	11.1-fold	(±3.6)	 observed	 for	 the	 weakest	 J23150	 promoter.	 Normalized	 fluorescence	 divided	 by	optical	density	at	600	nm	(Fluorescence/OD)	 is	plotted	on	 the	 lower	axes,	with	 the	dark	gray	 bars	 representing	 the	 OFF	 level	 (no-STAR	 control	 plasmid)	 and	 the	 green	 bars	representing	the	ON	level	(STAR	present).	Fold	activation	(Fluorescence/OD	ON	divided	by	Fluorescence/OD	OFF)	is	plotted	on	the	upper	axes	as	a	series	of	light	gray	bars.	Error	bars	represent	 sample	 standard	deviation	over	3	 independent	 replicates	with	3	 colonies	 each	(n=9).	 The	 *	 symbol	 indicates	 statistically	 significant	 (p<0.05)	 improvement	 in	 fold	activation	 compared	 to	 the	 wild-type	 sense	 promoter	 configuration	 (J23119	 SpeI)	 as	determined	 by	 a	 two-sided	 T-test.	 Statistical	 significances	 of	 fold	 activation	 changes	between	different	promoters	are	presented	in	Table	B.3.						
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3.4.3	 Improving	fold	activation	of	STARs	by	engineering	the	STAR	antisense		Since	manipulating	RNA	stability	is	a	key	point	of	control	for	RNA	mechanisms	(Chappell	et	al.,	2013;	Smolke	and	Keasling,	2002),	we	next	sought	to	examine	how	altering	the	stability	of	the	STAR	antisense	could	be	used	as	another	strategy	for	improving	fold	activation.	The	steady-state	 level	 of	 STAR	 antisense	 molecules	 available	 for	 activation	 at	 any	 time	 is	governed	by	the	balance	between	two	key	rates:	the	rate	of	synthesis	(transcription)	and	the	rate	of	degradation.	Since	the	STAR	antisense	was	already	expressed	from	a	high-copy	plasmid	(ColE1	origin	of	replication)	under	the	control	of	a	strong	promoter,	reducing	the	degradation	rate	presented	a	more	accessible	way	to	increase	the	level	of	STAR	antisense	and	thus	fold	activation.	We	sought	to	decrease	the	degradation	rate	of	the	STAR	antisense	by	adding	strong	RNA	hairpins	to	the	5’	end,	following	previous	work	using	these	hairpins	to	stabilize	mRNAs	(Carrier	and	Keasling,	1999)	(Figure	3.3A).		 Our	 STAR	 stabilization	 strategy	 was	 based	 on	 the	 fact	 that	 secondary	 structures	located	at	 the	5’	end	of	bacterial	mRNAs	can	confer	stability	(Carrier	and	Keasling,	1997;	Emory	et	al.,	1992)	by	blocking	RNAse	E-mediated	degradation.	In	particular,	this	strategy	has	 been	 shown	 to	 improve	 mRNA	 stability	 and	 lengthen	 mRNA	 half-lives	 (Carrier	 and	Keasling,	 1999).	 To	 investigate	 whether	 or	 not	 these	 stability	 hairpins	 added	 to	 STARs	would	 improve	 fold	 activation,	 we	 added	 three	 previously	 published	 synthetic	 RNA	stability	hairpins	(pHP14,	pHP16,	and	pHP17)	(Carrier	and	Keasling,	1999)	to	the	5’	end	of	the	 pbuE	 STAR.	 We	 then	 characterized	 the	 resulting	 fold	 activation	 of	 these	 modified	STARs	(Figure	3.3B).	Compared	to	the	initial	wild-type	(WT)	pbuE	STAR,	the	variant	with	the	added	pHP16	5’	stability	hairpin	demonstrated	modest,	yet	statistically	significant,			
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Figure	3.3	 Improving	fold	activation	by	engineering	the	STAR	antisense.	(A)	Schematic	of	the	changes	made	to	the	pbuE	STAR.	Stability	hairpins	(purple)	were	added	to	the	5’	end	of	the	pbuE	STAR	to	block	RNase	E-mediated	degradation	(Carrier	and	Keasling,	1997).	sRNA	scaffolds	 (green)	 were	 added	 to	 the	 3’	 end	 to	 improve	 sRNA	 function,	 as	 previously	demonstrated	by	Sakai	 et	 al.	 (2013).	The	 J23119	SpeI	promoter	was	used	 to	express	 the	pbuE	 STAR	 variant	 and	 sense	 target	 RNAs.	 Data	 is	 plotted	 as	 in	 Figure	 3.2.	 (B)	 In	 vivo	functional	characterization	of	stability	hairpin	STAR	variants	indicates	that	the	addition	of	the	pHP16	5’	stability	hairpin	confers	a	modest	increase	in	activation	function	to	the	pbuE	STAR	regulator.	(C)	In	vivo	functional	characterization	of	sRNA	scaffold	pbuE	STAR	variants	indicates	that	only	the	addition	of	 the	Spot42	sRNA	scaffold	results	 in	a	small	 increase	 in	fold	 activation,	 though	 this	 is	 not	 statistically	 significant	 over	 the	 initial	 wild-type	 (WT)	pbuE	STAR.	Addition	of	the	MicF	or	Dsra1.3	sRNA	scaffolds	to	the	pbuE	STAR	was	shown	to	decrease	fold	activation.	(D)	Testing	of	the	Spot42	sRNA	scaffold	variant	of	the	pbuE	STAR	in	BW25113	and	BW25113	Δhfq	 strains	demonstrates	 slightly	higher	 activation	 levels	 in	the	absence	of	Hfq.	(E)	Combining	both	sRNA	scaffolds	and	5’	stability	hairpins	yields	the	highest	fold	activation	for	the	combinations	of	Spot42/pHP14	and	Spot42/pHP16.	In	parts	
(B),	(C),	and	(E)	 the	*	symbol	indicates	a	statistically	significant	(p<0.05)	increase	in	fold	activation	 over	 WT	 as	 determined	 by	 a	 two-sided	 T-test.	 In	 part	 (D)	 *	 indicates	 a	statistically	significant	(p<0.05)	difference	in	fold	activation	between	the	two	strains	tested	as	determined	by	a	two-sided	T-test.				
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improvements	in	in	vivo	fold	activation,	going	from	5.2-fold	(±2.1)	for	the	WT	pbuE	STAR	to	7.7-fold	(±2.2)	with	pHP16	(Figure	3.3B).	Interestingly,	the	level	of	increased	activation	did	not	 directly	 correlate	 with	 the	 previously	 reported	 half-lives	 of	 these	 stability	 hairpins	(Carrier	and	Keasling,	1999).	While	pHP14,	pHP16,	and	pHP17	had	been	shown	by	Carrier	and	 Keasling	 (1999)	 to	 confer	 successively	 longer	 half-lives	 (in	 numerical	 order),	 in	 the	context	of	the	pbuE	STAR,	only	pHP16	appeared	to	confer	a	statistically	significant	increase	in	fold	activation.			 To	test	whether	these	hairpins	conferred	stability	in	the	STAR	context,	we	used	RT-qPCR	 (Reverse	 transcription	 quantitative	 polymerase	 chain	 reaction)	 to	 quantify	 the	relative	 degradation	 of	 the	 pHP14,	 pHP16	 and	WT	pbuE	 STAR	variants	 at	 different	 time	points	after	the	addition	of	rifampicin	to	the	media	to	halt	transcription	(see	Appendix	B.3:	Supplemental	 Methods).	 We	 found	 that	 both	 pHP14	 and	 pHP16	 significantly	 reduced	degradation	 of	 pbuE	 compared	 to	 the	WT	 pbuE	 STAR	 (Figure	 B.3)	 indicating	 that	 both	hairpins	do	in	fact	stabilize	the	pbuE	STAR.	To	understand	why	only	modest	levels	of	fold	activation	 increase	 were	 observed	 with	 these	 hairpins,	 we	 used	 computational	 RNA	structure	 modeling	 with	 RNAStructure	 (Reuter	 and	 Mathews,	 2010)	 to	 predict	 the	structures	 of	 the	 pbuE	 STAR	 variant	with	 the	 added	 stability	 hairpins	 (Figure	 B.4).	 This	analysis	showed	that	the	stability	hairpins	could	alter	the	predicted	structure	of	the	pbuE	STAR	RNAs.	This	folding	could	be	enough	to	offset	the	benefits	of	increasing	STAR	stability,	though	in	the	case	of	pHP16	the	benefits	of	stability	outweighed	the	possible	alteration	of	STAR	structure.		 As	an	alternate	method	of	increasing	fold-activation	through	engineering	the	STAR	antisense,	we	tested	adding	sRNA-derived	scaffolds	to	the	3’	end	of	the	STAR,	upstream	of	
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the	 transcriptional	 terminator.	 This	 strategy	was	 based	 upon	 recent	 research	 (Na	 et	 al.,	2013;	Sakai	et	al.,	2013;	Sharma	et	al.,	2012)	showing	that	the	addition	of	sRNA	scaffolds	to	transcriptional	and	translational	synthetic	sRNA	regulators	can	lead	to	improved	function.	Not	only	are	the	scaffolds	theorized	to	stabilize	the	RNA	through	the	addition	of	secondary	structure,	 these	 particular	 sRNA-derived	 scaffolds	 are	 also	 designed	 to	 include	 binding	sites	 for	 the	RNA-binding	chaperone	protein	Hfq.	Among	 its	many	roles,	Hfq	 is	known	to	aid	 sRNA	 function	 by	 mediating	 sRNA	 interactions	 with	 target	 mRNAs	 for	 many	 trans-encoded	sRNAs	that	regulate	 translation	(Møller	et	al.,	2002;	Zhang	et	al.,	2003).	Hfq	can	also	modulate	sRNA	stability	by	affecting	ribonuclease	accessibility	or	susceptibility	 to	3’	polyadenylation	and	subsequent	degradation	(Vogel	and	Luisi,	2011).	To	test	the	ability	of	sRNA	scaffolds	to	increase	fold	activation	for	STAR	regulators,	we	chose	the	MicF,	Dsra1.3	and	Spot42	scaffolds	that	were	previously	shown	to	lead	to	the	greatest	improvements	in	activation	and	repression	 levels	 in	the	RNA	regulators	tested(Sakai	et	al.,	2013).	We	then	fused	 each	 scaffold	 to	 the	 3’	 end	 of	 the	 pbuE	 STAR,	 directly	 before	 the	 transcriptional	terminator	(Figure	3.3A).	Functional	testing	 in	vivo	showed	variable	results	depending	on	the	scaffold	used.	In	particular,	while	the	addition	of	the	Spot42	scaffold	to	the	pbuE	STAR	antisense	 slightly	 increased	 activation,	 both	 MicF	 and	 Dsra1.3	 markedly	 decreased	activation	 levels	 (Figure	 3.3C).	 Structural	 prediction	 with	 RNAStructure	 (Reuter	 and	Mathews,	2010)	 indicated	 that	a	number	of	 the	most	probable	 low-energy	 structures	 for	the	antisense	 fused	with	MicF	or	Dsra1.3	 interfered	with	 the	native	structure	of	both	the	STAR	 antisense	 and	 the	 sRNA	 scaffolds	 (Figure	 B.5).	 	 Thus	 the	 observed	 decrease	 in	activation	 in	 the	 case	 of	 the	MicF	 and	Dsra1.3	 scaffolds	 could	 be	 the	 result	 of	 structural	interference	between	the	scaffold	and	the	STAR.			
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	 While	 the	 Spot42	 variant	 fold	 activation	was	 statistically	 different	 from	 the	 other	two	 scaffold	 variants,	 it	 was	 not	 statistically	 different	 from	 the	 WT	 pbuE	 STAR	 fold	activation.	 Despite	 this,	 we	 did	 confirm	 that	 the	 Spot42	 sRNA	 scaffold	 increased	 STAR	stability	 compared	 to	 the	WT	pbuE	STAR,	 though	not	 as	much	as	 the	pHP14	and	pHP16	stability	hairpins	 (Figure	B.3).	 Since	 it	was	 the	only	 functioning	 scaffold	variant,	we	next	sought	to	test	the	role	of	Hfq	in	the	observed	modest	increase	in	STAR	activation	with	the	Spot42	 scaffold.	 To	 test	 this,	 we	 repeated	 the	 in	 vivo	 functional	 characterization	 of	 the	Spot42	fusions	in	both	the	Keio	collection	Δhfq	knockout	strain	and	its	parent	E.	coli	K-12	BW25113	strain	 (Baba	et	al.,	2006)	 (Figure	3.3D).	We	 found	 that	 the	absence	of	Hfq	had	little	to	no	effect	on	the	wild-type	pbuE	STAR	activation,	as	expected	given	that	the	wild-type	does	not	contain	an	Hfq-recruiting	scaffold	sequence.	Surprisingly,	we	found	that	the	activation	 level	of	 the	pbuE	STAR-Spot42	 fusion	 significantly	 improved	 in	 the	absence	of	Hfq,	in	contrast	to	previous	observations	of	the	reliance	of	sRNA	scaffolds	on	Hfq	for	added	stability	(Sakai	et	al.,	2013).		Next,	we	examined	whether	we	could	increase	fold	activation	further	by	combining	the	 stability	 hairpin	 and	 sRNA	 scaffold	 strategies	 together.	 To	 test	 this,	 we	 created	 all	possible	combinations	of	the	pbuE	STAR	antisense	containing	both	5’	stability	hairpins	and	3’	 sRNA	 scaffolds.	 In	 vivo	 characterization	 indicated	 that	 the	 combination	 of	 the	 Spot42	scaffold	with	either	 the	pHP14	or	pHP16	stability	hairpin	granted	significantly	 improved	activation	over	any	of	the	variants	with	only	hairpin	or	scaffold	(Figure	3.3E).	In	particular,	we	observed	7.2-fold	(±2.1)	activation	for	the	variant	with	both	Spot42	and	pHP14	and	7.2-fold	(±2.0)	activation	for	the	variant	with	Spot42	and	pHP16,	both	significantly	better	than	the	4.8-fold	 (±1.9)	activation	 seen	 for	Spot42	alone,	 though	statistically	 indistinguishable	
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from	 each	 other.	 The	 addition	 of	 both	 a	 5’	 stability	 hairpin	 and	 the	 Spot42	 scaffold	may	alter	 the	 STAR	 structure	 so	 that	 it	 can	 fully	benefit	 from	 the	 stabilization	of	 the	 stability	hairpin	to	increase	overall	fold	activation.	Interestingly,	these	increases	in	fold	activation	are	larger	than	the	improvements	in	transcription	 repression	 seen	 when	 scaffolds	 were	 applied	 to	 the	 pT181	 RNA-based	transcriptional	repressor	(Sakai	et	al.,	2013).	However,	Sakai	et	al.	were	able	to	successfully	use	these	strategies	to	improve	the	fold	activation	of	an	RNA	translational	activator.	These	results	 could	 suggest	 a	more	 general	 principle	 for	 antisense	 RNA	 engineering	 strategies	being	more	effective	 for	gene	expression	activation	or	could	 indicate	 these	strategies	are	more	effective	when	applied	to	relatively	unstructured	antisense	RNAs.	Overall,	 our	 results	 showed	 that	 the	 incremental	 improvements	 in	 fold	 activation	generated	by	the	addition	of	5’	stability	hairpins	and	3’	scaffolds	alone	can	be	combined	to	generate	 STARs	 with	 even	 higher	 fold	 activation.	 However,	 more	 work	 is	 needed	 to	uncover	 the	 structural	 basis	 of	 non-functioning	 variants,	 as	well	 as	 the	 synergistic	 effect	among	the	functional	variants	in	order	to	make	this	strategy	more	predictable.	
	
3.4.4	 A	general	method	for	increasing	STAR	activation	by	combining	expression	level	
tuning	and	RNA	engineering	strategies		We	 subsequently	 investigated	 whether	 combining	 expression	 level	 tuning	 and	 RNA	engineering	strategies	could	be	used	to	further	optimize	fold	activation	for	the	pbuE	STAR.	To	 do	 this,	 we	 combined	 the	 Spot42/pHP14	 pbuE	 antisense	 variant	 together	 with	 the	weakened	 promoter	 strength	 series	 on	 the	 sense	 target	 RNA.	 Combining	 the	 stabilized	STARs	 with	 the	 weaker	 promoter	 sense	 target	 plasmids	 yielded	 another	 increase	 in	
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activation	 level,	 reaching	 as	 high	 13.4-fold	 (±3.8)	 activation	 in	 the	 case	 of	 the	 Spot42	pHP14	antisense	combined	with	the	sense	target	plasmid	containing	the	J23151	promoter	(Figure	 3.4A).	 While	 the	 general	 trend	 was	 toward	 higher	 fold	 activation	 with	 weaker	promoters,	 there	 was	 high	 error,	 and	 the	 trend	 was	 less	 uniform	 than	 seen	 previously,	though	 the	 differences	 between	 the	 J23151	 variant	 and	 all	 others	 were	 statistically	significant.	 Nevertheless,	 the	 higher	 fold	 activation	 seen	 from	 combining	 the	 optimized	pbuE	STAR	with	weaker	sense	target	promoters	indicates	that	RNA	engineering	strategies	can	be	combined	with	expression	tuning	to	increase	fold	activation.	Having	successfully	optimized	the	pbuE	transcriptional	activator	from	its	initial	5.3-fold	 (±2.2)	 activation	 level	 to	 13.4-fold	 (±3.8)	 activation,	 we	 next	 sought	 to	 test	 the	generality	of	this	combined	method	for	improving	STAR	fold	activation.	We	started	with	a	previously	constructed	STAR	generated	from	the	prgX	conjugation	control	system	(Weaver,	2007)	that	only	displayed	a	2.1-fold	(±0.4)	activation	(Chappell	et	al.,	2015)	(Figure	3.4B).	In	particular,	we	applied	the	same	5’	stability	hairpins	as	used	above	and	the	Spot42	sRNA	scaffold	to	the	prgX	STAR.	In	vivo	testing	revealed	that	while	some	of	the	hairpin	additions	modestly	improved	fold	activation	(Figure	3.4B),	the	addition	of	the	Spot42	scaffold	did	not	(Figure	 B.6).	 When	 combined	 with	 weaker	 sense	 target	 promoters,	 the	 best	 prgX	 STAR	variant	 (pHP14)	 had	 an	 even	 greater	 increase	 in	 fold	 activation	 (Figure	 3.4C),	 providing	further	proof	of	 the	modularity	of	 the	strategies	 for	modifying	sense	promoter	and	STAR	antisense	 stability.	 Overall,	 the	 best	 prgX	 variant	 displayed	 14.6-fold	 (±3.7)	 activation,	 a	vast	 improvement	 from	 the	 original	 2.1-fold	 (±0.5)	 activation	 and	 a	 validation	 that	 the	optimization	strategies	work	on	an	additional,	unrelated	STAR	system.		
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Figure	 3.4	 Combining	 expression	 level	 tuning	 and	RNA	 engineering	 strategies	 improves	STAR	fold	activation	in	multiple	systems.	Data	is	plotted	as	in	Figure	3.2.	(A)	Combining	the	pbuE	STAR	antisense	fused	with	the	Spot42	scaffold	and	the	pHP16	stability	hairpin	with	weaker	 target	 sense	 promoters	 yields	 up	 to	 13.4-fold	 (±2.0)	 activation	 for	 the	 J23151	promoter	 pairing.	 (B)	 5’	 stability	 hairpins	 slightly	 improve	 fold	 activation	 for	 the	 prgX	STAR	regulator.	(C)	Combining	the	prgX	STAR	fused	with	the	pHP14	stability	hairpin	with	weaker	 strength	 target	 promoters	 yields	 another	 boost	 in	 fold	 activation,	 showing	 the	broader	applicability	of	 these	STAR	optimization	strategies.	Wild-type	(WT)	 indicates	 the	initial	pbuE	STAR	regulator	in	part	(A)	and	the	initial	prgX	STAR	regulator	in	part	(B)	and	
(C),	 both	 of	 which	 use	 the	 strong	 J23119	 SpeI	 promoter	 to	 drive	 both	 STAR	 and	 target	RNAs.	The	*	indicates	a	statistically	significant	(p<0.05)	increase	in	fold	activation	over	WT,	as	determined	by	a	two-sided	T-test.		
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3.4.5	 Testing	 the	 orthogonality	 of	 optimized	 STARs	 to	 each	 other	 and	 to	 RNA	
transcriptional	repressors	We	next	sought	to	test	whether	the	best	variants	of	our	two	newly	optimized	STARs	were	orthogonal	 to	 the	 previously	 reported	 ribA	 STAR	 (Chappell	 et	 al.,	 2015)	 and	 three	previously	developed	transcriptional	repressors	(Lucks	et	al.,	2011;	Takahashi	and	Lucks,	2013).	If	two	regulators	are	orthogonal,	then	the	antisense	of	one	should	not	regulate	the	sense	 target	 RNA	 of	 the	 other	 (and	 vice	 versa),	 allowing	 them	 to	 be	 used	 together	 in	 a	complex	regulatory	system	without	cross-talk.	Such	orthogonality	is	non-trivial,	especially	given	that	the	inclusion	of	additional	RNA	sequence	within	the	optimized	STARs	increases	the	 potential	 for	 off-target	 interactions,	 as	 does	 increasing	 the	 concentration	 ratios	 of	STARs	to	 their	 targets.	Moreover,	orthogonality	of	 these	component	parts	 is	key	 for	 their	use	in	the	higher-order	logic	gates	and	circuits	that	STARs	and	transcriptional	repressors	have	been	used	to	construct	(Chappell	et	al.,	2015;	Lucks	et	al.,	2011;	Takahashi	and	Lucks,	2013).	For	example,	the	ability	to	build	circuits	using	orthogonal	elements	allows	synthetic	biologists	to	program	systems	with	complex	functionalities	like	ligand-sensitive	NOR	gates	(Qi	et	al.,	2012b)	and	RNA	cascades	that	control	the	timing	of	gene	expression	(Takahashi	et	al.,	2014),	a	vital	capability	for	biotechnology	applications.	To	 perform	 the	 orthogonality	 test,	 we	 challenged	 each	 optimized	 STAR	 antisense	variant	 against	 the	 sense	 targets	 from	 the	 pbuE	 and	 prgX	 systems	 (using	 the	 J23151	promoter),	along	with	the	sense	target	from	the	previously	reported	ribA	STAR	(Chappell	et	 al.,	 2013).	We	 also	 checked	 for	 orthogonality	 to	 sense	 target	 regions	 from	 three	 RNA	transcriptional	repressors:	pT181.H1	from	Lucks	et	al.	(2011),	Fusion	4,	and	Fusion	6	from	
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Takahashi	 and	 Lucks	 (2013).	 As	 a	 further	 test,	 we	 challenged	 each	 RNA	 transcriptional	repressor	 antisense	 variant	 against	 the	 same	 set	 of	 sense	 targets.	 This	 resulted	 in	 a	 6x6	matrix	of	conditions	demonstrating	the	observed	orthogonality	of	these	regulators	to	one	another	 (Figure	 3.5,	 Figure	B.7).	 Both	 of	 the	 newly	 optimized	 STARs	 showed	 reasonable	orthogonality	 to	 the	 other	 regulators.	We	 did	 observe	 that	 the	 only	 off-target	 activation	was	 between	 the	 pbuE	 STAR	 antisense	 and	 the	 prgX,	 ribA	 and	 pT181.H1	 sense	 targets,	though	 this	 effect	 was	 well	 below	 the	 activation	 seen	 with	 its	 cognate	 target,	 and	 was	associated	 with	 high	 experimental	 variability	 (Figure	 B.7).	 More	 work	 is	 needed	 to	understand	 the	 nature	 of	 the	 transient	 interactions	 that	may	 occur	 between	 STARs	 and	their	 potential	 targets	 during	 the	 dynamic	 process	 of	 transcription	 to	 understand	 this	effect.	 These	results	confirm	that	these	STAR	optimization	strategies	largely	do	not	affect	the	orthogonality	of	 STARs	between	 themselves	 and	RNA	 transcriptional	 repressors.	Not	only	will	the	addition	of	new	orthogonal	STARs	allow	for	more	complex	RNA	circuitry,	the	optimization	 strategies	 used	 to	 improve	 STAR	 activation	 will	 allow	 for	 the	 future	development	of	more	highly	functional	RNA	transcriptional	activators.									
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Figure	 3.5	 Testing	 the	 orthogonality	 of	 improved	 STAR	 regulators	with	 each	 other	 and	with	 RNA	 transcriptional	 repressors.	 	 Characterization	 of	 a	 6	 x	 6	 orthogonality	 matrix	consisting	of	the	newly	optimized	pbuE	and	prgX	STAR	regulators,	the	previously	reported	ribA	 STAR	 regulator	 (Chappell	 et	 al.,	 2015),	 the	 pT181.H1	 repressor	 (Lucks	 et	 al.,	 2011)	and	 Fusion	 4	 and	 Fusion	 6	 transcriptional	 repressors	 reported	 by	 Takahashi	 and	 Lucks	(2013).	Each	matrix	square	represents	the	fold	change	of	gene	expression	for	the	indicated	combination	of	STAR	or	repressor	plasmid	and	target	plasmid,	compared	to	the	condition	with	 target	 plasmid	 and	 an	 empty	 no-antisense	 control	 plasmid.	 	 Fluorescence	characterization	 (measured	 in	 units	 of	 Fluorescence/OD,	 fluorescence	 divided	 by	 optical	density	at	600	nm)	was	used	 to	calculate	average	 fold	change,	which	 is	 represented	by	a	color	scale	in	which	≥	10-fold	is	the	darkest	blue	(activation),	1-fold	is	white	(no	activation	or	 repression)	 and	 -5-fold	 is	 red	 (repression).	 Fluorescence/OD	plots	 for	 each	 individual	combination	 are	 shown	 in	 Figure	 B.7.	 Data	 represents	 mean	 values	 of	 n	 =	 9	 biological	replicates.							
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3.5	 Conclusions	In	 this	 work,	 we	 tested	 several	 RNA	 engineering	 strategies	 for	 optimizing	 the	 fold	activation	 of	 small	 transcription	 activating	 RNAs.	 In	 particular,	we	 focused	 on	 strategies	designed	 to	stabilize	and	 improve	 the	STAR	antisense	design	and	alter	 the	concentration	ratio	between	the	STAR	and	its	target.	Using	the	pbuE	STAR	as	a	test	case,	we	showed	that	the	addition	of	5’	stability	hairpins	and	sRNA	scaffolds	to	the	STAR	antisense	and	the	ability	to	 adjust	 the	 ratio	 of	 STAR	 antisense	 to	 target	 sense	 via	 promoter	 strength	 tuning	 gave	convenient	and	sometimes	modular	ways	to	alter	the	transcription	activation	levels	of	two	distinct	STAR	systems.	Specifically,	we	 found	that	 these	strategies	as	applied	 to	 the	pbuE	STAR	 system	 increased	 the	 fold	 activation	 from	 5.3-fold	 (±2.2)	 to	 13.4-fold	 (±3.8).	Moreover,	 we	 showed	 that	 these	 strategies	 were	 general	 and,	 when	 applied	 to	 the	unrelated	prgX	STAR	regulator,	yielded	an	increase	in	transcription	activation	from	2.1-fold	(±0.4)	 to	14.6-fold	 (±3.7).	Furthermore,	we	showed	 that	 these	 changes	 largely	preserved	the	 orthogonality	 of	 the	 optimized	 STARs	 to	 each	 other	 and	 to	 a	 panel	 of	 RNA	transcriptional	 repressors	 that	 have	 been	 used	 to	 construct	 higher-order	 RNA	transcriptional	circuits	(Chappell	et	al.,	2015;	Lucks	et	al.,	2011).	These	 results	 are	 significant	 for	 several	 reasons.	 First,	 these	 optimizations	 have	expanded	the	repertoire	of	STARs	-	the	starting	point	fold	activations	for	the	pbuE	and	prgX	STAR	 regulators	 prohibited	 their	 use	 for	 higher	 order	 circuit	 construction,	 a	 problem	remedied	by	our	optimizations.	Second,	the	optimization	strategies	used	on	the	pbuE	and	prgX	 systems	 should	be	applicable	 to	many	other	STARs,	paving	 the	way	 for	 even	 larger	libraries	 of	 RNA	 regulators.	 Finally,	 the	 demonstrated	 orthogonality	 between	 the	 newly	
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optimized	activators	and	previously	reported	regulators,	in	addition	to	representing	a	non-trivial	achievement,	makes	them	highly	useful	for	future	circuit-building.	It	should	be	noted	that	the	majority	of	the	improvement	in	STAR	fold	activation	was	achieved	through	decreasing	the	OFF	level.	If	a	high	ON	level	were	required	for	a	particular	application,	other	strategies	could	be	used	to	increase	ON	levels	while	maintaining	low	OFF	levels.	For	 instance,	 if	high	protein	expression	were	desired,	modular	strategies	aimed	at	tuning	translation	through	altering	ribosome	binding	site	strength	and	accessibility	could	be	 used	 as	 an	 alternate	 way	 of	 manipulating	 target	 gene	 expression	 levels	 (Salis	 et	 al.,	2009).	In	 addition	 to	 optimizing	 STAR	 fold	 activation,	 the	 tested	 strategies	 have	 led	 to	 a	series	of	STARs	with	varying	ON,	OFF	and	fold	activation	levels.	These	strategies	have	thus	created	a	panel	of	variants	that	can	be	used	for	fine-tuning	of	transcription	activation.	The	importance	 of	 fine-tuning	 individual	 regulators	 to	 enable	 the	 correct	 performance	 of	 a	larger	circuit	has	been	demonstrated	 in	numerous	examples	of	synthetic	circuits	 (Ellis	et	al.,	2009;	Elowitz	and	Leibler,	2000;	Wang	et	al.,	2009),	making	the	suite	of	functional	STAR	variants	 a	 useful	 library	 to	 draw	 from	 for	 future	 circuit	 design.	 Strategies	 like	 these	 are	becoming	 more	 important	 as	 synthetic	 biology	 looks	 to	 implement	 increasingly	sophisticated	genetic	circuitry,	requiring	the	ability	to	carefully	tune	the	biological	circuit	components.		In	summary,	we	have	successfully	expanded	our	capabilities	 for	genetic	regulation	and	 made	 highly	 useful	 additions	 to	 the	 synthetic	 biology	 toolkit	 through	 systematic	optimizations	of	a	set	of	small	transcription	activating	RNAs.	These	newly-improved	STAR	regulators	will	allow	for	the	construction	of	complex	cellular	circuitry,	and	the	optimization	
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strategies	will	be	highly	useful	 for	 creating	a	generation	of	 additional	STARs	 for	use	 in	a	broad	range	of	biotechnologies.	
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CHAPTER	4	
ENGINEERING	LIGAND-RESPONSIVE	RNA	ACTIVATORS		
4.1	 Abstract	Generating	biological	circuits	capable	of	sensing	their	environment	is	one	of	the	key	goals	of	synthetic	biology.	With	this	 in	mind,	 I	sought	 to	expand	upon	our	previous	work	developing	 small	 transcription	activating	RNAs	 (STARs)	 (see	Chapter	3)	by	making	 them	responsive	 to	externally	 supplied	 ligands	 through	 fusion	 to	an	RNA	aptamer	domain.	We	engineered	 these	 candidate	 “aptaSTARs”	 through	 a	 variety	 of	 strategies,	 including	randomized	screening	and	computational	design,	eventually	 isolating	a	handful	of	 ligand-sensitive	 variants	 that	 demonstrate	 2	 to	 3-fold	 activation	 in	 response	 to	 the	 presence	 of	ligand.	Although	many	applications	may	require	greater	fold	activation,	these	preliminary	results	demonstrate	the	feasibility	of	the	aptaSTAR	concept	and	re-affirm	the	flexibility	of	RNA	regulation.		
4.2	 Introduction		Natural	 and	artificial	RNA	 regulators	offer	 synthetic	biologists	 important	 tools	 for	manipulating	gene	expression,	allowing	the	construction	of	biological	circuitry	with	lower	metabolic	burden	than	circuits	built	from	protein	regulators.	The	recent	advent	(Chappell	et	al.,	2015)	and	optimization	 (Meyer	et	al.,	2016)	of	 small	 transcription	activating	RNAs	(STARs)	filled	a	gap	in	the	suite	of	naturally-occurring	regulators	by	generating	small	RNAs	that	 activate	 transcription	 in	 trans,	 thus	 further	 expanding	 the	 regulatory	 capabilities	 of	RNA.	Now	we	seek	to	take	these	STARs	one	step	further	and	make	them	ligand-responsive	
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by	 fusing	 them	 to	 RNA	 aptamers,	 segments	 of	 RNA	 that	 bind	 a	 particular	 target	 ligand.		These	 newly	 created	 “aptaSTAR”	 fusions	 will	 allow	 for	 greater	 complexity	 and	responsiveness	in	RNA-only	circuitry.	Of	course,	ligand-sensing	RNAs	in	the	form	of	natural	and	synthetic	riboswitches	are	already	 well	 represented	 in	 the	 literature	 (Chappell	 et	 al.,	 2013;	 Winkler	 and	 Breaker,	2005).	The	wide-spread	occurrence	of	 riboswitches	within	bacterial	genomes	(Kim	et	al.,	2015;	Mandal	and	Breaker,	2004;	Mandal	et	al.,	2004;	Serganov	et	al.,	2006)	underscores	the	importance	and	utility	of	linking	gene	expression	to	the	surrounding	environment,	and	the	 engineering	 of	 synthetic	 riboswitches	 has	 also	 been	 a	 topic	 of	 active	 research	 in	 the	synthetic	biology	community	(Borujeni	et	al.,	2015;	Ceres	et	al.,	2013a;	Lynch	and	Gallivan,	2009;	Mishler	and	Gallivan,	2014).	Work	by	Ceres	et	al.	(2013a,	2013b)	generated	synthetic	riboswitches	 by	 combining	 naturally	 occurring	 riboswitch	 expression	 platforms	 with	alternate	 aptamer	 domains	 in	 a	 carefully-designed	 manner,	 while	 other	 research	 has	focused	 on	 isolating	 functional	 riboswitches	 by	 screening	 vast	 libraries	 of	 potential	sequences	in	which	key	linker	regions	were	varied	to	allow	for	ligand-mediated	structural	transitions	(Lynch	and	Gallivan,	2009;	Lynch	et	al.,	2007).	AptaSTARs	would	 add	 to	 this	 pre-existing	 toolbox	 of	 small-molecule	 sensors	 and	even	 allow	 for	 more	 complex	 circuit	 construction—because	 aptaSTARs	 act	 in	 trans	 and	depend	upon	the	presence	of	two	elements	(ligand	and	aptaSTAR)	in	order	to	activate	the	target	gene,	they	allow	for	higher-level	conditional	control.	AptaSTAR-based	circuits	could	tie	the	transcription	of	 the	aptaSTAR	itself	 to	an	 independent	contingency	apart	 from	the	presence	of	ligand,	allowing	for	the	creation	of	AND	gates	and	other	logical	operators.		 In	our	efforts	to	engineer	aptaSTARs,	we	relied	on	a	number	of	different	strategies—	
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ranging	 from	 rational	 and	 computational	 design	 to	 the	 screening	 of	 carefully	 designed	randomized	libraries—and	sought	to	develop	aptaSTARs	with	a	number	of	different	ligand	specificities.	 The	 preliminary	 work	 presented	 here	 demonstrates	 the	 development	 of	aptaSTARs	 with	 reasonable	 activation	 in	 response	 to	 the	 presence	 of	 external	 ligand,	providing	proof-of-concept	for	the	construction	of	ligand-sensing	STARs.			
4.3	 Results	
4.3.1	 Rational	design	of	a	theophylline-sensitive	RNA	activator		 My	 initial	 attempts	 at	 aptaSTAR	 design	 used	 the	 well-characterized	 theophylline	aptamer,	which	has	proved	amenable	to	engineering	in	the	past	(Qi	et	al.,	2012;	Stojanovic	and	Kolpashchikov,	 2004;	Wachsmuth	 et	 al.,	 2013).	 In	 addition	 to	 being	highly	 selective,	
	
Figure	4.1	Schematic	of	a	designed	pseudoknot	aptaSTAR.	In	the	absence	of	theophylline,	a	designed	pseudoknot	forms	between	the	theophylline	aptamer	and	STAR	anti-terminator,	but	theophylline	binding	disrupts	the	pseudoknot,	freeing	the	STAR	for	trans-activation	of	its	sense	target	RNA.	
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easily	discriminating	between	theophylline	and	its	close	analog,	caffeine,	the	theophylline	aptamer	 binds	 theophylline	 through	 interactions	 with	 nucleotides	 within	 an	 inner	 loop	region	in	its	stem-loop	structure	(Figure	C.1),	leaving	the	loop	region	free	for	engineering	without	 affecting	 the	 aptamer’s	 affinity	 for	 theophylline	 (Zimmermann	 et	 al.,	 1997).	Exploiting	 this	 loop	sequence	 flexibility	 in	a	manner	 following	work	by	Qi	et	al.	 (2012),	 I	designed	a	series	of	potential	aptaSTARs	 in	which	the	theophylline	aptamer	was	 fused	to	either	 the	 3’	 or	 5’	 end	 of	 the	 STAR	 antisense,	 with	 a	 designed	 pseudoknot	 between	 the	aptamer	 loop	 region	 and	 a	 13-nucleotide	 section	 of	 the	 STAR	antisense	 (see	 Figure	4.1).	The	 library	of	aptaSTARs	was	designed	so	 that	 the	13-nucleotide	window	of	 interference	was	walked	along	the	length	of	the	STAR	anti-terminator,	generating	24	potential	designs		
	
Figure	4.2	In	vivo	testing	of	theophylline	aptaSTARs	with	designed	5’	pseudoknot.	OFF	and	ON	 show	 the	 behavior	 of	 the	 original	 pT181	 STAR	 system	 without	 and	 with	 STAR	antisense,	 respectively,	 and	 CTRL	 denotes	 a	 previously-reported	 theophylline-sensitive	repressor.	AptaSTAR	variants	1-12	are	designed	 so	 that	 the	pseudoknot	binding	 location	progresses	along	the	STAR	anti-terminator	region	from	3’	to	5’.	
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based	on	the	particular	pT181-based	STAR	used	as	a	starting	point.	The	 potential	 theophylline	 aptaSTARs	 were	 tested	 in	 vivo	 alongside	 the	 original	pT181-based	 STAR	 and	 the	 control	 theophylline-sensitive	 repressor	 previously	 reported	by	Qi	et	al.	(2012)	to	assay	theophylline-sensitive	activation.	However,	as	shown	in	Figure	4.2,	aptaSTARs	with	the	designed	5’	pseudoknot	failed	to	activate	even	in	the	presence	of	2	mM	theophylline,	and	the	same	proved	true	of	the	other	designs	tested.	 It	seems	that	the	STAR	 anti-terminator	 is	 particularly	 sensitive	 to	 structural	 interference	 and	 that	 the	pseudoknotted	interaction	was	too	strong	to	be	easily	disrupted	by	ligand	binding,	leaving	the	 STAR	 in	 an	 interfered	 state	 and	 unable	 to	 activate	 transcription.	 Faced	 with	 the	difficulty	 of	 rationally	 designing	 an	 interaction	 of	 the	 optimal	 strength	 to	 interfere	with	STAR	function,	yet	be	easily	disrupted	by	ligand	binding,	I	turned	to	functional	screening	as	a	way	to	test	a	larger	potential	sequence	space.		
4.3.2	 Screening	for	a	theophylline-sensitive	RNA	activator		 Taking	 my	 cues	 from	 previous	 work	 demonstrating	 the	 use	 of	 high	 through-put	screening	 to	 identify	 a	 synthetic	 translational	 riboswitch	 (Lynch	 et	 al.,	 2007),	 I	experimented	with	using	a	randomized	transducer	to	provide	sequence	flexibility	for	signal	propagation	 from	 the	 theophylline	 aptamer	 to	 the	 STAR	 antisense.	 In	 my	 aptaSTAR	screening	 libraries,	 I	 fused	 the	 theophylline	 aptamer	 to	 previously	 generated	 STARs	(pT181,	pbuE,	and	pAD1)	via	an	11-nucleotide	randomized	 transducer	region	 linking	 the	theophylline	aptamer	to	the	5’	end	of	the	STAR	or	to	the	STAR’s	3’	end	before	the	intrinsic	terminator	 (see	 Figure	 4.3).	 I	 then	 subjected	 these	 randomized	 libraries	 to	 functional	fluorescence	screening,	picking	individual	colonies	from	bacteria	transformed	with	the	ran-	
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Figure	4.3	Screening	for	a	theophylline-sensitive	aptaSTAR.	The	theophylline	aptamer	was	connected	 to	 a	 STAR	 via	 a	 randomized	 transducer	 region,	 and	 the	 resultant	 aptaSTAR	library	 was	 then	 screened	 for	 functionality	 using	 a	 96-well	 plate	 fluorescence	 assay	 to	compare	activation	with	and	without	theophylline.		domized	 aptaSTAR	 library	 and	 the	 sense	 plasmid	 containing	 SFGFP	under	 control	 of	 the	target	 transcriptional	 terminator.	 The	 colonies	 were	 then	 grown	 with	 and	 without	theophylline	and	assayed	 for	normalized	 fluorescence	alongside	wild-type	STAR	controls	and	a	known	theophylline-responsive	repressor,	previously	reported	by	Qi	et	al.	(2012).		During	the	screening	of	~1600	colonies	from	the	variously	constructed	libraries,	a	number	 of	 variants	 showed	modest	 levels	 of	 activation	 in	 response	 to	 theophylline.	 The	best	variant,	isolated	from	the	library	with	the	theophylline	aptamer	linked	to	the	5’	end	of	the	 pbuE	 STAR	 with	 pHP17	 stability	 hairpin,	 gave	 2.7-fold	 activation	 in	 response	 to	
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theophylline	 (Figure	 4.4),	 demonstrating	 that	 screening	 a	 randomized	 library	 can	successfully	generate	a	theophylline-sensitive	aptaSTAR.	
	
	
Figure	 4.4	 Theophylline	 sensitivity	 of	 an	 aptaSTAR	 variant.	 Upper	 graph	 shows	 fold	change	 of	 fluorescence	 in	 response	 to	 2	 mM	 theophylline,	 while	 lower	 graph	 shows	fluorescence	 values	 for	 tested	 aptaSTAR	 variant	 D1:D10	 in	 comparison	 to	 the	WT	 STAR	system	in	its	ON	and	OFF	states	and	a	theophylline-sensitive	repressor.			
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4.3.3	 Computational	design	of	theophylline-responsive	RNA	activators		 While	the	randomized	screening	approach	succeeded	in	generating	a	theophylline-sensitive	aptaSTAR	based	on	the	pbuE	STAR,	it	yielded	no	hits	for	aptaSTARs	based	on	the	more	highly-activating	STARs	 like	pAD1	and	pT181.	 In	an	effort	 to	generate	more	highly	activating	aptaSTARs,	we	turned	once	more	to	rational	design.	This	time	we	pursued	a	new	strategy	based	on	computational	prediction	of	probable	RNA	folding	states	in	order	to	take	into	account	the	relative	stabilities	of	the	ON	and	OFF	states	and	allow	for	proper	switching	(unlike	my	 first	 attempts	 at	 rational	design).	 In	 collaboration	with	Howard	Salis	 of	Penn	State,	we	sought	to	engineer	ligand	sensitivity	using	thermodynamic	calculations	to	predict	the	ideal	sequence	for	our	aptaSTARs.	The	approach	had	been	previously	validated	in	the	design	 of	 synthetic	 riboswitches	 using	 calculated	 free	 energies	 of	 ribosome-binding	 to	generate	riboswitch	variants	predicted	to	correctly	switch	between	ON	and	OFF	states	 in	response	 to	 a	 target	 ligand	 (Borujeni	 et	 al.,	 2015).	 In	 this	 case,	 we	 sought	 to	 generate	aptaSTAR	variants	where	the	binding	of	theophylline	would	trigger	STAR	re-folding	into	a	form	favored	to	bind	 its	sense	target.	Thermodynamic	calculations	were	used	to	evaluate	potential	 linker	 sequences	 (up	 to	 30	 nucleotides	 in	 length)	 to	 connect	 the	 STAR	 to	 the	aptamer	 so	 as	 to	 maximize	 switching	 between	 the	 ON	 and	 OFF	 states	 in	 response	 to	theophylline.	 The	 energy	 states	 under	 consideration	 in	 the	 design	 are	 schematized	 in	Figure	4.5.	The	goal	 for	 generating	potential	 aptaSTARs	was	 to	 find	designs	predicted	 to	have	 both	 a	 large	 free	 energy	 differences	 between	 the	 energy	 associated	 with	 anti-termination	in	the	presence	and	absence	of	theophylline,	in	order	to	encourage	switching	
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Figure	 4.5	 AptaSTAR	 energy	 states	 for	 computational	 design.	 State	 (1)	 represents	 the	minimum	free	energy	(MFE)	fold	for	the	unconstrained	STAR	with	free	energy	dGref,	while	state	(2)	with	energy	dG2	represents	the	aptaSTAR	when	the	STAR	anti-terminator	portion	is	 constrained	 to	 be	 single-stranded	 (S.S.).	 The	 aptaSTAR	 with	 the	 aptamer	 domain	constrained	to	its	ligand-binding	fold	is	state	(3),	with	energy	dG3,	and	state	(4)	refers	to	the	aptaSTAR	with	both	STAR	and	aptamer	constrained,	yielding	free	energy	dG4.	The	free	energy	differences	ddG(+A),	ddG(+L),	ddG(+T),	and	ddG(+H)	refer	respectively	to	the	free	energy	 changes	 associated	 with	 forming	 the	 anti-terminating	 STAR	 structure,	 ligand-binding,	 switching	 to	 the	 theophylline-bound	 state,	 and	 hybridizing	 to	 the	 target	 sense	RNA.	 The	 computational	 algorithm	 generated	 designs	 that	 maximized	 the	 difference	between	 ddG(+T+A)	 and	 ddG(+A)	 in	 order	 to	 encourage	 switching	 between	 states	 in	response	to	theophylline.	
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between	 OFF	 and	 ON	 states,	 and	 thermodynamically	 favorable	 anti-termination	 in	 the	presence	 of	 theophylline.	 The	 computational	methods	 applied	 by	 Dr.	 Salis	 were	 used	 to	generate	large	libraries	of	potential	aptaSTAR	designs	based	on	the	pT181,	pAD1,	and	ribA	STARs	previously	reported	(Chappell	et	al.,	2015).			 From	 these	 libraries	 were	 picked	 a	 range	 of	 potential	 designs	 with	 equal	 energy	gaps	between	anti-termination	states	with	and	without	theophylline,	but	with	varying	ddG	values	and	universally	favorable	(negative)	ddG	values	for	the	energy	of	anti-termination	in	the	presence	of	theophylline.	The	potential	aptaSTARs	were	then	cloned	and	tested	in	vivo	with	varying	 levels	of	 theophylline	from	0	μM	to	1000	μM	alongside	the	WT	ON	and	OFF	controls	 as	well	 as	a	non-cognate	STAR	control	 (Figure	4.6).	While	 the	 tested	aptaSTARs	based	 on	 the	 pAD1	 and	 ribA	 STARs	 showed	 little	 theophylline	 responsiveness,	 with	 all	variants	activating	SFGFP	production	regardless	of	theophylline	concentration,	a	few	of	the	designed	 pT181	 variants	 did	 show	 theophylline	 sensitivity	 (Figure	 4.6A),	 demonstrating	increasing	levels	of	activation	in	the	presence	of	increasing	levels	of	theophylline	that	were	confirmed	 by	 follow-up	 experiment	 (Figure	 C.2),	 with	 the	 best	 variant	 (design	 821)	showing	3-fold	activation	in	response	to	1	mM	theophylline.		 Seeking	to	reach	aptaSTAR	activation	levels	more	closely	matching	the	greater	than	50-fold	 activation	 seen	 by	 original	 pAD1	 STAR,	 we	 generated	 another	 set	 of	 potential	aptaSTARs	where	the	computationally	designed	linker	sequence	was	allowed	to	extend	to	60	nucleotides	(as	opposed	to	30	nucleotides	previously).	Our	hypothesis	was	that	a	longer	linker	sequence	would	allow	for	more	base-pair	interactions	to	stabilize	the	interference	of	the	STAR	antisense—allowing	 for	a	 lower	OFF	 level	and	higher	 fold-activation.	However,	the	resulting	designs	showed	little	theophylline	sensitivity	and	high	levels	of	activation	in	
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Figure	4.6	Testing	computationally	designed	aptaSTARs.	AptaSTARs	based	on	the	pT181,	pAD1,	and	ribA	systems	were	tested	for	theophylline	sensitivity	in	vivo	with	concentrations	of	 theophylline	ranging	 from	0	to	1000	μM	alongside	the	WT	type	system	in	the	OFF	(no	antisense)	and	ON	(with	STAR	antisense)	states	and	with	a	non-cognate	STAR	control.		
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the	 absence	 of	 theophylline	 (Figure	 C.3),	 indicating	 that	 the	 linker	 sequence	 did	 not	correctly	interfere	with	the	STAR	antisense.	Regardless,	the	previous	results	had	validated	the	 possibility	 of	 generating	 functional	 aptaSTARs	 via	 computation,	 although	 the	 uneven	success	of	the	designs	indicates	an	imperfect	model	for	predicting	the	energy	states	and	the	switching	between	them.		
4.3.4	 Alternate	 approaches:	 designing	 RNA	 activators	 responsive	 to	 MS2	 coat	
protein	and	fluoride	Having	 shown	 the	 potential	 to	 generate	 theophylline-sensitive	 aptaSTARs,	 we	turned	our	attention	toward	creating	aptaSTARs	able	to	sense	alternative	ligands	in	order	to	allow	for	multi-input	circuits.	The	ligands	I	chose	as	targets	were	the	fluoride	ion	and	the	phage	MS2	 coat	 protein,	 both	 of	which	have	highly	 specific,	well-characterized	 aptamers	with	sequence	flexibility	to	allow	for	fusion	engineering.	The	fluoride	aptamer	(Figure	C.4),	derived	 from	 a	 family	 of	 homologous	 bacterial	 riboswitches	 (Baker	 et	 al.,	 2012),	 has	 a	bulge-stem	structure	with	a	conserved	pseudoknot	that	generates	a	ligand-binding	pocket	where	 the	 fluoride	 ion	 is	 coordinated	 by	 a	 trio	 of	 hydrated	magnesium	 ions	 (Ren	 et	 al.,	2012).	 However,	 the	 bulge/loop	 portion	 of	 the	 aptamer	 show	 great	 variability	 between	different	 riboswitch	 variants	 (Baker	 et	 al.,	 2012),	 offering	 an	 attractive	 opportunity	 for	engineering	 alternate	 sequence	 interactions	 in	 an	 aptaSTAR	 context.	 The	 MS2	 aptamer	from	the	bacteriophage	MS2	binds	its	target,	the	coat	protein	that	forms	the	viral	capsid,	at	the	top	of	a	stem-loop	structure	(Convery	et	al.,	1998),	allowing	for	sequence	variation	in	the	hairpin	base	in	previously	engineered	variants	(Qi	et	al.,	2012).	
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To	 design	 the	 fluoride	 aptaSTAR,	 I	 used	 the	 T.	 petrophila	 variant	 of	 the	 fluoride	aptamer,	since	its	crystal	structure	has	been	solved	in	the	context	of	the	fluoride	riboswitch	(Ren	et	al.,	2012),	giving	us	good	insight	into	which	nucleotides	and	interactions	are	most	important	to	maintain.	I	used	a	STAR	variant	based	on	the	pAD1	system	designed	to	bind	its	target	via	a	toe-hold	recognition	region	(unpublished	data)—and	fused	it	to	the	fluoride	aptamer	in	a	manner	predicted	to	bind	the	STAR	anti-terminator	in	the	absence	of	aptamer	stabilization	 by	 fluoride	 binding.	 However,	when	 I	 tested	 its	 function	 in	 vivo	 against	 the	parent	 pAD1	 STAR,	 I	 found	 that	 showed	 no	 better	 response	 to	 fluoride	 than	 the	 parent	STAR	(Figure	4.7).		
	
Figure	4.7	Fluoride	aptaSTAR	testing	in	vivo.	Both	the	parent	STAR	and	designed	aptaSTAR	appear	 to	 show	 fluoride-sensitive	 activation	 in	 response	 to	 fluoride—however,	 this	 is	 an	artifact	 resulting	 from	 the	 greater	 SFGFP	 accumulation	 within	 the	 doubled	 growth	 time	required	to	reach	an	equivalent	OD	in	the	presence	of	fluoride.	
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For	the	MS2	aptaSTARs,	I	used	the	nucleic	acid	design	software	NUPACK	(Zadeh	et	al.,	2010)	to	design	the	MS2	hairpin	so	that	the	3’	half	of	the	hairpin	would	interfere	with	a	portion	of	the	fused	STAR	antisense	while	the	5’	half	of	the	hairpin	varied	in	order	to	keep	
	
Figure	4.8	MS2	hairpin	and	aptaSTAR	fusion	design.	(A)	Structures	of	the	wild-type	MS2	hairpin,	the	MS2	C-variant	previously	reported	to	have	stronger	binding	affinity	(Convery	et	al.,	1998),	and	the	MS2	hairpin	constraints	used	in	NUPACK	design	of	the	MS2	aptaSTAR.	
(B)	Designed	mechanism	of	the	MS2	aptaSTAR—the	3’	side	of	the	MS2	hairpin	is	designed	to	 be	 complementary	 to	 a	 portion	 of	 the	 STAR	 antisense.	 MS2	 protein	 addition	 should	stabilize	the	MS2	aptamer,	freeing	the	STAR	antisense	to	activate	transcription	of	its	target.	
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sequence	 complementarity	 (Figure	 4.8).	 The	 ‘AUCA’	 tetraloop	 and	 the	 single-nucleotide	adenine	 bulge	 on	 the	 5’	 portion	 of	 the	 hairpin	 stem	 were	 maintained	 in	 order	 to	 keep	MS2binding	specificity,	and	the	STAR	antisense	was	the	same	pAD1	STAR	variant	used	in	the	fluoride	aptaSTAR	design.	Seven	different	MS2	aptaSTAR	variants	were	designed	using	this	 strategy,	 each	 intended	 to	 interfere	 with	 a	 slightly	 different	 portion	 of	 the	 STAR	antisense.	The	variants	were	then	tested	for	activation	in	vivo	in	the	presence	and	absence	of	the	MS2	coat	protein,	produced	from	a	separate	plasmid	via	IPTG	induction	(Figure	4.9).		However,	none	of	the	variants	showed	the	appropriate	lack	of	activation	in	the	absence	of	MS2,	 instead	 showing	 activation	 on	 par	with	 the	 control	ON	 state	 regardless	 of	whether	MS2	was	present.	This	lack	of	MS2	responsiveness	indicated	that	the	designed	interference	
	
Figure	 4.9	 MS2	 aptaSTAR	 testing	 in	 vivo.	 Testing	 of	 NUPACK-designed	 MS2	 aptaSTAR	variants	for	MS2-responsive	activation	alongside	the	basis	pAD1	STAR	system	in	its	ON	and	OFF	 states	 indicated	 a	 lack	 of	 MS2	 responsiveness	 rather	 than	 activation	 only	 in	 the	presence	of	MS2.	
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hairpin	 may	 not	 have	 formed	 or	 may	 not	 have	 interfered	 with	 enough	 of	 the	 STAR	antisense	 in	 order	 to	 successfully	 inhibit	 activation.	 Further	 exploration	 is	 required	 to	pinpoint	the	reason	for	the	observed	lack	of	activation	from	this	particular	design	strategy.	
	
4.4	 Conclusions	Despite	the	fact	that	not	all	design	strategies	were	successful,	our	work	resulted	in	the	development	of	a	handful	of	 ligand-responsive	aptaSTARs	and	has	also	demonstrated	multiple	feasible	paths	toward	aptaSTAR	generation,	with	both	randomized	screening	and	computational	 design	 succeeding	 in	 creating	 functional	 aptaSTARs	 with	 great	 potential	applications	 in	genetic	circuitry.	However,	much	research	remains	 to	be	done	 in	order	 to	fully	 elucidate	 the	 underlying	 structural	 mechanism	 of	 aptaSTAR	 switching	 and	 to	understand	why	designs	predicted	to	be	equally	thermodynamically	favorable	have	varying	levels	of	theophylline	sensitivity.			
4.5	 Materials	and	methods	
Plasmid	construction	and	cloning	STAR	 system	 plasmids	 followed	 the	 same	 architecture	 outlined	 in	 Chapter	 3.3	 and	Appendix	B,	with	the	addition	of	aptamer	and	transducer	region	executed	via	iPCR,	except	in	the	case	of	the	MS2	aptaSTAR	plasmids,	which	were	generated	via	Gibson	Assembly.		
Strains,	media,	and	in	vivo	bulk	fluorescence	experiments	All	 cloning	 was	 performed	 in	 E.	 coli	 strain	 NEB	 Turbo	 (F'	 proA+B+	 lacIq	 ∆lacZM15/	
fhuA2	∆(lac-proAB)	glnV	galK16	 galE15	 R(zgb-210::Tn10)TetS	 endA1	 thi-1	 ∆(hsdS-mcrB)5),	
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while	 all	 bulk	 fluorescence	 experiments	 were	 performed	 in	 strain	 TG1	 (F'traD36	 lacIq	
Delta(lacZ)	M15	pro	A+B+/supE	Delta(hsdM-mcrB)5	 (rk-	mk-	McrB-)	 thi	Delta(lac-proAB)),	with	 the	 exception	 of	 the	 fluoride	 aptaSTAR	 experiments,	 which	were	 performed	 in	 the	CrcB	ion	transporter	knock-out	strain	from	the	Keio	Collection	(Baba	et	al.,	2006),	based	on	strain	 BW25113	 F-	 Δ(araD-araB)567	ΔlacZ4787(::rrnB-3)	 ΔcrcB763::kan	 λ-	 rph-1	Δ(rhaD-
rhaB)568	hsdR514.	Media	preparation	and	bulk	fluorescence	experiments	were	carried	out	as	described	in	Chapter	3.3	with	specific	changes	as	described	below. 
	
Functional	screening	of	theophylline	aptaSTARs	with	randomized	transducer	regions	The	functional	screens	associated	with	section	4.3.2	were	conducted	in	the	same	manner	as	the	 other	 bulk	 fluorescence	 experiments	 from	 Chapter	 3.3,	 but	 with	 duplicate	 96-well	blocks	 inoculated	 for	 the	 subculture	 step:	 one	 with	 chloramphenicol/carbenicillin	 M9	media	 containing	 2	 mM	 theophylline	 and	 one	 with	 chloramphenicol/carbenicillin	 M9	media	 with	 no	 theophylline.	 Each	 well-block	 screened	 also	 included	 one	 colony	 of	 the	previously-reported	theophylline-sensitive	repressor	(Qi	et	al.,	2012)	as	a	positive	control	in	addition	to	the	growth	control	and	the	parent	STAR	system	in	its	ON	and	OFF	states.		
Functional	testing	of	computationally	designed	theophylline	aptaSTARs	The	computationally	designed	aptaSTARs	were	tested	as	above,	but	in	biological	triplicate	(three	separate	colonies	for	each	tested	pair	of	sense	and	antisense)	with	sub-culturing	in	chloramphenicol/carbenicillin	M9	media	containing	0	μM,	1	μM,	10	μM,	100	μM,	and	1000	μM	 theophylline	 taking	 place	 in	 parallel.	 An	 additional	 non-cognate	 STAR	 OFF	 control	
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condition	 was	 also	 tested	 to	 confirm	 that	 transcription	 of	 an	 sRNA	 from	 a	 high-copy	plasmid	did	not	result	in	theophylline	sensitivity.		
Functional	testing	of	fluoride	and	MS2	aptaSTARs	MS2	 aptaSTAR	 testing	 took	 place	 using	 a	 three	 plasmid	 system:	 the	 p15a	 target	plasmid,	the	colE1	aptaSTAR	plasmid,	and	a	BBR1	plasmid	with	lac-inducible	expression	of	the	 MS2	 coat	 protein	 required	 to	 bind	 to	 the	 MS2	 aptamer.	 Two	 versions	 of	 the	 BBR1	plasmid	were	 tested:	one	harboring	a	kanamycin	resistance	gene	and	 the	other	encoding	spectinomycin	resistance.	As	a	result,	the	solid	and	liquid	media	used	had	the	appropriate	triple	antibiotics	(carbenicillin	and	chloramphenicol	as	before	and	100	μg/mL	kanamycin	or	 50	 μg/mL	 spectinomycin),	 and	 the	 in	vivo	 testing	 in	 the	with	MS2	 condition	 included	induction	with	1	mM	IPTG	during	the	sub-culture	phase,	while	the	condition	without	MS2	was	 not	 induced	 with	 IPTG.	 The	 remainder	 of	 the	 procedure	 followed	 the	 previously	reported	in	vivo	testing	protocol	from	Chapter	3.	As	 mentioned	 previously,	 fluoride	 aptaSTAR	 testing	 took	 place	 in	 the	 BW25113	CrcB	 transporter	 knock-out	 from	 the	Keio	 Collection	 in	 order	 to	 avoid	 having	 the	 added	fluoride	 simply	 shuttled	 out	 of	 the	 cell.	 In	 vivo	 testing	 followed	 the	 protocol	 described	previously,	 but	 with	 the	 addition	 of	 0.5	 mM	 NaF	 to	 one	 of	 the	 two	 sub-culture	 blocks.	Moreover,	because	of	the	slow	growth	caused	by	the	presence	of	fluoride,	the	cells	grown	in	the	presence	of	fluoride	were	grown	for	8	hours	and	40	minutes	in	order	to	match	the	optical	density	of	the	cells	grown	in	the	absence	of	fluoride.			
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CHAPTER	5	
CHARACTERIZING	THE	STRUCTURE-FUNCTION	RELATIONSHIP	
OF	A	NATURALLY-OCCURRING	RNA	THERMOMETER	
	
5.1	 Abstract			 A	wide	number	of	bacteria	have	been	found	to	govern	virulence	and	heat/cold	shock	responses	 using	 temperature-sensing	 RNAs	 known	 as	 RNA	 thermometers.	 A	 prime	example	is	the	agsA	 thermometer	known	to	translationally	regulate	the	production	of	the	AgsA	heat-shock	protein	in	Salmonella	using	a	“fourU”	structural	motif.	Using	the	SHAPE-Seq	 RNA	 structure-probing	 method	 in	 vivo	 and	 in	 vitro,	 we	 both	 confirmed	 that	 the	regulator	 functions	 by	 an	 equilibrium-determined	 partial	melting	 of	 the	 helix	 containing	the	ribosome	binding	site	and	demonstrated	the	ability	of	SHAPE-Seq	to	detect	ribosome	binding	 to	 the	agsA	mRNA.	These	 results	display	how	subtle	RNA	structural	 changes	 can	govern	 gene	 expression	 and	 illuminate	 the	 function	 of	 an	 important	 bacterial	 regulatory	motif.		
5.2	 Introduction	Bacterial	 survival	 depends	 on	 a	 bacterium’s	 ability	 to	 react	 appropriately	 to	environmental	cues,	altering	its	behavior	in	response	to	its	ever-changing	surroundings.	In	particular,	variations	in	temperature	require	coordinated	system-wide	responses	in	order	to	avoid	deleterious	effects	(Kortmann	and	Narberhaus,	2012),	resulting	in	the	evolution	of	a	 wide	 array	 of	 molecular	 thermosensors—including	 RNA	 thermometers	 (Shapiro	 and	Cowen,	2012).	These	RNA	thermometers	allow	bacteria	to	govern	wide-spread	responses	
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to	 heat	 and	 cold	 shock	 and	 to	 control	 temperature-dependent	 virulence	 effects,	 an	important	consideration	for	pathogens	with	warm-blooded	hosts	(Konkel	and	Tilly,	2000).		The	RNA	 thermometers	 regulating	bacterial	 cold	 shock	are	perhaps	 the	 least	well	understood:	 although	 the	 details	 are	 yet	 to	 be	 elucidated,	 they	 are	 known	 to	 work	 by	modulating	temperature-dependent	changes	in	transcript	structure	and	stability	for	CspA	mRNAs	 (Giuliodori	 et	 al.,	 2010;	 Yamanaka	 et	 al.,	 1999).	 This	 governs	 production	 of	 the	CspA	family	of	cold	shock	proteins,	which	act	as	RNA	chaperones	and	transcription	factors	in	conditions	of	cold	stress	(Uppal	et	al.,	2008),	thus	regulating	gene	expression	on	a	post-transcriptional	level	in	response	to	environmental	temperature.	Similarly,	 the	 thermosensing	 RNAs	 controlling	 heat	 shock	 also	 function	 post-transcriptionally—	generally	relying	on	the	formation	of	temperature-sensitive	secondary	structure	 to	 fully	 or	 partially	 occlude	 the	 RBS	 (Narberhaus,	 2010;	 Shapiro	 and	 Cowen,	2012),	 thus	 decreasing	 translation	 efficiency	 (de	 Smit	 and	 van	 Duin,	 1990)	 in	 a	temperature-dependent	 manner.	 The	 most	 widely	 characterized	 RNA	 thermometers	 are	the	broad	family	of	ROSE	(repression	of	heat	shock	gene	expression)	elements	present	in	the	 5’	 UTRs	 of	 heat	 shock	 genes	 (Kortmann	 and	 Narberhaus,	 2012).	 First	 discovered	 in	
Bradyrhizobium	 japonicum	 (Narberhaus	 et	 al.,	 1998)	 and	 other	 rhizobia	 (Nocker	 et	 al.,	2001),	 ROSE	 elements	 were	 later	 found	 to	 be	 common	 among	 α-	 and	 γ-proteobacteria,	including	E.	coli	(Waldminghaus	et	al.,	2005,	2009),	and	amenable	to	identification	through	bioinformatics-based	 approaches	 (Waldminghaus	 et	 al.,	 2005,	 2007a).	 ROSE	 elements	(Figure	 5.1)	 share	 a	 common	 sequence	motif	 predicted	 to	 pair	 with	 the	 Shine-Dalgarno	sequence	 in	 a	 hairpin	 (Narberhaus,	 2010).	 Detailed	 structural	 information	 obtained	through	NMR	spectroscopy	indicates	that	this	conserved	ROSE	motif	depends	on	a	non-	
	 122	
	
		
Figure	 5.1	 Consensus	 structure	 of	 repression	 of	 the	 heat	 shock	 gene	 expression	 (ROSE)	element.	Hairpins	I,	III,	and	the	optional	hairpin	II	vary	widely	in	sequence	and	length,	and	the	Shine-Dalgarno	sequence	is	paired	to	a	conserved	UUGCU	sequence	within	hairpin	IV.		canonical	 interaction	 and	 an	 unusual	 base	 triple	 for	 hairpin	 stability	 and	 melting	(Chowdhury	et	al.,	2006).		 Other	heat	shock	RNA	thermometers,	 like	 the	one	governing	translation	of	 the	σ32	heat	 shock-dependent	 σ	 factor,	 involve	 the	 formation	 of	 complex	 structures	 that	 block	ribosome	 entry	without	 directly	 pairing	with	 the	 RBS	 (Morita	 et	 al.,	 1999a,	 1999b).	 Yet	another	 mechanism,	 found	 in	 the	 RNA	 thermometer	 regulating	 the	 Hsp17	 heat	 shock	protein	 in	cyanobacteria	Synechocystis	 (Kortmann	et	al.,	2011),	depends	upon	an	 internal	hairpin	bulge	to	allow	for	stem	melting	in	response	to	increased	temperature	(Wagner	et	
ROSE
Element
[    ]
I
II
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IV
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al.,	2015).	This	same	hairpin	bulge	pattern	reappears	in	the	Salmonella	enterica	agsA	RNA	thermometer	 (Figure	 5.2A),	 where	 an	 internal	 stem	 bulge	 followed	 by	 a	 stretch	 of	 four	uridines	paired	to	the	Shine-Dalgarno	sequence	confers	thermosensing	capability	to	the	5’	UTR	of	the	agsA	gene	encoding	the	aggregation	suppression	protein	agsA	(Waldminghaus	et	 al.,	 2007b),	 a	 molecular	 chaperone	 that	 forms	 part	 of	 the	 heat	 shock	 response	 in	
Salmonella	(Tomoyasu	et	al.,	2003).	This	“fourU”	motif	has	since	been	characterized	in	vitro	via	NMR	spectroscopy,	giving	key	insights	into	relative	stabilities	of	the	different	pairings	within	the	thermometer	hairpin	(Rinnenthal	et	al.,	2010)	and	the	magnesium-dependence	of	hairpin	melting	(Rinnenthal	et	al.,	2011).		 Although	 the	 fourU	 RNA	 thermometer	 motif	 was	 first	 coined	 in	 reference	 to	 the	
agsA	thermometer	from	Salmonella	(Waldminghaus	et	al.,	2007b),	the	previously	reported	virulence	 control	 mechanism	 of	 the	 plague	 bacterium	 Yersinia	 pestis	 also	 relies	 a	 four	uridine	 base-pairing	 to	 the	 Shine-Dalgarno	 sequence	 to	 grant	 temperature-dependent	translational	 control	 (Hoe	 and	 Goguen,	 1993).	 Similarly,	 the	 temperature-dependent	virulence	 response	 of	Vibrio	cholerae	was	 recently	 tied	 to	 a	 fourU	 element	within	 the	 5’	UTR	of	ToxT,	a	key	transcriptional	activator	of	virulence	factors	(Weber	et	al.,	2014).	While	other	temperature-based	virulence	controls	rely	on	alternate	mechanisms	(Johansson	et	al.,	2002;	Loh	et	al.,	2009),	the	reoccurrence	of	the	fourU	motif	 in	regulating	both	heat	shock	and	virulence	underlines	its	widespread	utility	as	an	RNA	thermometer.		 Here	we	seek	to	better	understand	the	mechanistic	details	of	its	function	in	vivo	by	applying	the	SHAPE-Seq	method	of	RNA	structural	determination	to	the	fourU	element	of	the	agsA	RNA	thermometer.	By	combining	structural	probing	data	obtained	under	different	temperatures	 and	 conditions	 we	 dissect	 the	 structural	 mechanism	 of	 this	 naturally	
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occurring	 RNA	 thermometer	 and	 highlight	 the	 effect	 of	 ribosome	 binding	 upon	 the	structure	of	the	agsA	5’	UTR.		
5.3	 Results	and	discussion	
Confirming	agsA	thermometer	function	in	vivo	As	a	 first	step,	we	confirmed	the	temperature-sensitivity	of	 the	agsA	 thermometer	by	 fusing	 the	agsA	5’	UTR	directly	 to	 the	 super-folder	 green	 fluorescent	protein	 (SFGFP)	coding	sequence	and	testing	the	construct’s	heat-responsiveness	in	vivo	in	Escherichia	coli	(Figure	5.2).	Alongside	the	wild-type	(WT)	agsA	 thermometer,	we	also	tested	a	control	5’	UTR	 known	 to	 allow	 downstream	 translation	 at	 all	 temperatures	 and	 a	 pair	 of	 agsA	mutants	 known	 to	 exhibit	 altered	 temperature	 responsiveness	 (Waldminghaus	 et	 al.,	2007b).	Specifically,	the	G21C	mutation	is	predicted	to	extend	the	agsA	P2	helix	to	include	the	AUG	start	codon	at	its	base,	resulting	in	tighter	repression	of	translation	at	30	°C	than	the	wild-type.	 The	 A29C	mutation	 removes	 a	 predicted	 single	 base-pair	 internal	 hairpin	loop,	 thus	strengthening	 the	P2	helix	and	preventing	RBS	access	at	both	30	°C	and	42	°C	(Figure	5.2A).		To	 test	 the	 responsiveness	 of	 the	 constructs	 to	 heat-shock,	we	 transformed	 them	into	E.	coli	and	grew	triplicate	colonies	overnight	in	liquid	media.	Duplicate	subcultures	of	each	colony	were	grown	at	30	°C	for	4	hours,	and	then	one	was	subjected	to	a	30-minute	heat-shock	at	42	°C	while	the	other	remained	at	30	°C.	We	then	measured	fluorescence	and	optical	 density	 via	 plate-reader,	 giving	 the	 normalized	 fluorescence	 data	 presented	 in	Figure	5.2B.		The	control	showed	a	slight	increase	in	normalized	fluorescence	under	heat-shock,	corresponding	to	the	faster	production	and	maturation	of	SFGFP	at	the	higher		
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Figure	5.2	Structure	and	function	of	the	agsA	 thermometer.	(A)	Putative	structure	of	the	
agsA	5’	 UTR	 RNA	 thermometer	 from	 Salmonella	with	 key	 P1	 and	 P2	 helices,	 the	 Shine-Dalgarno	(SD)	sequence,	start	codon,	and	mutations	of	 interest	 labeled.	(B)	Functional	 in	
vivo	 testing	 of	 the	 agsA	 thermometer	 and	 mutants	 using	 a	 fluorescent	 reporter	 gene	demonstrated	their	responsiveness	to	heat-shock.	The	G21C	mutation	extends	the	P2	helix	to	include	the	start	codon,	resulting	in	lower	fluorescence	in	both	the	low	temperature	and	heat	shock	conditions.	The	A29C	mutation	closes	the	inner-hairpin	loop	within	the	P2	helix,	causing	complete	repression	of	gene	expression	under	both	temperature	conditions.			 									
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temperature,	 but	 the	WT	 agsA	variant	 showed	 clear	 activation	 in	 response	 to	 the	 heat-shock,	with	 a	 2.5-fold	 increase	 in	 normalized	 fluorescence	 over	 the	 30	 °C	 condition.	 The	G21C	agsA	variant	gave	lower	overall	levels	of	fluorescence	but	still	showed	increased	gene	expression	 in	 response	 to	 heat-shock,	 while	 the	 A29C	 variant	 did	 not	 express	 SFGFP	 at	either	 30	 °C	 or	 42	 °C	 (Figure	 5.2B).	 These	 results	 confirm	 the	 behavior	 of	 the	 agsA	thermometer	 and	 the	 designed	 mutants	 as	 originally	 reported	 in	 Walminghaus	 et	 al.	(2007b)	and	support	the	model	of	thermometer	regulation	tied	to	hairpin	melting	at	higher	temperatures,	 since	 mutations	 that	 stabilized	 the	 hairpin	 resulted	 in	 decreased	 gene	expression.		
Determining	agsA	thermometer	structure	in	vivo	with	SHAPE-Seq		 In	order	to	determine	the	structure	of	the	agsA	5’	UTR	in	vivo,	we	turned	to	SHAPE-Seq,	 an	 RNA	 structure	 probing	 technique	 using	 a	 small	 chemical	 probe	 (1-methyl-7-nitroisatoic	anhydride)	that	covalently	modifies	RNA	nucleotides	in	a	structure-dependent	fashion	(Lucks	et	al.,	2011;	Watters	et	al.,	2015a,	2015b).	The	probe,	which	can	penetrate	through	cell	walls	and	membranes	for	in-cell	structure	determination,	preferentially	reacts	with	unconstrained	nucleotides	 like	 those	 in	 loops	and	 single	 stranded	 regions,	but	does	not	modify	nucleotides	constrained	by	base-pairing	or	stacking	interactions	(Bindewald	et	al.,	 2011).	 The	 locations	 of	modifications	 are	 detected	 through	 reverse	 transcription	 and	sequencing,	 allowing	 for	 the	 determination	 of	 the	 relative	 reactivities	 of	 the	 underlying	RNA	 nucleotides	 to	 the	 SHAPE-Seq	 probe—high	 reactivities	 correspond	 to	 unpaired	 or	unconstrained	 nucleotides,	 while	 low	 reactivities	 indicate	 base-pairing	 or	 constrained	stacking	 interactions.	 These	 experimentally	 measured	 SHAPE	 reactivities	 can	 be	
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incorporated	into	structural	prediction	programs	as	a	pseudo-energy	constraint	that	favors	structures	matching	the	observed	reactivity	patterns	 in	order	to	arrive	at	highly	accurate	predictions	 of	 RNA	 secondary	 structure	 (Loughrey	 et	 al.,	 2014;	 Low	 and	 Weeks,	 2010;	Reuter	and	Mathews,	2010).		We	 applied	 in-cell	 SHAPE-Seq	 to	 the	 agsA	 thermometer	 variants,	 probing	 the	thermometer	 structures	 at	 30	 °C	 and	 42	 °C	 simultaneously	 with	 the	 bulk	 fluorescence	assays	presented	in	Figure	5.2.	The	resulting	reactivity	profiles	(Figure	5.3A)	were	used	to	constrain	 RNA	 structural	 prediction	 (Figure	 5.3B)	 using	 the	 RNAStructure	 software	package	(Reuter	and	Mathews,	2010)	to	predict	RNA	folding	at	the	correct	temperature.	A	comparison	 of	 the	 reactivity	 profiles	 and	 most	 likely	 RNA	 structures—the	 predicted	minimum	 free	 energy	 (MFE)	 folds—between	 agsA	 variants	 and	 temperatures	 reveals	 a	number	of	interesting	differences.	For	the	wild-type	agsA	RNA,	slight	reactivity	increases	in	the	 nucleotides	 comprising	 the	 base	 of	 the	 P2	 helix	 under	 heat-shock	 correspond	 to	 a	predicted	partial	melting	of	the	P2	hairpin	at	42	°C.		This	correlates	well	with	the	functional	data	 showing	 increased	gene	expression	at	higher	 temperatures,	potentially	mediated	by	better	ribosome	access	 to	 the	Shine-Dalgarno	region	as	 the	hairpin	partially	melts.	While	the	 G21C	mutation	 does	 extend	 the	 P2	 helix	 to	 contain	 the	 start	 codon	 at	 30	 °C,	 slight	reactivity	 increases	 at	 42	 °C	 match	 a	 predicted	 expansion	 of	 the	 internal	 hairpin	 loop,	correlating	 with	 the	 reported	 increase	 in	 fluorescence	 under	 heat-shock	 conditions.	Neither	of	 these	 temperature	 transitions	was	 correctly	predicted	by	RNAStructure	 in	 the	absence	of	SHAPE	constraints	(Figure	D.1),	but	the	subtle	reactivity	changes	measured	by	SHAPE-Seq	 influenced	 the	 folding	 algorithm	 enough	 to	 alter	 the	 predicted	 structures	 for	the	wild-type	and	the	G21C	variant.		In	comparison,	the	A29C	mutation	that	closes	the	
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Figure	 5.3	 SHAPE-Seq	 characterization	of	 the	agsA	thermometer	 in	vivo.	 (A)	 SHAPE-Seq	normalized	 reactivity	 plots	 for	 agsA	 WT,	 G21C,	 and	 A29C	 variants	 from	 triplicate	experiments	 in	 vivo	 performed	 at	 30	 °C	 and	 under	 42	 °C	 heat-shock	 conditions.	 (B)	Experimentally-derived	minimum	free	energy	(MFE)	RNA	structures	as	predicted	using	the	RNAStructure	program	with	the	reactivity	values	from	(A)	taken	as	pseudoenergy	folding	constraints.	Blue-highlighted	nucleotides	undergo	key	structural	changes	according	to	the	folding	 models	 and	 correspond	 to	 the	 inset	 boxes	 in	 (A),	 while	 red	 nucleotides	 denote	variant	mutations.	
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inner	hairpin	loop	creates	a	variant	with	strikingly	low	reactivities	throughout	the	P2	helix	and	 displays	 no	 predicted	 structural	 change	 between	 30	 °C	 and	 42	 °C,	 retaining	 an	extended	hairpin	form	even	under	heat-shock.		This	lack	of	hairpin	opening	corresponds	to	undetectable	 levels	 of	 gene	 expression	 at	 both	 temperatures,	 bolstering	 the	 proposed	mechanism	of	translational	control	through	hairpin	opening	and	ribosome	access.		 However,	it	is	worth	noting	that	even	at	42	°C,	the	most	likely	WT	structure	is	still	predicted	to	have	perfect	base-pairing	of	the	Shine-Dalgarno	sequence,	somewhat	at	odds	with	 the	 model	 of	 increasing	 ribosome	 access	 along	 with	 hairpin	 melting.	 	 Careful	inspection	of	the	RNAStructure	ensemble	base-pairing	probabilities	for	the	WT	variant	at			
	
Figure	5.4	Base-pairing	probabilities	of	the	agsA	WT	Shine-Dalgarno	sequence.		The	base-pairing	 probabilities	 for	 the	 first	 five	 nucleotides	 of	 the	 Shine-Dalgarno	 sequence	 as	determined	by	the	structural	ensemble	predictions	constrained	by	in	vivo	SHAPE-Seq	data.	
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30	°C	and	42	°C	(Figures	D.2	and	D.3),	shows	shifts	toward	lower	probability	base-pairing	in	 the	 P2	 stem	 at	 the	 higher	 temperature.	 However,	 the	 changes	 in	 the	 Shine-Dalgarno	sequence	are	quite	slight	(Figure	5.4),	with	the	ensemble-pairing	probabilities	shifting	by	just	a	few	percentage	points	from	approximately	99%	pairing	to	94-97%	pairing,	perhaps	corresponding	to	a	small	population	of	transiently	“breathing”	hairpins.	 	 Intriguingly,	this	small	ensemble	shift	in	RBS	accessibility	is	enough	to	more	than	double	the	expression	of	the	 downstream	 reporter	 gene,	 demonstrating	 how	 subtle	 shifts	 in	 RNA	 structural	ensembles	can	lead	to	large	changes	in	functional	output.		
Establishing	the	mechanism	of	the	agsA	thermometer’s	structural	transition		 Having	 observed	 agsA	 thermometer	 structure	 and	 function	 within	 the	 complex	cellular	 environment	 where	 transcription	 and	 translation	 happen	 simultaneously,	 we	turned	 to	 in	vitro	 studies	 in	 order	 to	 decouple	 the	 two	 processes	 and	 better	 discern	 the	underlying	mechanism	behind	 the	 shift	 in	 the	agsA	 structural	 ensemble.	 	We	 carried	out	our	assays	in	the	cell-free	PURExpress	protein	synthesis	system,	first	establishing	that	the	
agsA	thermometer	variants	gave	the	expected	reporter	output	in	PURExpress	from	plasmid	input,	allowing	for	both	transcription	and	translation	(Supplementary	Figure	D.4).	Next,	we	investigated	whether	the	shift	in	the	agsA	structural	ensemble	depended	on	the	kinetics	of	RNA	folding	during	transcription	(co-transcriptional	folding)	or	the	equilibrium	folding	of	already	 transcribed	RNAs.	To	do	so,	we	 tracked	 fluorescent	 reporter	gene	expression	via	plate	 reader	 for	 PURExpress	 reactions	 containing	 equal	 amounts	 of	 pre-transcribed,	purified	 mRNAs	 for	 the	 control	 and	 agsA	 variants,	 thus	 eliminating	 any	 effect	 from	 co-transcriptional	 folding	 at	 a	 particular	 temperature.	 The	 resulting	 hour-long	 fluorescence	
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traces	 (Figure	 5.5A)	 recapitulated	 the	 function	 observed	 in	 vivo,	 demonstrating	 higher	fluorescence	relative	to	the	control	at	42	°C	than	30	°C	for	the	WT	and	G21C	mutants	and	consistently	 low	 fluorescence	 for	 the	 A29C	 variant.	 The	 baseline	 increase	 in	 gene	expression	of	the	control	from	30	°C	to	42	°C	is	higher	than	seen	in	vivo,	due	partly	to	the	longer	 duration	 of	 the	 heat	 shock	 and	 partly	 to	 the	 magnifying	 effect	 of	 the	 high-yield	PURExpress	 system.	 Figure	 5.5B	 presents	 the	 measured	 rates	 of	 fluorescence	 increase	during	linear	growth,	reflecting	the	same	trends	observed	in	overall	fluorescence.	The		
	
Figure	5.5	Testing	agsA	thermometer	function	in	a	cell-free	protein	synthesis	system	using	purified	pre-transcribed	mRNA.	(A)	Fluorescence	growth	curves	 for	 translation	of	SFGFP	from	agsA	construct	and	control	mRNA	in	the	PURExpress	protein	synthesis	system	at	30	
°C	 and	 42	 °C.	 (B)	 SFGFP	 production	 rates	 during	 the	 linear	 synthesis	 regime	 for	 agsA	constructs	at	30	°C	(45-50	minutes)	and	42	°C	(30-35	minutes).	
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Figure	 5.6	 SHAPE-Seq	 characterization	of	 the	agsA	thermometer	 in	vitro	 in	PURExpress.	
(A)	SHAPE-Seq	normalized	reactivity	plots	for	agsA	WT	mRNA	from	triplicate	experiments	
in	 vitro	 performed	 on	 mRNAs	 at	 30	 °C	 and	 42	 °C,	 graphed	 alongside	 previous	 in	 vivo	reactivities	for	comparison.	Stars	denote	statistically	significant	differences	as	determined	by	 heteroscedastic	 Welch’s	 T-test,	 while	 the	 difference	 plot	 shows	 the	 magnitude	 of	reactivity	 change	 (in	 vitro	 reactitivies	 minus	 in	 vivo	 reactivities).	 (B)	 Experimentally-derived	 RNA	 structures	 as	 predicted	 using	 the	 RNAStructure	 program	 with	 the	 in	 vitro	reactivity	values	from	(A)	taken	as	pseudoenergy	folding	constraints.		
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temperature	 responsiveness	 of	 the	 pre-transcribed	agsA	 construct	mRNAs	 demonstrates	that	 RNA	 thermometer	 function	 does	 indeed	 depend	 on	 thermodynamic	 equilibrium	folding	as	previously	suggested	by	Waldminghaus	et	al.	(2007b),	as	opposed	to	relying	on	a	co-transcriptional	 effect	 where	 the	 kinetics	 of	 either	 transcription	 or	 simultaneous	transcription	and	translation	determine	RNA	structure	or	RBS	accessibility.		
Investigating	agsA	thermometer	folding	in	vitro	using	SHAPE-Seq	Having	confirmed	the	basic	mechanism	of	agsA	thermometer	function,	we	set	about	investigating	 agsA	 thermometer	 folding	 in	 vitro	 to	 explore	 whether	 we	 could	 detect	 a	stronger	signal	for	structural	switching	in	the	absence	of	other	cellular	factors.	Performing	SHAPE-Seq	 in	vitro	(in	 the	 PURExpress	 cell-free	 system	without	 ribosomes)	 on	agsA	WT	mRNA	at	30	°C	and	42	°C	produced	the	reactivity	plots	presented	 in	Figure	5.6A	(plotted	alongside	in	vivo	reactivities	for	comparison).	Quite	notably,	the	reactivity	profiles	at	both	temperatures	are	markedly	similar,	with	only	a	handful	of	nucleotides	showing	statistically	significant	differences	 in	 reactivity	 (labeled	with	stars).	When	 the	 in	vitro	 reactivities	are	used	to	constrain	the	RNA	structural	prediction,	the	resulting	structural	predictions	(Figure	5.6B)	parallel	those	seen	in	under	in	vivo	conditions,	but	with	two	key	differences:	at	30	°C	the	internal	loop	in	the	P2	helix	is	predicted	to	be	one	base-pair	smaller,	and	at	42	°C	the	P2	stem	 loop	 is	 predicted	 to	 be	 two	 base-pairs	 smaller.	 Similar	 patterns	 in	 reactivity	 and	structure	 were	 seen	 for	 in	 vitro	 experiments	 conducted	 in	 buffer	 as	 opposed	 to	PURExpress,	 demonstrating	 a	 stable	 pattern	 of	 helix	 formation	 with	 slight	 variations	 in	loop	size.	(See	Figures	D.5	and	D.6.)	
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Figure	5.7	Investigating	the	effect	of	translation	on	agsA	WT	structure	and	reactivity.	(A)	SHAPE-Seq	 reactivity	 plots	 for	 triplicate	 experiments	 carried	 out	 in	 vitro	 in	 PURExpress	without	 ribosomes,	 with	 active	 translation,	 and	 with	 stalled	 translation	 initiation	complexes	generated	by	supplying	only	methionine.	(B)	Difference	plot	of	reactivities	with	stalled	 translation	 initiation	 complexes	 minus	 those	 from	 the	 no	 ribosome	 case.	 Stars	represent	statistical	significance.		
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Determining	the	effect	of	translation	and	ribosome	binding	on	agsA	structure	Having	 established	 the	 baseline	 structure	 of	 the	 agsA	 thermometer	 in	 the	PURExpress	system	without	ribosomes	to	be	very	similar	to	the	in	vivo	structure,	we	next	set	 about	 determining	 the	 reactivity	 changes	 caused	 by	 ribosome	 binding	 and	 active	translation	in	the	clearly	defined	in	vitro	system.	To	do	so	we	performed	additional	SHAPE-Seq	 experiments	 in	 vitro	 in	 PURExpress	 involving	 both	 active	 translation	 and	 stalled	translation	initiation	complexes	(TIC)	(Figure	5.7).		For	the	active	translation	experiments,	we	probed	PURExpress	reactions	assembled	with	ribosomes,	and	for	the	stalled	translation	initiation	experiments,	we	probed	PURExpress	reactions	assembled	lacking	all	amino	acids	except	 for	methionine—thus	 causing	 the	 translation	 initiation	 complex	 to	 stall	 after	 the	addition	 of	 the	 first	 amino	 acid.	 The	major	 reactivity	 changes	 caused	 by	 the	 addition	 of	stalled	 translation	 initiation	 complexes	become	 clear	when	 the	 reactivity	 spectra	 (Figure	5.7A)	 are	 compared—the	 magnitudes	 of	 the	 reactivity	 differences	 are	 plotted	 in	 Figure	5.7B.	 There	 is	 a	 stark	 reactivity	 drop	 directly	 downstream	 of	 the	 ribosome	 binding	 site,	corresponding	to	the	ribosome	footprint	as	the	stalled	translation	initiation	complex	blocks	SHAPE	modification.	Moreover,	many	of	the	nucleotides	that	formed	the	P2	helix,	on	the	5’	side	 and	 the	 upper	 portion	 of	 the	 3’	 side,	 undergo	 large	 increases	 in	 reactivity	corresponding	 to	 increased	 flexibility	brought	about	by	 the	dissolution	of	 the	P2	helix	 in	concert	with	 ribosome	binding.	 Larger	 changes	 in	 reactivity	 at	 42	 °C	 than	 30	 °C	 suggest	greater	 ribosome	access	 at	 the	higher	 temperature,	matching	 the	 functional	 data	 seen	 in	
vivo	and	in	vitro.	However,	given	that	the	ribosomes	were	supplied	in	excess	to	the	mRNA	(8:1	ratio)	and	allowed	20	minutes	to	reach	binding	equilibrium,	it	is	unsurprising	that	the	reactivities	indicate	ribosome	binding	to	a	large	portion	of	the	mRNA	ensemble	under	both	
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temperature	 conditions—the	 presence	 of	 background	 gene	 expression	 at	 30	 °C	 in	functional	testing	indicates	some	level	of	ribosome	access	even	at	the	lower	temperature,	most	 likely	 linked	 to	 a	 small	 fraction	 of	 the	 ensemble	 undergoing	 transient	 hairpin	breathing	that	allows	for	ribosome	capture.		 Comparing	 the	 reactivities	 for	 the	 no	 ribosome	 and	 stalled	 translation	 initiation	complex	cases	aids	with	interpretation	of	the	reactivity	spectra	from	the	active	translation	experiments.	 The	 reactivities	 immediately	 downstream	 of	 the	 ribosome	 binding	 site	 are	lower	than	without	ribosomes	but	higher	than	with	stalled	translation	initiation	complexes,	as	one	would	expect	for	an	ensemble	measurement	in	which	some	but	not	all	of	the	mRNAs	have	ribosomes	blocking	the	initiation	site	or	the	beginning	of	the	downstream	gene.	That	the	 reactivities	 are	 slightly	 lower	 than	 in	vivo	 (Figure	D.7)	may	 indicate	a	higher	 level	of	gene	 expression	within	PURExpress	without	 the	need	 to	 compete	with	 other	mRNAs	 for	translational	machinery.		
Discussion	of	agsA	structural	mechanism	and	perspectives		 Combined	 with	 the	 structural	 and	 functional	 data	 from	 in	 vivo	 experiments,	 the	PURExpress	 probing	 data	 confirms	 the	 previously	 suggested	 mechanism	 of	 agsA	thermometer	action:	higher	temperatures	lead	to	partial	melting	of	the	hairpin	containing	the	ribosome	binding	site,	thus	allowing	for	translation	initiation.	Moreover,	we	show	clear	indications	 that	 the	 mechanism	 operates	 in	 thermodynamic	 equilibrium	 as	 opposed	 to	depending	 upon	 co-transcriptional	 RNA	 folding.	 In	 addition,	 we	 have	 shown	 strong	evidence	 for	agsA	structural	switching	 in	vivo,	unlike	previous	structural	studies	of	 fourU	thermometers	 (Rinnenthal	 et	 al.,	 2010,	 2011;	 Waldminghaus	 et	 al.,	 2007b),	 which	 took	
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place	in	vitro	and	in	one	case,	in	non-physiologically	relevant	conditions	(Rinnenthal	et	al.,	2010)—NMR	buffer	 in	 the	absence	of	magnesium,	a	key	determinant	of	RNA	 folding	and	structure	 (Misra	 and	 Draper,	 2002).	 Subtle	 differences	 between	 the	 RNA	 structures	observed	 in	 vivo	 and	 in	 vitro	 reaffirm	 the	 importance	 of	 probing	 RNAs	 in	 their	 native	environment,	although	 in	vitro	assays	allowed	for	the	dissection	of	important	mechanistic	details	 and	 demonstration	 of	 the	 opening	 of	 the	 agsA	 P2	 helix	 in	 response	 to	 ribosome	binding.		The	elegantly	simple	hairpin	melting	mechanism	behind	agsA	thermo-sensing	offers	a	 potential	 template	 for	 future	 design	 of	 synthetic	 RNA	 thermometers	 with	 different	properties—for	 instance,	 alternate	 ranges	 of	 temperature	 sensing	 or	 levels	 of	 gene	activation	could	be	achieved	by	altering	the	structure	of	the	thermometer	hairpin.	Previous	work	 in	 engineering	 temperature-sensing	 RNAs	 has	 drawn	 on	 a	 number	 of	 design	strategies,	 from	 computational	 methods	 (Neupert	 and	 Bock,	 2009;	 Neupert	 et	 al.,	 2008;	Waldminghaus	et	al.,	2008)	to	rational	design	(Hoynes-O’Connor	et	al.,	2015),	with	varying	levels	 of	 success,	 but	 the	 simplicity	 and	modularity	 of	 the	 fourU	 thermometer	make	 it	 a	particularly	 attractive	 starting	 point	 for	 future	 engineering.	 In	 fact,	 recent	 work	 by	 has	drawn	on	these	particular	properties	to	generate	combined	riboswitch-RNA	thermometer	systems	 allowing	 for	 complex	 temperature	 and	 ligand	 based	 regulation	 of	 synthetic	systems.	It	is	our	hope	that	a	better	understanding	of	the	structural	mechanism	underlying	the	agsA	fourU	thermometer	will	promote	future	engineering	of	this	fascinating	molecular	sensor.			
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5.4	 Materials	and	methods	
Cloning	and	plasmid	construction	Relying	on	the	sequences	reported	by	Waldminghaus	et	al.	(2007),	the	agsA	5’	UTR	in	 both	 its	wild-type	 and	 point-mutant	 forms	was	 cloned	 into	 a	 p15a	 plasmid	 backbone	harboring	chloramphenicol	resistance.	Using	inverse	PCR	(iPCR)	for	scarless	insertion,	the	
agsA	 sequence	was	 introduced	 directly	 between	 the	E.	 coli	 consensus	 promoter	 and	 the	SFGFP	 start	 codon.	 See	Appendix	D	 for	plasmid	maps	 (Figure	D.8)	 and	 sequences	 (Table	D.1).		
In	vivo	bulk	fluorescence	assays	and	in-cell	SHAPE-Seq	All	 bulk	 fluorescence	 and	 in-cell	 SHAPE-Seq	 experiments	 were	 performed	 in	
Escherichia	 coli	 (E.	 coli)	 strain	 TG1	 (F'traD36	 lacIq	 Delta(lacZ)	 M15	 pro	 A+B+/supE	
Delta(hsdM-mcrB)5	(rk-	mk-	McrB-)	thi	Delta(lac-proAB))	with	three	independent	biological	replicates.	 For	 each	 independent	 replicate,	 an	 empty	 control	 plasmid	 (JBL	 001),	 gene	expression	 control	 plasmid	 (JBL2348),	 and	 agsA	 WT	 and	 mutant	 plasmids	 were	transformed	into	chemically	competent	E.	coli	TG1	cells,	plated	on	Difco	LB	+	Agar	plates	with	 34	mg/ml	 chloramphenicol	 and	 incubated	 overnight	 at	 37	 °C	 for	 approximately	 17	hours.	After	overnight	incubation,	the	plates	were	removed	from	the	incubator	and	kept	at	room	 temperature	 for	 approximately	 7	 hours.	 Three	 separate	 colonies	 were	 picked	 for	each	control	and	one	for	each	tested	variant,	and	each	colony	was	used	to	inoculate	1	mL	of	LB	media	with	 34	mg/mL	 chloramphenicol	 in	 a	 2	mL	 96-well	 block	 (Costar	 3960).	 The	block	was	 covered	with	a	breathable	 seal	 (Aeraseal	BS-25)	and	 incubated	at	37	 °C	while	shaking	 at	 a	 speed	of	 1,000	 rpm	 in	 a	Labnet	Vortemp	56	bench-top	 shaker	 for	18	hours	
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overnight.	 From	 these	 overnight	 cultures	 24	 µL	 were	 taken	 and	 used	 to	 inoculate	 two	duplicate	96-well	blocks	containing	1.2	mL	LB	media	with	34	mg/mL	chloramphenicol.	The	blocks	were	 shaken	at	30	 °C	and	1,000	 rpm	 for	4	hours,	 and	 then	one	of	 the	blocks	was	moved	to	shake	at	42	°C	(heat-shock	condition),	while	 the	other	was	kept	at	30	°C.	From	there,	 the	 in-cell	 SHAPE-Seq	probing	and	 the	bulk	 fluorescence	sample	preparation	were	carried	out	as	described	by	Watters	et	al.	(2015a	and	2015b),	using	1	mL	of	the	sample	for	in-cell	 SHAPE-Seq	 and	 150	 µL	 for	 the	 bulk	 fluorescence	 measurements.	 Any	 deviations	from	the	published	protocol	are	described	below.	The	samples’	optical	density	(OD)	at	600	nm	and	fluorescence	(485	nm	excitation,	520	nm	emission)	were	measured	with	a	Biotek	Synergy	 H1	 plate	 reader	 for	 the	 bulk	 fluorescence.	 Following	 RNA	 probing	 as	 described	(Watters	et	al.,	2015b),	the	modified	and	unmodified	RNAs	were	extracted	using	the	TRIzol	Max	 Bacterial	 RNA	 Isolation	 Kit	 (Thermo	 Fisher).	 The	 extracted	 RNAs	 were	 reverse	transcribed	 from	within	 the	 SFGFP	 gene	 (primer	 =	 CAACAAGAATTGGGACAACTCCAGTG)	using	3	µL	of	50	nM	(not	0.5	µM)	primer	per	reaction.	The	following	RNA	hydrolysis	step	was	extended	 from	5	minutes	 to	15	minutes,	and	 the	partial	neutralization	with	HCl	was	omitted.	 Subsequent	 ethanol	 precipitation,	 adaptor	 ligation,	 and	 bead	 purification	 steps	followed	the	published	protocol	exactly	(Watters	et	al.,	2015b),	and	the	quality	analysis	and	library	construction	were	performed	following	the	previously	reported	PCR	modifications	to	minimize	side-product	formation	for	libraries	from	weakly	expressed	RNAs	(Watters	et	al.,	2015a).	Data	analysis	was	executed	using	the	Spats	pipeline	as	described	by	Watters	et	al.	 (2015a)	 in	order	 to	generate	raw	θ	reactivities	 (Aviran	et	al.,	2011),	which	were	 then	converted	to	ρ	reactivities	by	multiplying	by	the	length	of	the	probed	RNA	(Loughrey	et	al.,	2014)	and	normalized	using	the	box-plot	strategy	described	by	Deigan	et	al.	(2008).		
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mRNA	preparation	DNA	 templates	 for	 in	vitro	 transcription	were	 generated	 using	PCR	 to	 add	 the	T7	promoter	to	the	agsA	variants	and	control	and	to	amplify	the	region	from	the	5’	UTR	to	the	intrinsic	terminator	following	the	SFGFP	gene.	The	resulting	templates	were	transcribed	as	described	in	section	2.5,	with	triple	the	amount	of	T7	polymerase	to	correct	for	differences	in	activity	among	different	preparations	of	the	enzyme.	The	resulting	mRNAs	were	purified	using	Ampure	XP	beads	(Beckman	Coulter)	following	the	manufacturer’s	protocol	and	run	alongside	 RiboRuler	 High	 Range	 RNA	 ladder	 (Thermo	 Fisher)	 on	 a	 3%	 denaturing	polyacrylamide	gel.	The	gel	was	stained	using	SYBR	Gold	(Thermo	Fisher)	and	visualized	on	a	ChemiDoc	XRS+	(Bio-Rad)	to	check	for	template	length	and	purity.		
PURExpress	assays		 The	 cell-free	 assays	 showing	 temperature-sensitive	 expression	 from	 both	 DNA	templates	 and	pre-transcribed	mRNA	were	performed	 in	 the	PURExpress	ΔRibosome	Kit	(New	England	Biolabs).	To	each	transcription-translation	reaction	were	added	4	µL	of	kit	Solution	A,	1.2	uL	Factor	Mix,	1.8	uL	E.	coli	ribosomes	(New	England	Biolabs),	0.75	µL	E.	coli	RNA	polymerase	holoenzyme	(New	England	Biolabs),	0.4	uL	SUPERase	In	RNase	Inhibitor	(Thermo	Fisher),	100	ng	plasmid	template,	and	enough	nuclease-free	water	to	reach	a	total	volume	of	10	µL.	Each	 translation-only	 reaction	contained	4	µL	Solution	A,	1.2	uL	Factor	Mix,	1.8	uL	E.	coli	ribosomes,	3.24	pmol	purified	mRNA	template,	and	enough	nuclease-free	water	 to	 reach	 a	 total	 volume	 of	 10	 µL.	 Reactions	 were	 pipetted	 into	 a	 clear-bottomed,	black	384-well	plate	(Griner)	loaded	onto	a	Biotek	Synergy	H1	plate	reader	pre-warmed	to	either	 30	 °C	 or	 42	 °C	 where	 fluorescence	 (485	 nm	 excitation,	 520	 nm	 emission)	 was	
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monitored	 for	 3	 hours	with	measurements	 being	 taken	 every	 5	minutes.	Measurements	were	corrected	for	background	fluorescence	by	subtracting	the	average	reading	for	three	empty	wells.		
In	vitro	SHAPE-Seq	in	buffer	
In	 vitro	 SHAPE-Seq	 was	 carried	 out	 largely	 following	 the	 in	 vitro	 SHAPE-Seq	protocol	 from	Watters	et	al.	(2015a)	performed	on	10	pmol	of	purified	mRNA	folded	and	probed	 at	 either	 30	 °C	 or	 42	 °C.	 After	modification,	 the	 RNAs	were	 ethanol	 precipitated	with	 the	addition	of	90	µL	nuclease-free	water,	10	µL	3	M	sodium	acetate	 (pH	5.5),	1	µL	glycogen,	and	300	µL	ice-cold	100%	ethanol,	followed	by	freezing	for	30	minutes	at	-80	°C	and	centrifugation	at	4	°C	and	15,000	rpm	for	30	minutes.	All	liquid	was	aspirated,	and	the	pellets	were	washed	with	200	µL	70%	ethanol	before	further	centrifugation	for	2	minutes,	removal	of	the	wash	liquid,	and	re-suspension	in	10	µL	of	nuclease-free	water.	From	there,	the	 remainder	 of	 experimental	 the	 protocol—from	 reverse	 transcription	 through	 raw	reactivity	 calculation	 followed	 the	 published	 method	 from	 Watters	 et	 al.	 (2015a).	Reactivities	were	normalized	as	above.		
In	vitro	SHAPE-Seq	in	PURExpress		 For	 experiments	 probing	 the	 structure	 of	 the	 agsA	 WT	 and	 control	 mRNAs	 in	PURExpress	 without	 ribosomes,	 with	 active	 translation,	 or	 with	 stalled	 translation	initiation	complexes,	3.24	picomoles	of	purified	mRNA	were	probed	at	either	30	°C	or	42	
°C.	The	translation	initiation	complex	reactions	were	assembled	using	the	PURExpress	Δaa	ΔtRNA	kit	(New	England	Biolabs),	with	each	10	µL	reaction	containing	2	µL	kit	Solution	A,	1	
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µL	 3	 mM	 L-methionine	 (Sigma	 Aldrich),	 1	 µL	 kit	 tRNA,	 3	 µL	 kit	 Solution	 B,	 and	 3.24	picomoles	of	mRNA—the	lack	of	amino	acids	other	than	methionine	resulted	in	ribosomal	complex	 stalling	 at	 the	 start	 codon.	 The	 PURExpress	 probing	 experiments	 without	ribosomes	were	carried	out	in	a	similar	fashion	using	the	PURExpress	ΔRibosome	Kit	(New	England	Biolabs),	with	 each	10	µL	 reaction	 containing	4	µL	 kit	 Solution	A,	 1.2	 µL	Factor	Mix,	 and	 3.24	 picomoles	 of	 mRNA;	 the	 PURExpress	 active	 translation	 experiments	contained	1.2	uL	of	E.	coli	ribosomes	in	addition.	Reactions	were	incubated	for	20	minutes	(or	35	minutes	for	active	translation)	at	30	°C	or	42	°C	before	being	split	for	modification—5	µL	of	reaction	were	added	to	0.56	µL	65	mM	1M7	in	DMSO	(positive	channel)	and	to	0.56	µL	 DMSO	 (negative	 channel)	 and	 incubated	 for	 an	 additional	 minute	 before	 being	transferred	to	ice.	From	there,	the	modified	and	unmodified	RNA	were	extracted	using	the	Trizol	Max	Bacterial	RNA	Isolation	Kit	(Thermo	Fisher),	and	the	remainder	of	the	protocol	followed	the	same	method	as	the	in-cell	SHAPE-Seq	samples.		
Statistical	analysis	and	data	presentation		 All	experiments	were	carried	out	with	three	distinct	replicates.	Error	bars	represent	sample	 standard	 deviation,	 and	 significance	 was	 determined	 using	 two-sided	heteroscedastic	 t-tests.	 For	 difference	 plots,	 error	 was	 propagated	 using	 standard	propagation	of	error	techniques.		
RNAStructure	structure	prediction		 Minimum	free	energy	RNA	structures	were	predicted	using	the	fold	command	from	the	 RNAStructure	 command-line	 interface	 (Reuter	 and	 Mathews,	 2010).	 Box-plot	
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normalized	reactivities	were	specified	as	pseudoenergy	constraints	using	RNAStructure’s	“-sh”	option,	and	the	SHAPE	restraint	 intercept	(b)	and	slope	(m)	were	set	at	-0.3	kcal/mol	and	1.1	kcal/mol,	respectively,	based	on	the	optimum	values	for	weighting	ρ	reactivities	as	determined	by	Loughrey	et	al.	 (2014).	Temperature	was	specified	as	either	303.15	K	(30	
°C)	 or	 315.15K	 (42	 °C)	 using	 the	 “-t”	 temperature	 option.	 Structures	 were	 output	 as	connectivity	(ct)	files,	converted	to	dot-bracket	notation	(dbn)	using	the	ct2dot	utility	from	RNAStructure,	 and	 drawn	 using	 the	 VARNA	 graphical	 user	 interface	 (Hofacker,	 2003).	Structures	 represent	 predictions	 for	 agsA	 variant	 5’	 UTRs.	 Structures	 including	 the	 full	mRNA	sequence	constrained	by	SHAPE	data	for	the	5’	UTR	and	SFGFP	leader	sequence	are	presented	 in	 Figures	 D.9	 through	 D.12.	 	 Partition	 function	 generation	 of	 the	 RNA	probability	pairing	matrices	was	performed	using	the	RNAStructure	webserver’s	partition	function,	with	the	same	temperature,	SHAPE	constraints,	and	pseudoenergy	constraints	as	the	minimum	free	energy	structure	prediction.	
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CHAPTER	6	
CONCLUSIONS	AND	PERSPECTIVES	
6.1	 Conclusions	
	 In	this	work	I	have	expanded	our	understanding	of	RNA	regulators	and	added	to	the	toolbox	of	genetic	parts	available	for	synthetic	biologists.	Through	my	attempts	to	engineer	light-responsive	RNAs,	 I	 illuminated	 the	 capability	 of	 SHAPE-Seq	 to	pinpoint	 locations	of	ligand-binding	 in	 RNA	 aptamers,	 and	 on	 the	 way	 to	 creating	 a	 series	 of	 better	 RNA	activators,	 I	 developed	 a	 suite	 of	 generalizable	 strategies	 for	 stabilizing	 small	 RNAs.	 The	STARs	 I	 helped	 optimize	 have	 filled	 a	 gap	 in	 the	 capabilities	 of	 RNA	 genetic	 regulation,	enabling	 the	 construction	 of	 more	 sophisticated	 RNA	 circuitry,	 and	 my	 creation	 of	theophylline-sensitive	 aptaSTARs	 shows	 the	 potential	 to	 extend	 STAR	 function	 even	further.	 Combined	 with	 pre-existing	 RNA	 repressors	 and	 riboswitches,	 these	 regulators	could	 allow	 for	 the	 construction	 all-RNA	networks	 capable	 of	 sensing	 and	 responding	 to	multiple	small-molecule	inputs	and	performing	complex	logical	manipulations.	In	addition,	elucidating	the	mechanism	of	the	naturally	occurring	agsA	thermometer	has	 set	 the	 stage	 for	 the	 design	 of	 future	 synthetic	 thermometers	 and	 demonstrated	 the	promise	of	the	newly	developed	in-cell	SHAPE-Seq	technique.	 In-cell	SHAPE-Seq	revealed	the	 subtle	 differences	 in	 agsA	RNA	 reactivity	 at	 different	 temperatures,	 allowing	 me	 to	probe	 the	 structural	 mechanism	 of	 a	 regulatory	 RNA	 in	 its	 native	 context	 in	 a	 way	 not	previously	 possible.	 In	 vitro	 data	 gave	 somewhat	 different	 results,	 confirming	 the	importance	of	 studying	RNAs	 in	 the	 cellular	 context	and	underlining	 the	utility	of	 in	vivo	probing	for	future	research.		
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6.2	 Perspectives	on	the	future	of	RNA	synthetic	biology		 As	 a	 field,	 synthetic	 biology	 holds	 great	 promise,	 but	 has	 only	 recently	 begun	 to	deliver	on	its	potential—one	of	the	most	exciting	prospects	 is	the	recent	report	of	paper-based	 diagnostics	 capable	 of	 detecting	 RNAs	 associated	with	 Ebola	 (Pardee	 et	 al.,	 2014)	and	Zika	(Pardee	et	al.,	2016).	The	diagnostics	use	paper-mounted	freeze-dried	cell	extract	containing	a	gene	network	that	produces	a	colorimetric	output	in	response	to	the	presence	of	 a	 trigger	 RNA,	 opening	 the	 door	 for	 rapid,	 affordable	 viral	 testing.	 This	 remarkable	advance	relies	on	a	few	key	enabling	technologies:	RNA	toehold	switches,	accurate	nucleic	design,	and	cell-free	transcription-translation	systems.		 The	 toehold	 strategy,	 first	 reported	 in	 DNA	 by	 Zhang	 et	 al.	 (2007),	 relies	 on	 the	exposure	of	a	small	linear	region	of	sequence,	the	“toehold”,	designed	to	seed	an	interaction	with	 an	 invading	 trans-acting	 trigger	 sequence	 that	 causes	 large-scale	 structural	rearrangement.	Recent	work	applied	this	principle	to	RNA,	designing	RNA	toehold	switches	where	the	invading	trigger	RNA	seeded	refolding	in	its	target	mRNA	so	as	to	make	the	RBS	newly	accessible,	thus	activating	gene	expression	(Green	et	al.,	2014)	(See	Figure	1.4).	The	design	scheme	relied	on	the	use	of	NUPACK,	a	computational	package	that	can	design	RNA	sequences	 predicted	 to	 fold	 into	 particular	 structures	 or	 complexes	 (Zadeh	 et	 al.,	 2011),	easily	automating	the	process	of	designing	new	constructs.	Combining	easily	designed	RNA	toehold	 switches	 with	 a	 freeze-dried	 version	 of	 the	 pre-existing	 cell-free	 systems	 for	transcription	and	translation	(overviewed	in	section	1.6)	allowed	for	facile	sample	addition	and	 increased	 portability.	 While	 work	 remains	 to	 be	 done	 in	 lowering	 the	 detection	threshold	 for	 trigger	 RNAs	 and	 establishing	 function	 in	 clinical	 samples,	 paper-based	
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diagnostics	 remain	 an	 exciting	 prospect	 with	 extremely	 relevant	 clinical	 applications	throughout	the	developing	world.		 In	 addition	 to	 providing	 promising	 healthcare	 diagnostics,	 RNA	 synthetic	 biology	has	made	 recent	 strides	 within	 the	 realm	 of	metabolic	 engineering.	 RBS	 engineering	 by	Farasat	 et	 al.	 (2014)	 optimized	 flow	 through	 a	 carotenoid	 biosynthesis	 pathway,	 while	targeted	RNA	 interference	(RNAi)	(Si	et	al.,	2015)	and	sRNAs	(Na	et	al.,	2013)	have	been	used	to	increase	metabolic	flux	through	a	desired	pathway	by	targeting	genes	in	competing	pathway	 for	 down-regulation.	 The	 recently	 engineered	Clustered	Regulatory	 Interspaced	Short	Palindromic	Repeats	 interference	(CRISPRi)	method	(Qi	et	al.,	2013)	allows	similar	potential	for	gene	knockdown.	CRISPRi	relies	on	engineered	small	guide	RNAs	(sgRNAs)	to	direct	 a	 catalytically	 dead	 variant	 of	 the	 Cas9	 enzyme	 to	 a	 complementary	 DNA	 target,	thereby	suppressing	 transcription.	Other	 techniques	extend	 the	potential	of	 specific	Cas9	localization	by	fusing	Cas9	to	transcription	factors	(Farzadfard	et	al.,	2013)	or	fluorescent	proteins	(Chen	et	al.,	2013)	 for	 transcriptional	regulation	and	 imaging.	There	 is	no	doubt	that	 the	 ability	 of	 the	 engineered	 Cas9/sgRNA	 complex	 to	 co-localize	 nearly	 any	 protein	and	nucleic	acid	will	continue	to	open	up	future	prospects	for	synthetic	biology.		 The	continued	progress	of	the	field	will	also	depend	upon	the	development	of	more	sophisticated	modes	of	gene	regulation—timing	circuits	that	generate	metabolic	pathway	enzymes	 just	 as	 their	 substrates	 accumulate,	 decision	 networks	 that	 allow	 microbes	 to	sense	multiple	 cell	 markers	 to	 determine	 the	 delivery	 of	 a	 pharmaceutical	 payload,	 and	perhaps	 most	 importantly,	 robust	 modes	 of	 control	 for	 the	 containment	 of	 the	 genetic	modifications	 that	 will	 enable	 this	 type	 of	 technology.	 Ensuring	 proper	 controls	 will	
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safeguard	 the	 future	 of	 synthetic	 biology	 as	 a	 field	 and	 enable	 scientists	 to	 address	humanity’s	most	pressing	needs	in	sustainability,	medicine,	and	biochemical	production.		
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APPENDIX	A	
SUPPLEMENTARY	INFORMATION	FOR	TOWARD	A	LIGHT-ACTIVATED	RNA	
REGULATOR	(CHAPTER	3)	
A.1	 Supplementary	Figures	
	
Figure	A.1	Absorbance	spectra	of	dihydropyrene	ligand.		Absorbance	spectra	of	the	PEG-attached	BDHP	and	BCDP	isomers	as	(A)	measured	on	our	samples	and	(B)	reported	by	Lee	et	al.	(2007).	*		*Figure	reproduced	here	from	original	publication.	
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Figure	A.2	TX-TL	testing	of	fusion	of	pT181	antisense	and	dihydropyrene	aptamer.		Kinetic	fluorescence	 traces	 were	 measured	 in	 the	 TX-TL	 extract	 system	 for	 various	 antisense	plasmid	 and	 ligand	 combinations,	 all	 paired	 with	 a	 pT181	 sense	 plasmid	 in	 which	 the	regulator	controlled	transcription	of	SFGFP.		With	the	exception	of	the	designed	antisense	paired	 with	 DMSO	 (ligand-less	 solvent	 control),	 all	 the	 traces	 appeared	 consistent	 with	BDHP-triggered	repression	by	the	designed	antisense.					
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Figure	A.3	TX-TL	testing	of	previously	reported	and	newly	designed	artificial	riboswitches.	TX-TL	 confirmation	 of	 function	 of	 artificial	 riboswitches	 using	 modular	 expression	platforms,	previously	reported	by	the	Batey	Lab	(Ceres	et	al.,	2013):	(A)	metE-theophylline	riboswitch,	 (B)	 yitJ-theophylline	 riboswitch,	 and	 (C)	 lysC-theophylline	 riboswitch.	 	 (D)	Functional	testing	of	various	designed	fusions	to	minimal	BDHP	aptamers	using	the	same	riboswitch	expression	platforms.	
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Figure	A.4	Sequencing	alignment	of	billiverdin	aptamers	from	round	10	SELEX	pool.													
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Figure	A.5	Absorbance	spectra	of	dihydropyrene	ligand.		Absorbance	spectra	of	the	PEG-attached	BDHP	and	BCDP	isomers	as	(A)	measured	on	our	samples	and	(B)	reported	by	Lee	et	al.	(2007).	*		*Figure	reproduced	here	from	original	publication.	
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Figure	A.6	Spiropyran	aptamer	SHAPE	reactivities	with	and	without	ligand.		The	SHAPE-	CE	reactivities	with	and	without	spiropyran	are	not	statistically	different,	showing	no		detectable		evidence	of	ligand	binding.				
	
	
without ligand
with ligand (spiropyran)
Re
ac
tiv
ity
0
0.5
1.0
1.5
2.0
2.5
3.0
Sequence
G G G C C A A G G A T T A A C T C C T A T C C G A T T T G A A G C A G T A C C C T A T T C C A C C G A T C
Spiropyran aptamer reactivities with and without spiropyran
	 164	
A.2	 Supplementary	Background:	Systematic	evolution	by	exponential	enrichment	
(SELEX)	Systematic	 evolution	 by	 exponential	 enrichment	 (SELEX)	 (Ellington	 and	 Szostak,	 1990;	Tuerk	and	Gold,	1990)	refers	to	a	valuable	technique	for	generating	RNA	or	DNA	aptamers	specific	 to	 a	particular	 ligand.	A	 randomized	 library	of	 single-stranded	DNA	or	RNAs	are	incubated	 with	 the	 a	 filter	 or	 resin	 functionalized	 with	 the	 ligand	 of	 interest,	 and	 the	sequences	 that	do	not	bind	are	washed	away.	 	Then	 the	binding	aptamers	are	 recovered	(often	 through	heat	elution	or	competitive	binding)	 for	subsequent	amplification	via	PCR	(in	the	case	of	DNA)	or	reverse	transcription,	amplification	and	transcription	(in	the	case	of	RNA).	 	 The	 resulting	 pool	 of	 selected	 aptamers	 is	 subjected	 to	 additional	 rounds	 of	 the	same	protocol,	generally	in	the	range	of	8-20	cycles,	until	the	pool	is	sufficiently	enriched	in	sequences	with	high	affinity	for	the	target	ligand.		The	pool	is	then	sequenced	to	determine	the	particular	aptamer	sequences	that	bind	the	chosen	target.	
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Figure	 A.7	 Systematic	 evolution	 by	 exponential	 enrichment	 (SELEX).	 A	 random	 pool	 of	RNAs	are	transcribed,	selected	for	binding	to	the	target	ligand,	and	reverse	transcribed.		A	selectively	 enriched	 RNA	 pool	 is	 then	 re-generated	 through	 PCR	 amplification	 and	transcription	to	undergo	the	selection	cycle	anew.	 	Successive	cycles	of	SELEX	result	 in	a	pool	of	aptamers	with	strong	preference	for	the	target	ligand,	which	can	then	be	sequenced	and	analyzed.	
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APPENDIX	B	
	
SUPPLEMENTARY	INFORMATION	FOR	IMPROVING	FOLD	ACTIVATION	OF	SMALL	
TRANSCRIPTION	ACTIVATING	RNAS	(STARS)	WITH	RATIONAL	RNA	ENGINEERING	
STRATEGIES	(CHAPTER	3)	
	
	
B.1		 Supplementary	Tables	
	
Table	B.1	Plasmids	used	in	this	study.			Color	code:	yellow-promoter,	light	blue-terminator,	dark	blue-5’	stability	hairpin,	red-sRNA	scaffold,	magenta-BamHI-BglII	scar,	light	grey-strong	RBS,	dark	grey-resistance	marker,	purple-origin	of	replication,	bright	green-SFGFP,	green-repC	fragment	(pT181-based	systems)		
Plasmid	
Number	
Name/	
Reference	
Plasmid	
backbone/	
architecture	
Key	sequence	 Figures	
JBL001	 Control	(empty)	sense	 TrrnB	–	CmR	–	p15A	origin		 GAAGCTTGGGCCCGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCCGTCGACCATCATCATCATCATCATTGAGTTTAAACGGTCTCCAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACTAATTATCTAGACTGCAGTTGATCGGGCACGTAAGAGGTTCCAACTTTCACCATAATGAAATAAGATCACTACCGGGCGTATTTTTTGAGTTATCGAGATTTTCAGGAGCTAAGGAAGCTAAAATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTTCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGT
All	(control)	
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Plasmid	
Number	
Name/	
Reference	
Plasmid	
backbone/	
architecture	
Key	sequence	 Figures	
TCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAATTTGATATCGAGCTCGCTTGGACTCCTGTTGATAGATCCAGTAATGACCTCAGAACTCCATCTGGATTTGTTCAGAACGCTCGGTTGCCGCCGGGCGTTTTTTATTGGTGAGAATCCAAGCCTCCGATCAACGTCTCATTTTCGCCAAAAGTTGGCCCAGGGCTTCCCGGTATCAACAGGGACACCAGGATTTATTTATTCTGCGAAGTGATCTTCCGTCACAGGTATTTATTCGGCGCAAAGTGCGTCGGGTGATGCTGCCAACTTACTGATTTAGTGTATGATGGTGTTTTTGAGGTGCTCCAGTGGCTTCTGTTTCTATCAGCTGTCCCTCCTGTTCAGCTACTGACGGGGTGGTGCGTAACGGCAAAAGCACCGCCGGACATCAGCGCTAGCGGAGTGTATACTGGCTTACTATGTTGGCACTGATGAGGGTGTCAGTGAAGTGCTTCATGTGGCAGGAGAAAAAAGGCTGCACCGGTGCGTCAGCAGAATATGTGATACAGGATATATTCCGCTTCCTCGCTCACTGACTCGCTACGCTCGGTCGTTCGACTGCGGCGAGCGGAAATGGCTTACGAACGGGGCGGAGATTTCCTGGAAGATGCCAGGAAGATACTTAACAGGGAAGTGAGAGGGCCGCGGCAAAGCCGTTTTTCCATAGGCTCCGCCCCCCTGACAAGCATCACGAAATCTGACGCTCAAATCAGTGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGCGGCTCCCTCGTGCGCTCTCCTGTTCCTGCCTTTCGGTTTACCGGTGTCATTCCGCTGTTATGGCC
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Plasmid	
Number	
Name/	
Reference	
Plasmid	
backbone/	
architecture	
Key	sequence	 Figures	
GCGTTTGTCTCATTCCACGCCTGACACTCAGTTCCGGGTAGGCAGTTCGCTCCAAGCTGGACTGTATGCACGAACCCCCCGTTCAGTCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGAAAGACATGCAAAAGCACCACTGGCAGCAGCCACTGGTAATTGATTTAGAGGAGTTAGTCTTGAAGTCATGCGCCGGTTAAGGCTAAACTGAAAGGACAAGTTTTGGTGACTGCGCTCCTCCAAGCCAGTTACCTCGGTTCAAAGAGTTGGTAGCTCAGAGAACCTTCGAAAAACCGCCCTGCAAGGCGGTTTTTTCGTTTTCAGAGCAAGAGATTACGCGCAGACCAAAACGATCTCAAGAAGATCATCTTATTAATCAGATAAAATATTTCTAGATTTCAGTGCAATTTATCTCTTCAAATGTAGCACCTGAAGTCAGCCCCATACGATATAAGTTGTAATTCTCATGTTTGACAGCTTATCATCGATAAGCTTCCGATGGCGCGCCGAGAGGCTTTACACTTTATGCTTCCGGCTGAATTCTAAAGATCCTAACTCGAGTAATGA	Sense	Plasmid	Scaffold	 Empty	sense	plasmid	with	reporter	gene	
SFGFP	–	TrrnB	–	CmR	–	p15A	origin	*All	plasmids	based	on	the	sense	plasmid	scaffold	backbone	have	their	key	sequence	inserted	directly	upstream	of	SFGFP	(bright	green)	without	cloning	scars.		
ATGAGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCCGTGGAGAGGGTGAAGGTGATGCTACAAACGGAAAACTCACCCTTAAATTTATTTGCACTACTGGAAAACTACCTGTTCCGTGGCCAACACTTGTCACTACTCTGACCTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCACATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGGGACCTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAGTTAAAGGGTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAAACTCGAGTACAACTTTAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAATGGAATCAAAGCTAACTTCAAAATTCGCCACAACGTTGAAGATGGTTCCGTTCAACTAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCGACACAATCTGTCCTTTC
None	(for	plasmid	mapping	only)	
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Plasmid	
Number	
Name/	
Reference	
Plasmid	
backbone/	
architecture	
Key	sequence	 Figures	
GAAAGATCCCAACGAAAAGCGTGACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGGATGAGCTCTACAAATAAGGATCTGAAGCTTGGGCCCGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCCGTCGACCATCATCATCATCATCATTGAGTTTAAACGGTCTCCAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACTGGATCCTTACTCGAGTCTAGACTGCAGTTGATCGGGCACGTAAGAGGTTCCAACTTTCACCATAATGAAATAAGATCACTACCGGGCGTATTTTTTGAGTTATCGAGATTTTCAGGAGCTAAGGAAGCTAAAATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTTCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGA
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Plasmid	
Number	
Name/	
Reference	
Plasmid	
backbone/	
architecture	
Key	sequence	 Figures	
ATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAATTTGATATCGAGCTCGCTTGGACTCCTGTTGATAGATCCAGTAATGACCTCAGAACTCCATCTGGATTTGTTCAGAACGCTCGGTTGCCGCCGGGCGTTTTTTATTGGTGAGAATCCAAGCCTCCGATCAACGTCTCATTTTCGCCAAAAGTTGGCCCAGGGCTTCCCGGTATCAACAGGGACACCAGGATTTATTTATTCTGCGAAGTGATCTTCCGTCACAGGTATTTATTCGGCGCAAAGTGCGTCGGGTGATGCTGCCAACTTACTGATTTAGTGTATGATGGTGTTTTTGAGGTGCTCCAGTGGCTTCTGTTTCTATCAGCTGTCCCTCCTGTTCAGCTACTGACGGGGTGGTGCGTAACGGCAAAAGCACCGCCGGACATCAGCGCTAGCGGAGTGTATACTGGCTTACTATGTTGGCACTGATGAGGGTGTCAGTGAAGTGCTTCATGTGGCAGGAGAAAAAAGGCTGCACCGGTGCGTCAGCAGAATATGTGATACAGGATATATTCCGCTTCCTCGCTCACTGACTCGCTACGCTCGGTCGTTCGACTGCGGCGAGCGGAAATGGCTTACGAACGGGGCGGAGATTTCCTGGAAGATGCCAGGAAGATACTTAACAGGGAAGTGAGAGGGCCGCGGCAAAGCCGTTTTTCCATAGGCTCCGCCCCCCTGACAAGCATCACGAAATCTGACGCTCAAATCAGTGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGCGGCTCCCTCGTGCGCTCTCCTGTTCCTGCCTTTCGGTTTACCGGTGTCATTCCGCTGTTATGGCCGCGTTTGTCTCATTCCACGCCTGACACTCAGTTCCGGGTAGGCAGTTCGCTCCAAGCTGGACTGTATGCACGAACCCCCCGTTCAGTCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGAAAGACATGCAAAAGCACCACTGGCAGCAGCCACTGGTAATTGATTTAGAGGAGTTAGTCTTGAAGTCATGCGCCGGTTAAGGCTAAACTGAAAGGACAAGTTTTGGTGACTGCGCTCCTCCAAGCCAGTTACCTCGGTTCAAAGAGTTGGTAGCTCAGAGAACCTTCGAAAAACCGCCCTGCAAGGCGGTTTTTTCGTTTTCAGAGCAAGAGATTACGCG
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Plasmid	
Number	
Name/	
Reference	
Plasmid	
backbone/	
architecture	
Key	sequence	 Figures	
CAGACCAAAACGATCTCAAGAAGATCATCTTATTAATCAGATAAAATATTTCTAGATTTCAGTGCAATTTATCTCTTCAAATGTAGCACCTGAAGTCAGCCCCATACGATATAAGTTGTAATTCTCATGTTTGACAGCTTATCATCGATAAGCTTCCGATGGCGCGCCGAGAGGCTTTACACTTTATGCTTCCGGCTGAATTCTAAAGATCC	JBL002	 Control	(empty)	antisense	 J23119	SpeI	–	TrrnB	–	ColE1	origin	–	AmpR		*All	plasmids	based	on	the	JBL002	backbone	have	their	key	sequence	inserted	in	place	of	J23119	SpeI	and	TrrnB.			
TTGACAGCTAGCTCAGTCCTAGGTATAATACTAGTGGATCTGAAGCTTGGGCCCGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCCGTCGACCATCATCATCATCATCATTGAGTTTAAACGGTCTCCAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACTGGATCCTTACTCGAGTCTAGACTGCAGGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCACAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAG
All	(subtracted	growth	control	and	no	antisense	condition)	
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Plasmid	
Number	
Name/	
Reference	
Plasmid	
backbone/	
architecture	
Key	sequence	 Figures	
CGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGA
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Plasmid	
Number	
Name/	
Reference	
Plasmid	
backbone/	
architecture	
Key	sequence	 Figures	
CACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCAGAATTTCAGATAAAAAAAATCCTTAGCTTTCGCTAAGGATGATTTCTGGAATTCTAAAGATCT	JBL2184	 WT	pbuE	sense	(Chappell	et	al.,	2015)	
Sense	plasmid	backbone		 ttgacagctagctcagtcctaggtataatactagtGTGTCTACCAGGAACCGTAAAATCCTGATTACAAAATTTGTTTATGACATTTTTTGTAATCAGGATTTTTTTTggatctaggaggaaggatct	
3.1B,	3.2B,	3.3B-E,	3.4A,	B.2	
JBL2191	 WT	pbuE	antisense	(Chappell	et	al.,	2015)	
JBL002	 ttgacagctagctcagtcctaggtataatactagtATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.1B,	3.2B,	3.3B-E,	B.2,	B.3	JBL1737	 pbuE	sense	with	J23100	promoter	
Sense	plasmid	backbone	 ttgacggctagctcagtcctaggtacagtgctagcGTGTCTACCAGGAACCGTAAAATCCTGATTACAAAATTTGTTTATGACATTTTTTGTAATCAGGATTTTTTTTggatctaggaggaaggatct	
3.2B,	3.4A	
JBL1738	 pbuE	sense	with	J23102	promoter	
Sense	plasmid	backbone	 ttgacagctagctcagtcctaggtactgtgctagcGTGTCTACCAGGAACCGTAAAATCCTGATTACAAAATTTGTTTATGACATTTTTTGTAATCAGGATTTTTTTTggatctaggaggaaggatct	
3.2B,	3.4A	
JBL1739	 pbuE	sense	with	J23119	promoter	
Sense	plasmid	backbone	 ttgacagctagctcagtcctaggtataatgctagcGTGTCTACCAGGAACCGTAAAATCCTGATTACAAAATTTGTTTATGACATTTTTTGTAATCAGGATTTTTTTTggatctaggaggaaggatct	
3.2B,	3.4A	
JBL1740	 pbuE	sense	with	J23150	promoter	
Sense	plasmid	backbone	 tttacggctagctcagtcctaggtattatgctagcGTGTCTACCAGGAACCGTAAAATCCTGATTACAAAATTTGTTTATGACATTTTTTGTAATCAGGATTTTTTTTggatctaggaggaaggatct	
3.2B,	3.4A	
JBL1741	 pbuE	sense	with	J23151	promoter	
Sense	plasmid	backbone	 ttgatggctagctcagtcctaggtacaatgctagcGTGTCTACCAGGAACCGTAAAATCCTGATTACAAAATTTGTTTATGACATTTTTTGTAATCAGGATTTTTTTTggatctaggaggaaggatct	
3.2B,	3.4A,	3.5,	B.7	
JBL3087	 pbuE	 JBL002	 ttgacggctagctcagtcctaggtacagtgctagc B.2	
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Name/	
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Plasmid	
backbone/	
architecture	
Key	sequence	 Figures	
antisense	with	J23100	promoter	
ATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	JBL3088	 pbuE	antisense	with	J23102	promoter	
JBL002	 ttgacagctagctcagtcctaggtactgtgctagcATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
B.2	
JBL3089	 pbuE	antisense	with	J23119	promoter	
JBL002	 ttgacagctagctcagtcctaggtataatgctagcATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
B.2	
JBL3090	 pbuE	antisense	with	J23150	promoter	
JBL002	 tttacggctagctcagtcctaggtattatgctagcATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
B.2	
JBL3091	 pbuE	antisense	with	J23151	promoter	
JBL002	 ttgatggctagctcagtcctaggtacaatgctagcATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
B.2	
JBL1765	 pbuE	antisense	with	5’	pHP14	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgactctcgagtgagattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3B,	B.3	
JBL1766	 pbuE	antisense	with	5’	pHP16	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagtctctgcagagattcgatgatattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3B,	B.3	
JBL1767	 pbuE	antisense	with	5’	pHP17	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagactgcagttcaatagagatattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3B	
JBL1775	 pbuE	antisense	with	3’	MicF	sRNA	scaffold	
JBL002	 ttgacagctagctcagtcctaggtataatactagtATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctCGTCATTCATTTCTGAATGTCTGTTTACCCCTATTTCAACCGGATGCCTCGCATTC
3.3C,	E	
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backbone/	
architecture	
Key	sequence	 Figures	
GGTTTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	JBL1777	 pbuE	antisense	with	3’	Dsra1.3	sRNA	scaffold	
JBL002	 ttgacagctagctcagtcctaggtataatactagtATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctGAATTTTTTAAGTGCccCcgGCTTcgGCggGcTTCATCCCGgCCCCCTCAGGGcCGGGATTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3C,	E	
JBL1778	 pbuE	antisense	with	3’	Spot42	sRNA	scaffold	
JBL002	 ttgacagctagctcagtcctaggtataatactagtATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctGATTTGGCTGAATATTTTAGCCGCCCCAGTCAGTAATGACTGGGGCGTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3C-E,	B3	
JBL1668		 pbuE	antisense	with	3’	MicF	sRNA	scaffold	and	5’	pHP14	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgactctcgagtgagattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctCGTCATTCATTTCTGAATGTCTGTTTACCCCTATTTCAACCGGATGCCTCGCATTCGGTTTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3E	
JBL1681	 pbuE	antisense	with	3’	MicF	sRNA	scaffold	and	5’	pHP16	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagtctctgcagagattcgatgatattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctCGTCATTCATTTCTGAATGTCTGTTTACCCCTATTTCAACCGGATGCCTCGCATTCGGTTTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3E	
JBL1684	 pbuE	antisense	with	3’	MicF	sRNA	scaffold	and	5’	pHP17	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagactgcagttcaatagagatattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctCGTCATTCATTTCTGAATGTCTGTTTACCCCTATTTCAACCGGATGCCTCGCATTCGGTTTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3E	
JBL1725	 pbuE	antisense	with	3’	Dsra1.3	sRNA	scaffold	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgactctcgagtgagattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctGAATTTTTTAAGTGCccCcgGCTTcgGCggGcTTCATCCCGgCCCCCTCAGGGcC
3.3E	
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and	5’	pHP14	hairpin	 GGGATTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	JBL1726	 pbuE	antisense	with	3’	Dsra1.3	sRNA	scaffold	and	5’	pHP16	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagtctctgcagagattcgatgatattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctGAATTTTTTAAGTGCccCcgGCTTcgGCggGcTTCATCCCGgCCCCCTCAGGGcCGGGATTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3E	
JBL1792	 pbuE	antisense	with	3’	Dsra1.3	sRNA	scaffold	and	5’	pHP17	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagactgcagttcaatagagatattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctGAATTTTTTAAGTGCccCcgGCTTcgGCggGcTTCATCCCGgCCCCCTCAGGGcCGGGATTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3E	
JBL1793	 pbuE	antisense	with	3’	Spot42	sRNA	scaffold	and	5’	pHP14	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgactctcgagtgagattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctGATTTGGCTGAATATTTTAGCCGCCCCAGTCAGTAATGACTGGGGCGTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3E	
JBL1794	 pbuE	antisense	with	3’	Spot42	sRNA	scaffold	and	5’	pHP16	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagtctctgcagagattcgatgatattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACggatctGATTTGGCTGAATATTTTAGCCGCCCCAGTCAGTAATGACTGGGGCGTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.3E,	3.4A,	3.5,	B.7	
JBL1795	 pbuE	antisense	with	3’	Spot42	sRNA	scaffold	and	5’	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagactgcagttcaatagagatattgttgacggtaccgtattttATAAACAAATTTTGTAATCAGGATTTTACGGTTCCTGGTAGACACAgatctGATTTGGCTGAATATTTTAGCCGCCCCAGTCAGTAATGACTGGGGCGTTTTTTcaaaGCCCGCCg
3.3E	
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pHP17	hairpin	 aaaGGCGGGCtttttttt	JBL2111	 WT	prgX	sense	(Chappell	et	al.,	2015)	
Sense	plasmid	backbone		 ttgacagctagctcagtcctaggtataatactagtAATGTTGAGCAGCGGGGAATGTATACAGTTCATGTATATGTTCCCCGCTTTTTTTTggatctaggaggaaggatct	
3.4B,	B.6	
JBL2117	 WT	prgX	antisense	(Chappell	et	al.,	2015)	
JBL002	 ttgacagctagctcagtcctaggtataatactagtTGAACTGTATACATTCCCCGCTGCTCAACATTggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.4B,	B.6	
JBL3010	 prgX	antisense	with	5’	pHP14	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgactctcgagtgagattgttgacggtaccgtattttTGAACTGTATACATTCCCCGCTGCTCAACATTggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.4B,	3.4C,	3.5,	B.7	
JBL3011	 prgX	antisense	with	5’	pHP16	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagtctctgcagagattcgatgatattgttgacggtaccgtattttTGAACTGTATACATTCCCCGCTGCTCAACATTggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.4B	
JBL3012	 prgX	antisense	with	5’	pHP17	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagactgcagttcaatagagatattgttgacggtaccgtattttTGAACTGTATACATTCCCCGCTGCTCAACATTggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.4B	
JBL3022	 prgX	antisense	with	3’	Spot42	sRNA	scaffold	
JBL002	 ttgacagctagctcagtcctaggtataatactagtTGAACTGTATACATTCCCCGCTGCTCAACATTggatctGATTTGGCTGAATATTTTAGCCGCCCCAGTCAGTAATGACTGGGGCGTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
B.6	
JBL3026	 prgX	antisense	with	3’	Spot42	sRNA	scaffold	and	5’	pHP14	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgactctcgagtgagattgttgacggtaccgtattttTGAACTGTATACATTCCCCGCTGCTCAACATTggatctGATTTGGCTGAATATTTTAGCCGCCCCAGTCAGTAATGACTGGGGCGTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
B.6	
JBL3027	 prgX	antisense	with	3’	Spot42	sRNA	scaffold	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagtctctgcagagattcgatgatattgttgacggtaccgtattttTGAACTGTATACATTCCCCGCTGCTCAACATTggatctGATTTGGCTGAATATTTTAGCCGCCCCAGTCAGTAATGACTGGGGCGTTTT
B.6	
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and	5’	pHP16	hairpin	 TTcaaaGCCCGCCgaaaGGCGGGCtttttttt	JBL3028	 prgX	antisense	with	3’	Spot42	sRNA	scaffold	and	5’	pHP17	hairpin	
JBL002	 ttgacagctagctcagtcctaggtataatactagtacgtcgacttatctcgagactgcagttcaatagagatattgttgacggtaccgtattttTGAACTGTATACATTCCCCGCTGCTCAACATTggatctGATTTGGCTGAATATTTTAGCCGCCCCAGTCAGTAATGACTGGGGCGTTTTTTcaaaGCCCGCCgaaaGGCGGGCtttttttt	
B.6	
JBL3038	 prgX	sense	with	J23100	promoter	
Sense	plasmid	backbone	 ttgacggctagctcagtcctaggtacagtgctagcAATGTTGAGCAGCGGGGAATGTATACAGTTCATGTATATGTTCCCCGCTTTTTTTTggatctaggaggaaggatct	
3.4C	
JBL3039	 prgX	sense	with	J23102	promoter	
Sense	plasmid	backbone	 ttgacagctagctcagtcctaggtactgtgctagcAATGTTGAGCAGCGGGGAATGTATACAGTTCATGTATATGTTCCCCGCTTTTTTTTggatctaggaggaaggatct	
3.4C	
JBL3040	 prgX	sense	with	J23119	promoter	
Sense	plasmid	backbone	 ttgacagctagctcagtcctaggtataatgctagcAATGTTGAGCAGCGGGGAATGTATACAGTTCATGTATATGTTCCCCGCTTTTTTTTggatctaggaggaaggatct	
3.4C	
JBL3041	 prgX	sense	with	J23150	promoter	
Sense	plasmid	backbone	 tttacggctagctcagtcctaggtattatgctagcAATGTTGAGCAGCGGGGAATGTATACAGTTCATGTATATGTTCCCCGCTTTTTTTTggatctaggaggaaggatct	
3.4C	
JBL3042	 prgX	sense	with	J23151	promoter	
Sense	plasmid	backbone	 ttgatggctagctcagtcctaggtacaatgctagcAATGTTGAGCAGCGGGGAATGTATACAGTTCATGTATATGTTCCCCGCTTTTTTTTggatctaggaggaaggatct	
3.4C,	3.5,	B.7	
JBL007	 pT181.H1	attenuator	sense	(Lucks	et	al.,	2011)	
Sense	plasmid	backbone	 ttgacagctagctcagtcctaggtataatactagtAACAAAATAAAAAGGAGTCGCTCTGTCCCTCGCCAAAGTTGCAGAACGACATCATTCAAAGAAAAAAACACTGAGTTGTTTTTATAATCTTGTATATTTAGATATTAAACGATATTTAAATATACATAAAGATATATATTTGGGTGAGcgattccttaaacgaaattgagattaaggagtcgCtCttttttatgtataaaaacaatcatgcaaatcattcaaatcatttggaaaatcacgatttagacaatttttctaaaaccggctactctaatagccggttgtaaggatctaggaggaaggatct	
3.5,	B.7	
JBL008	 pT181.H1	attenuator	 JBL002	 ttgacagctagctcagtcctaggtataatactagtATACAAGATTATAAAAACAACTCAGTG 3.5,	B.7	
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antisense	(Lucks	et	al.,	2011)	 TTTTTTTCTTTGAATGATGTCGTTCTGCAACTTTGGCGAGGGACAGAGCGACTCCTTTTTATTTggatctgaagcttgggcccgaacaaaaactcatctcagaagaggatctgaatagcgccgtcgaccatcatcatcatcatcattgagtttaaacggtctccagcttggctgttttggcggatgagagaagattttcagcctgatacagattaaatcagaacgcagaagcggtctgataaaacagaatttgcctggcggcagtagcgcggtggtcccacctgaccccatgccgaactcagaagtgaaacgccgtagcgccgatggtagtgtggggtctccccatgcgagagtagggaactgccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaact	JBL1020	 Fusion	6	attenuator	sense	(Takahashi	and	Lucks,	2013)	
Sense	plasmid	backbone	 ttgacagctagctcagtcctaggtataatactagtAACAAAATAAAAAGGAGTCGCTCACTTACGAACTTGGCGGAACGACGTGAACGACATCATTCAAAGAAAAAAACACTGAGTTGTTTTTATAATCTTGTATATTTAGATATTAAACGATATTTAAATATACATAAAGATATATATTTGGGTGAGcgattccttaaacgaaattgagattaaggagtcgCtCttttttatgtataaaaacaatcatgcaaatcattcaaatcatttggaaaatcacgatttagacaatttttctaaaaccggctactctaatagccggttgtaaggatctaggaggaaggatct	
3.5,	B.7	
JBL1029	 Fusion	6	attenuator	antisense	(Takahashi	and	Lucks,	2013)	
JBL002	 ttgacagctagctcagtcctaggtataatactagtATACAAGATTATAAAAACAACTCAGTGTTTTTTTCTTTGAATGATGTCGTTCACGTCGTTCCGCCAAGTTCGTAAGTGAGCGACTCCTTTTTATTTggatctgaagcttgggcccgaacaaaaactcatctcagaagaggatctgaatagcgccgtcgaccatcatcatcatcatcattgagtttaaacggtctccagcttggctgttttggcggatgagagaagattttcagcctgatacagattaaatcagaacgcagaagcggtctgataaaacagaatttgcctggcggcagtagcgcggtggtcccacctgaccccatgccgaactcagaagtgaaacgccgtagcgccgatggtagtgtggggtctccccatgcgagagtagggaactgccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaact	
3.5,	B.7	
JBL1126	 Fusion	4	attenuator	sense	(Takahashi	and	Lucks,	
Sense	plasmid	backbone	 ttgacagctagctcagtcctaggtataatactagtAACAAAATAAAAAGGAGTCGCTCACGTTCAACTTTGGCGAGTACGATGTGAACGACATCATTCAAAGAAAAAAACACTGAGTTGTTTTTATAATCTTGTATATTT
3.5,	B.7	
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2013)	 AGATATTAAACGATATTTAAATATACATAAAGATATATATTTGGGTGAGcgattccttaaacgaaattgagattaaggagtcgCtCttttttatgtataaaaacaatcatgcaaatcattcaaatcatttggaaaatcacgatttagacaatttttctaaaaccggctactctaatagccggttgtaaggatctaggaggaaggatct	JBL1033	 Fusion	4	attenuator	antisense	(Takahashi	and	Lucks,	2013)	
JBL002	 ttgacagctagctcagtcctaggtataatactagtATACAAGATTATAAAAACAACTCAGTGTTTTTTTCTTTGAATGATGTCGTTCACATCGTACTCGCCAAAGTTGAACGTGAGCGACTCCTTTTTATTTggatctgaagcttgggcccgaacaaaaactcatctcagaagaggatctgaatagcgccgtcgaccatcatcatcatcatcattgagtttaaacggtctccagcttggctgttttggcggatgagagaagattttcagcctgatacagattaaatcagaacgcagaagcggtctgataaaacagaatttgcctggcggcagtagcgcggtggtcccacctgaccccatgccgaactcagaagtgaaacgccgtagcgccgatggtagtgtggggtctccccatgcgagagtagggaactgccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaact	
3.5,	B.7	
JBL2844	 ribA	activator	antisense	(Chappell	et	al.,	2015)	
Sense	plasmid	backbone	 ttgacagctagctcagtcctaggtataatactagtTATTGTTGAACGCGTACCATTGATTGTAGGTCGTAACCCCAATAACGAACATTATCTCGATACCAAAGCCGAGAAAATGGGCCATTTGCTGAACAAATAACCCTCTTGCATTGTGTAATTCATTTGCTTGCCGGAAGCAAAATAACCGGCAAGCAAATAGTTGTTACTggatctaggaggaaggatct	
3.5,	B.7	
JBL3403	 ribA	activator	sense	(Chappell	et	al.,	2015)	
JBL002	 ttgacagctagctcagtcctaggtataatactagtTTATTTTGCTTCCGGCAAGCAAATGAATTACACAATGCAAGAGGGTTATTTGTTCAGCAAATGGggatctcaaaGCCCGCCgaaaGGCGGGCtttttttt	
3.5,	B.7	
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Table	 B.2	 	 Promoters	 used	 in	 this	 study.	 	 Promoters	 are	 referred	 to	 by	 their	 iGEM	BioBrick	numbers,	with	the	exception	of	BBa_J23119	SpeI,	which	is	a	variant	of	BBa_J23119	that	has	been	mutated	to	include	a	SpeI	restriction	site	directly	before	the	+1	transcription	start	 site.	 	 Sequence	 differences	 from	 the	 consensus	 promoter	 (BBa_J23119)	 have	 been	highlighted	 in	 red.	 	 Relative	 strength	 data	 (corrected	 for	 different	 standards)	 is	 derived	from	 Kelly	 et	 al.	 (2009)	 as	 marked	 by	 *	 or	 the	 Anderson	 catalog	(http://parts.igem.org/Promoters/Catalog/Anderson)	as	marked	by	**.	
	
	
	
Promoter	
name	
Sequence	 Strength	BBa_J23119	 ttgacagctagctcagtcctaggtataatgctagc		 n/a	(>1)	BBa_J23119	SpeI	 ttgacagctagctcagtcctaggtataatactagt	 n/a	(>1)	BBa_J23100	 ttgacggctagctcagtcctaggtacagtgctagc		 1	**	BBa_J23102	 ttgacagctagctcagtcctaggtactgtgctagc		 0.86	**	BBa_J23151	 ttgatggctagctcagtcctaggtacaatgctagc		 0.266-0.424*	BBa_J23150	 tttacggctagctcagtcctaggtattatgctagc		 0.098-0.161*															
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Table	B.3	 	Statistical	significance	of	comparisons	 in	Figure	2b.	P-value	significance	of	comparisons	 in	 fold	 activation	 between	 different	 pbuE	 sense	 promoter	 variants.	 The	 *	indicates	significance	by	a	two-sided	T-test	(p<0.05).			 	 Sense	Promoter	Variant	
J23119	
SpeI	 J23119	 J23100	 J23102	 J23151	 J23150	
Se
ns
e	
Pr
om
ot
er
	V
ar
ia
nt
	
J23119	
SpeI	 -	 -	 -	 -	 -	 -	
J23119	 0.8988	 -	 -	 -	 -	 -	
J23100	 0.0008*	 0.0010*	 -	 -	 -	 -	
J23102	 0.0013*	 0.0014*	 0.9990	 -	 -	 -	
J23151	 0.0002*	 0.0002*	 0.0494*	 0.0526	 -	 -	
J23150	 7.54E-5*	 5.50E-5*	 0.0039*	 0.0041*	 0.1814	 -			
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B.2		 Supplementary	Figures	
	
	
	
													
STAR Antisense  t500 ColE1 AmpR
  Target Sense TrnB p15A CmRSFGFP
A
B
D
 TrnB ColE1 AmpR
TrnB p15A CmR
F
C
Repressor Antisense  TrnB ColE1 AmpR
  Attenuator TrnB p15A CmRSFGFP
E
	
	
Figure	B.1	Maps	of	DNA	plasmids	used	 in	 this	study.	(A)	STAR	antisense	plasmid,	(B)	Target	 sense	 plasmid,	 (C)	 Repressor	 antisense	 plasmid,	 (D)	 Repressor	 target	 sense	(attenuator)	plasmid,	(E)	STAR/repressor	antisense	control	plasmid,	and	(F)	Target	sense	control	 plasmid.	 t500	 and	 TrrnB	 are	 transcriptional	 terminators.	 ColE1	 and	 p15A	 are	origins	 of	 replication.	 AmpR	 and	 CmR	 are	 ampicillin/carbenicillin	 and	 chloramphenicol	resistance	cassettes,	respectively.				
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Figure	 B.2	 Fold	 activation	 characterization	 for	 the	 pbuE	 STAR	 expressed	 from	
decreasing	 strength	 promoters.	Normalized	 fluorescence	 divided	 by	 optical	 density	 at	600	nm	(Fluorescence/OD)	is	plotted	for	the	OFF	case	(no-STAR	control	plasmid)	and	the	ON	case	(STAR	present)	on	the	lower	plot.	Promoter	strength	refers	to	the	promoter	used	to	express	the	STAR	RNA	(see	Table	B.2).	All	sense	targets	were	expressed	from	the	J23119	SpeI	promoter.	Fold	activation	(Fluorescence/OD	ON	divided	by	Fluorescence/OD	OFF)	is	plotted	above	as	a	series	of	gray	bars.	Error	bars	represent	sample	standard	deviation	over	3	 independent	 replicates	with	 3	 colonies	 each	 (n=9).	 The	 *	 symbol	 indicates	 statistically	significant	 (p<0.05)	 differences	 in	 fold	 activation	 between	 the	wild-type	 STAR	 promoter	configuration	(J23119	SpeI)	and	a	specific	STAR	promoter	as	determined	by	a	two-sided	T-test	(p<0.05).	It	is	clear	from	this	data	that	weakening	the	STAR	promoter	decreases	FL	ON	and	therefore	fold	activation	as	we	would	expect.	
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Figure	B.3	pbuE	STAR	degradation	as	a	function	of	time	as	determined	by	RT-qPCR.	E.	
coli	were	transformed	with	plasmids	encoding	several	pbuE	STAR	variants	 from	Figure	3	containing	RNA	stability	hairpins	 (pHP14,	pHP16),	 an	 sRNA	scaffold	 (Spot42),	or	neither	(WT).	After	overnight	culture,	cells	were	subcultured	for	5	hours,	at	which	point	rifampicin	was	added	to	the	media	to	stop	transcription	(see	B.3	Supplementary	Methods).	Total	RNA	was	 extracted	 from	 cells	 after	 0,	 5	 and	 20	minutes	 after	 rifampicin	 addition.	 Each	 pbuE	STAR	 variant	 and	 16s	 rRNA	was	 quantified	 for	 each	 time	 point	 using	 RT-qPCR	 primers	specific	 to	 these	RNAs.	These	values	were	then	used	to	calculate	a	normalized	amount	of	pbuE	variant	RNA	relative	to	16s	rRNA	following	Bernstein(Bernstein	et	al.,	2004).	Relative	pbuE	variant	RNA	amounts	at	the	5	and	20	minute	time	points	were	then	divided	by	the	0	minute	 time	 point	 value	 to	 calculate	 the	 fraction	 of	 STAR	 RNA	 remaining	 according	 to	Pfaffle	(2001),	see	Supplementary	Methods	(B.3).	Each	RT-qPCR	reaction	was	performed	in	triplicate	on	three	biological	replicates		(9	reactions	total	for	each	variant).	Bars	represent	averages	over	these	replicates,	and	error	bars	represent	the	standard	deviation	following	propagation	of	errors	over	these	replicates	through	the	normalization	calculations	(Pfaffl,	2001).	It	is	clear	from	this	analysis	that	the	pHP14	and	pHP16	hairpins	stabilize	the	pbuE	RNA	to	a	greater	extent	than	the	Spot42	scaffold.		
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Figure	B.4	Minimum	free-energy	(MFE)	RNA	fold(s)	for	pbuE	WT	STAR	and	stability	
hairpin	fusions	to	the	pbuE	STAR	as	predicted	by	RNAStructure	(Reuter	and	Mathews,	2010).	(A)	and	(B)	two	MFE	folds	for	pbuE	WT.	Single	MFE	folds	for	(C)	pbuE	pHP14,	(D)	pbuE	pHP16,	and	(E)	pbuE	pHP17.					
	 188	
A
U
A
A
A
C
A
A
A
U
U U U
G
U
A
A
U
C
A
G
G
A
U
U
U
U
A C
G
G
U
U
C
C
U
G
G
U
A
G
A
C
A
C
G
G
A
U C
U
G
A
A U
U
U
U
U
UAA
G
U
GC
C
C C C G
G C U U
C
G
G
C
G
G
G
C
U
U
C
A
U
C
C
C
G
G
C
C
C
C
C
U C
A
G
G
G
C
C
G
G
G
A
U U
U
U
U
U
U
CA
A
A
G
C
C
C
G
C
C
G
AAAG
GCGGG
C
U
U
U
U
UUUU
1
10
20
30
40
50
60
70
80
90
100
110
120
130
140
147 pbuE Dsra1.3
pbuE MicF
sRNA scaffold
pbuE STAR
t500 terminator
cloning scar
A
U
A
A
A
C
A
A
A
U
U
U
U
G
U
A
A
U
C
A
G
G
AUU
U
U
A
C G G
U
U
C
C
U
G
G
U A
G
A
C
A
C G
G
A
U
C
U
C
G
U
C
A
U
U
C
A
U
U
U
C
U
G
A
A
U
G
U
C
U
G
U
U
U
A
C
C C C
U
A
U
U
U
C
A A
C C
G G
A U
G C
C
U
CGCAUUCGGUU
U
U
U
U
U
U
C
A
A
A
G
C
C
C
G
C
C
G
A
A
A
G
G
C
G
G
G
C
U
U
UUUUU
U
1
10
20
30
40 50
60
70
80
90
100
110
120
130
140
147
A
UAAAC
A
A
A
U
U
U
U
G
U
A
A
U
C
A
G
G
A
U
UU
U
ACG
G
UU
C
C
U
G
G
UA
G
A
C
A
C
G
G
A
U C
U C
G U
C
A
U
U
C
A
U
U
U C
U
G
A
A
U
G U C U
G U
U U
A
C
C
C
C
U
A
U U
U C A
A
C
C
G
G
A
U
G
C
C U
C
G
C
A
U
U
C
G
G
U
U
U
U
U
U
U
U
C
A
A
A
G
C
C
C
G
C
C
G
A
AA
G
G
C
G
G
G
C
U
U
U
U
UUUU
1
10
20
30
40
50
60
70
80
90
100
110
120
130
140147
pbuE MicF
A
U
A
A
A
C
A
A
A
U U
U U G
U
A
A
U
C A
G
G
A
U
U U
U
A C
G
G
U U
C
C
U
G
G
U A
G
A
C
A
CG
G
A
UC
U
G
A
A
U
UU
U
U
U
A
A
GU
G
C
C
C C
C G
G C U
U
C
G
G
C
G
G
G
C
U
U
C
A
U
C
C
C
G
G
C
C
C
C
C
U C
A
G
G
G
C
C
G
G
G
A
U U
U
U
U
U
U
CAA
A
G
C
C
C
G
C
C
G
AAAG
GCGGG
C
U
U
U
U
UUUU
1
10
20
30
40
50
60
70
80
90
100
110
120
130
140
147
pbuE Dsra1.3
A B
DC
		
	
Figure	 B.5	 Low-energy	 RNA	 folds	 for	 sRNA	 scaffold	 fusions	 to	 the	 pbuE	 STAR	 as	
predicted	 by	 RNAStructure	 (Reuter	 and	 Mathews,	 2010).	 (A)	 and	 (B)	 pbuE	 Dsra1.3	fusion,	(C)	and	(D)	pbuE	MicF	fusion.	Structures	for	pbuE	WT	are	presented	in	Figure	B.4.																
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Figure	 B.6	 Testing	 the	 addition	 of	 Spot42	 to	 prgX	 antisense	 variants	 with	 and	
without	stability	hairpins.	Normalized	fluorescence	divided	by	optical	density	at	600	nm	(Fluorescence/OD)	is	plotted	on	the	lower	axes,	with	the	dark	gray	bars	representing	the	OFF	level	(no-STAR	control	plasmid)	and	the	green	bars	representing	the	ON	level	(STAR	present).	Fold	activation	(Fluorescence/OD	ON	divided	by	Fluorescence/OD	OFF)	is	plotted	on	the	upper	axis	as	a	series	of	gray	bars.	Error	bars	represent	sample	standard	deviation	over	3	independent	replicates	with	3	colonies	each	(n=9).									
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Figure	B.7	In	vivo	fluorescence	data	from	Figure	3.5	orthogonality	testing.	Data	shows	testing	 of	 optimized	 pbuE	 and	 prgX	 STAR	 variants	 against	 the	 previously	 reported	 ribA	STAR	 (Chappell	 et	 al.,	 2015)	 and	 pT181.H1	 (Lucks	 et	 al.,	 2011),	 Fusion	 4,	 and	 Fusion	 6	repressors	 (Takahashi	 and	 Lucks,	 2013).	 Data	 is	 plotted	 as	 normalized	 fluorescence	divided	 by	 optical	 density	 at	 600	 nm	 (Fluorescence/OD).	 Error	 bars	 represent	 sample	standard	deviation	over	3	independent	replicates	with	3	colonies	each	(n=9).												
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B.3	 Supplementary	Methods	
	
Total	 RNA	 extraction	 for	 quantitative	 PCR.	 For	 all	 extraction	of	 total	RNA	 for	 reverse	transcription	 quantitative	 PCR	 (RT-qPCR)	 experiments	 E.	 coli	 strain	 TG1	 was	 used.	Plasmids	were	transformed	and	subsequent	colonies	grown	overnight	as	described	for	 in	
vivo	 bulk	 fluorescence	measurements.	 For	 each	 of	 three	 biological	 replicates,	 34	 μL	 of	 a	single	 overnight	 culture	 were	 added	 to	 wells	 containing	 1666	 μL	 (1:50	 dilution)	 of	supplemented	M9	minimal	media	containing	the	selective	antibiotics	and	grown	for	5	h	at	the	same	conditions	as	the	overnight	cultures.	At	this	point,	8.5	µL	of	50	mg/mL	rifampicin	in	 DMSO	 were	 added	 to	 halt	 transcription.	 From	 this	 transcription-halted	 sample	 were	taken	three	time-point	samples	of	500	µL	at	0,	5,	and	20	minutes	after	rifampicin	addition.		The	 time-point	 samples	 were	 pelleted	 by	 centrifugation	 at	 13,000	 rpm	 for	 1	 min.	 The	supernatant	 was	 removed	 and	 the	 remaining	 pellet	 resuspended	 in	 750	 µL	 of	 Trizol	reagent	 (Life	 Technologies),	 homogenized	 by	 repetitive	 pipetting,	 incubated	 at	 room	temperature	for	5	min,	and	then	stored	on	ice	for	approximately	2	hours.	Then	150	µL	of	chloroform	 (Sigma	 Aldrich)	 were	 added,	 and	 the	 samples	 were	 mixed	 for	 15	 sec	 and	incubated	 at	 room	 temperature	 for	 3	 min.	 Following	 incubation,	 the	 samples	 were	centrifuged	for	15	min	at	15,000	rpm	at	4	°C	and	200	µL	of	the	top	aqueous	layer	removed.	One	µL	of	glycogen	(20	mg/mL)	(Life	Technologies)	and	375	µL	of	chilled	isopropanol	were	added	 to	 the	 aqueous	 phase,	which	was	 incubated	 at	 room	 temperature	 for	 10	min	 and	centrifuged	for	15	min	at	15,000	rpm	at	4	°C.	Following	centrifugation	the	isopropanol	was	carefully	removed	from	the	total	RNA/glycogen	pellets,	which	were	then	washed	in	600	µL	of	chilled	70	%	ethanol	(EtOH)	and	centrifuged	for	2	min	at	15,000	rpm	at	4	°C.	The	EtOH	was	removed	and	the	tubes	centrifuged	for	another	2	min	at	15,000	rpm	at	4	°C	followed	by	additional	ethanol	removal	and	drying	at	room	temperature	for	10	minutes	to	evaporate	any	additional	 ethanol.	Pellets	were	 resuspended	 in	20	µL	of	RNase	 free	double-distilled	water	(ddH20).	
	
DNase	 treatment	of	 total	RNA	for	qPCR.	Purified	total	RNA	samples	were	quantified	by	the	Qubit	Fluorometer	(Life	Technologies)	and	were	diluted	to	a	concentration	of	10	ng/µL	
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in	a	total	of	10	µL	RNase	free	ddH20	and	digested	by	Turbo	DNase	(Life	Technologies)	for	1	h	 at	 37	 °C	 using	 3	 µL	 Turbo	 DNAse	 per	 50	 µL	 reaction	 with	 buffer	 concentration	 as	specified	 by	 manufacturer.	 After	 digestion	 150	 µL	 of	 RNase	 free	 ddH20	 and	 200	 µL	phenol/chloroform	 (Acros	Organics)	were	 added,	 and	 the	 samples	were	 vortexed	 for	 10	sec	 and	 incubated	 for	 3	 min	 at	 room	 temperature	 before	 centrifugation	 for	 10	 min	 at	15,000	 rpm	 at	 4	 °C.	 After	 centrifugation,	 190	µL	 of	 the	 top	 aqueous	 layer	was	 carefully	removed,	190	µL	of	chloroform	added,	and	the	samples	were	vortexed	for	10	sec,	incubated	for	 3	min	 at	 room	 temperature	 and	 centrifuged	 for	 10	min	 at	 15,000	 rpm	 at	 4	 °C.	 After	centrifugation,	 170	 µL	 of	 the	 top	 aqueous	 layer	 was	 carefully	 removed,	 170	 µL	 of	chloroform	added,	and	the	samples	were	vortexed	for	10	sec,	incubated	for	3	min	at	room	temperature	and	centrifuged	for	10	min	at	15,000	rpm	at	4	°C.	After	centrifugation,	120	µL	of	 the	 top	 aqueous	 layer	was	 carefully	 removed	 and	 added	 to	 1	µL	 glycogen,	 360	µL	 of	chilled	100	%	EtOH	and	12	µL	of	3	M	sodium	acetate	pH	5.5.	Samples	were	vortexed	for	10	sec	and	stored	at	-80	°C	for	1	h.	Samples	were	then	centrifuged	for	30	min	at	15,000	rpm	at	4	 °C.	 Supernatant	was	 removed	 and	 the	pellets	washed	 in	 600	µL	of	 chilled	70	%	EtOH.	Samples	were	 then	 centrifuged	 for	 2	min	 at	 15,000	 rpm	 at	 4	 °C	 and	 the	 EtOH	 removed.	Samples	were	re-centrifuged	for	2	min	at	15,000	rpm	at	4	°C	and	residual	EtOH	removed,	pellets	air-dried	for	10	min	and	eluted	in	10	µL	RNase	free	ddH2O.		
Normalization	 of	 total	 RNA,	 reverse	 transcription	 and	 qPCR	 measurements.	 Each	sample	was	 quantified	 by	Qubit	 Fluorometer	 and	 the	 sample	 diluted	 to	 1	 ng/µL	 of	 total	RNA	in	10	µL	RNase	free	ddH20.	Then	each	DNase-treated	total	RNA	dilution	was	subjected	to	reverse	transcription	of	the	target	pbuE	STAR	RNA	and	of	16s	rRNA	(for	normalization).	In	 the	 reverse	 transcription	 reaction,	 1	µL	of	 1	ng/µL	 total	RNA,	0.5	µL	of	 2	µM	reverse	transcription	 primer	 (Integrated	 DNA	 Technologies:	 16s	 rRNA	 RT	 primer	 =	TAAGGAGGTGATCCAACCG;	pbuE	STAR	RT	primer	=	AGATCCGTGTCTACCAGGAA),	0.5	µL	of	10	mM	of	dNTPs	(New	England	Biolabs)	and	RNase	free	ddH20	up	to	6.5	µL	were	incubated	for	 5	 min	 at	 65	 °C	 and	 cooled	 on	 ice	 for	 5	 min.	 0.25	 µL	 of	 Superscript	 III	 reverse	transcriptase	 (Life	 technologies),	 0.5	 µL	 of	 100	 mM	 Dithiothreitol	 (DTT),	 2	 µL	 5x	 first-strand	buffer	 (Life	 technologies),	 and	0.5	µL	RNaseOUT	(Life	Technologies)	and	0.25	 	µL	
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RNase	free	H2O	up	to	3.5	µL	were	then	added,	incubated	at	55	°C	for	1	h,	75	°C	for	15	min	and	then	stored	at	-20	°C.	qPCR	was	performed	on	the	reverse	transcription	products	using	5	µL	of	Maxima	SYBR	green	qPCR	master	mix	(Thermo	Scientific),	1	µL	of	cDNA	and	0.5	µL	of	 2	 µM	 pbuE	 qPCR	 primers	 (Integrated	 DNA	 Technologies,	 FWD	 =	ATAAACAAATTTTGTAATCAGGATTTTACGG,	 REV	 =	 AGATCCGTGTCTACCAGGAA)	 or	 16s	qPCR	primers	 (Integrated	DNA	Technologies,	 FWD	=GTCAGCTCGTGTTGTGAAATG,	REV	=	CCCACCTTCCTCCAGTTTATC)	and	RNase	 free	ddH2O	up	 to	10	µL.	Control	 reactions	using	0.1	ng/µL	DNase-treated	total	RNA	to	check	for	background	genomic	DNA	contamination	were	also	assembled,	and	primer	efficiency	was	quantified	by	a	five-point	standard	curve	using	 purified	 PCR	 product	 corresponding	 to	 the	 sequence	 generated	 by	 reverse-transcription.	It	was	shown	that	the	qPCR	primer	sets	had	primer	efficiencies	between	71-108%.	A	ViiA	7	real-time	PCR	machine	(Applied	Biosystems)	was	used	for	data	collection	using	the	following	PCR	program:	50	°C	for	2	min,	95	°C	for	10	min	followed	by	30	cycles	of,	95	 °C	 for	 15	 sec	 and	 53	 °C	 for	 1	 min.	 A	 MicroAmp	 EnduraPlate	 Optical	 384-well	 plate	(Applied	 Biosystems)	 and	 an	 optically	 clear	 seal	 (Applied	 Biosystems)	were	 used	 for	 all	measurements.	Results	were	analyzed	using	 the	ViiA	7	 software	 (Applied	Biosystems)	 to	identify	 CT	 values	 for	 each	 sample,	 which	 were	 then	 further	 analyzed	 according	 to	 the	description	 below.	 All	 cDNA	 samples	 were	 measured	 in	 triplicate,	 and	 non-template	controls	were	run	in	parallel	to	check	for	contamination	and	non-specific	amplification	or	primer	 dimers.	 These	 non-template	 controls	 showed	 insignificant	 amounts	 of	contamination,	 with	 the	 highest	 level	 being	 399	 times	 lower	 than	 the	 corresponding	measured	 sample.	 In	 addition,	qPCR	was	performed	on	 total	RNA	samples	 to	 confirm	no	DNA	plasmid	was	detected	under	conditions	used.	Melting	curve	analysis	was	performed	to	confirm	that	only	a	single	product	was	amplified.		
	
Data	Analysis	
	Calculations	of	 the	relative	abundance	of	pbuE	variant	STAR	RNA	remaining	at	each	time	point	 were	 made	 following	 the	 method	 laid	 out	 by	 Pfaffl	 (2001)	 which	 accounts	 for	differences	in	amplification	efficiency	between	target	and	reference.	 	Specifically,	for	each	time	point	ti,	we	used	this	analysis	to	calculate	a	normalized	pbuE	variant	RNA	abundance,	
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N(i),	 normalized	 to	 the	 abundance	 of	 16s	 rRNA	 at	 that	 time	 point	 following	 Bernstein	(2004):	
N(i) =
E
crefT (i)
ref
E
ctargetT (i)
target 	where	 Etarget	 is	 the	 primer	 efficiency	 for	 the	 pbuE	 RT-qPCR	 reaction,	 Eref	 is	 the	 primer	efficiency	for	the	16s	rRNA	RT-qPCR	reaction,	CTtarget(i)	is	the	CT	count	for	the	pbuE	variant	sample	and	CTref(i)	is	the	CT	count	for	the	16s	rRNA	sample.	Following	Pfaffl	(2001)	we	then	calculated	 the	 fraction	 of	 pbuE	 STAR	 variant	 remaining	 as	 N(i)/N(0)	 to	 obtain	 the	 final	formula:	
N(i)
N(0)
=
E
ctargetT (0) ctargetT (i)
target
E
crefT (0) crefT (i)
ref 	Each	reaction	was	run	in	triplicate,	giving	a	standard	deviation	over	CT	values	which	were	used	 to	 calculate	 an	 error	 in	 N(i)/N(0)	 using	 standard	 propagation	 of	 error	 techniques.	These	errors	were	then	combined	over	the	three	full	biological	replicates	of	the	time	course	experiment.	
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APPENDIX	C	
SUPPLEMENTARY	INFORMATION	FOR	ENGINEERING	
	LIGAND-RESPONSIVE	RNA	ACTIVATORS	
C.1	 Supplementary	Figures	
	
	
Figure	 C.1	 Structure	 of	 the	 theophylline	 aptamer	 complexed	 with	 theophylline	 as	determined	by	NMR	spectroscopy.		Theophylline	binds	nucleotides	within	an	internal	loop	region.	 Reprinted	 by	 permission	 from	 Macmillan	 Publishers	 Ltd:	 [Nature	 structural	biology]	 Zimmermann,	 G.R.,	 Jenison,	 R.D.,	 Wick,	 C.L.,	 Simorre,	 J.P.,	 and	 Pardi,	 A.	 (1997).	Interlocking	structural	motifs	mediate	molecular	discrimination	by	a	theophylline-binding	RNA.	Nat.	Struct.	Biol.	4,	644–649.,	copyright	1997.		
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Figure	 C.2	 Confirmation	 of	 theophylline-sensitive	 activation	 of	 pT181	 aptaSTARs.		Repeated	 in	 vivo	 testing	 of	 computationally	 designed	 pT181	 aptaSTARs	 confirms	theophylline	responsive	activation	in	the	presence	of	high	concentrations	of	theophylline.							
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Figure	C.3	Testing	theophylline-sensitivity	in	vivo	of	computationally	designed	aptaSTARs	with	long	linker	regions.		Theophylline	aptaSTAR	variants	based	on	the	pAD1,	pT181,	and	ribA	systems	and	designed	allowing	for	linker	sequences	up	to	60	nucleotides	were	tested	alongside	 a	 theophylline-sensitive	 repressor	 (Theo	 CTRL),	 a	 non-cognate	 STAR	 (CTRL	STAR),	and	the	original	non-theophylline-sensitive	STARs	(ON).		 				
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Figure	C.4	Structure	of	the	fluoride	aptamer.		The	basic	conserved	structure	includes	two	hairpin	 stems	 (P1	and	P3),	 as	well	 as	 an	 important	pseudoknot	 interaction.	 From	Baker,	J.L.,	 Sudarsan,	 N.,	 Weinberg,	 Z.,	 Roth,	 A.,	 Stockbridge,	 R.B.,	 and	 Breaker,	 R.R.	 (2012).	Widespread	 genetic	 switches	 and	 toxicity	 resistance	 proteins	 for	 fluoride.	 Science.	 335,	233–235.	Reprinted	with	permission	from	AAAS.	
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APPENDIX	D	
SUPPLEMENTARY	INFORMATION	FOR	CHARACTERIZING	A	
	NATURALLY-OCCURRING	RNA	THERMOMETER	(CHAPTER	5)	
D.1	Supplementary	Tables	
Table	D.1	Plasmids	used	in	this	study.		Color	code:	yellow-promoter,	----insertion	sequence,	green-SFGFP	light	blue-terminator,	dark	blue-chloramphenicol	resistance	marker,	and	grey-origin	of	replication	(p15a)		
Plasmid	
number	
Description		 Sequence	n/a	 p15a	backbone	 gaattctaaagatctttgacagctagctcagtcctaggtataatactagt------------------ATGagcaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaattttctgtccgtggagagggtgaaggtgatgctacaaacggaaaactcacccttaaatttatttgcactactggaaaactacctgttccgtggccaacacttgtcactactctgacctatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgccatgcccgaaggttatgtacaggaacgcactatatctttcaaagatgacgggacctacaagacgcgtgctgaagtcaagtttgaaggtgatacccttgttaatcgtatcgagttaaagggtattgattttaaagaagatggaaacattcttggacacaaactcgagtacaactttaactcacacaatgtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacgttgaagatggttccgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtcgacacaatctgtcctttcgaaagatcccaacgaaaagcgtgaccacatggtccttcttgagtttgtaactgctgctgggattacacatggcatggatgagctctacaaataaggatctgaagcttgggcccgaacaaaaactcatctcagaagaggatctgaatagcgccgtcgaccatcatcatcatcatcattgagtttaaacggtctccagcttggctgttttggcggatgagagaagattttcagcctgatacagattaaatcagaacgcagaagcggtctgataaaacagaatttgcctggcggcagtagcgcggtggtcccacctgaccccatgccgaactcagaagtgaaacgccgtagcgccgatggtagtgtggggtctccccatgcgagagtagggaactgccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaactggatccttactcgagtctagactgcagttgatcgggcacgtaagaggttccaactttcaccataatgaaataagatcactaccgggcgtattttttgagttatcgagattttcaggagctaaggaagctaaaatggagaaaaaaatcactggatataccaccgttgatatatcccaatggcatcgtaaagaacattttgaggcatttcagtcagttgctcaatgtacctataaccagaccgttcagctggatattacggcctttttaaagaccgtaaagaaaaataagcacaagttttatccggcctttattcacattcttgcccgcctgatgaatgctcatccggaatttcgtatggcaatgaaagacggtgagctggtgatatgggatagtgttcacccttgttacaccgttttccatgagcaaactgaaacgttttcatcgctctggagtgaataccacgacgatttccggcagtttctacacatatattcgcaagatgtggcgtgttacggtgaaaacctggcctatttccctaaagggtttattgagaatatgtttttcgtctcagccaatccctgggtgagtttcaccagttttgatttaaacgtggccaatatggacaacttcttcgcccccgttttcaccatgggcaaatattatacgcaaggcgacaaggtgctgatgccgctggcgattcaggttcatcatgccgtttgt
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gatggcttccatgtcggcagaatgcttaatgaattacaacagtactgcgatgagtggcagggcggggcgtaatttgatatcgagctcgcttggactcctgttgatagatccagtaatgacctcagaactccatctggatttgttcagaacgctcggttgccgccgggcgttttttattggtgagaatccaagcctccgatcaacgtctcattttcgccaaaagttggcccagggcttcccggtatcaacagggacaccaggatttatttattctgcgaagtgatcttccgtcacaggtatttattcggcgcaaagtgcgtcgggtgatgctgccaacttactgatttagtgtatgatggtgtttttgaggtgctccagtggcttctgtttctatcagctgtccctcctgttcagctactgacggggtggtgcgtaacggcaaaagcaccgccggacatcagcgctagcggagtgtatactggcttactatgttggcactgatgagggtgtcagtgaagtgcttcatgtggcaggagaaaaaaggctgcaccggtgcgtcagcagaatatgtgatacaggatatattccgcttcctcgctcactgactcgctacgctcggtcgttcgactgcggcgagcggaaatggcttacgaacggggcggagatttcctggaagatgccaggaagatacttaacagggaagtgagagggccgcggcaaagccgtttttccataggctccgcccccctgacaagcatcacgaaatctgacgctcaaatcagtggtggcgaaacccgacaggactataaagataccaggcgtttccccctggcggctccctcgtgcgctctcctgttcctgcctttcggtttaccggtgtcattccgctgttatggccgcgtttgtctcattccacgcctgacactcagttccgggtaggcagttcgctccaagctggactgtatgcacgaaccccccgttcagtccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggaaagacatgcaaaagcaccactggcagcagccactggtaattgatttagaggagttagtcttgaagtcatgcgccggttaaggctaaactgaaaggacaagttttggtgactgcgctcctccaagccagttacctcggttcaaagagttggtagctcagagaaccttcgaaaaaccgccctgcaaggcggttttttcgttttcagagcaagagattacgcgcagaccaaaacgatctcaagaagatcatcttattaatcagataaaatatttctagatttcagtgcaatttatctcttcaaatgtagcacctgaagtcagccccatacgatataagttgtaattctcatgtttgacagcttatcatcgataagcttccgatggcgcgccgagaggctttacactttatgcttccggct	JBL	3048	 WT	 agsA	 in	p15a	backbone	 Insertion	sequence:	ggacaagcaatgcttgccttgatgttgaacttttgaatagtgattcaggaggttaatg	JBL	3057	 agsA	G21C	mutant	in	p15a	backbone	
Insertion	sequence:	ggacaagcaatgcttgccttCatgttgaacttttgaatagtgattcaggaggttaatg	
JBL	3070	 agsA	A29C	mutant	in	p15a	backbone	
Insertion	sequence:	ggacaagcaatgcttgccttgatgttgaCcttttgaatagtgattcaggaggttaatg	
JBL	001	 empty	backbone	control	 gaattctaaagatcctaactcgagtaatgagaagcttgggcccgaacaaaaactcatctcagaagaggatctgaatagcgccgtcgaccatcatcatcatcatcattgagtttaaacggtctccagcttggctgttttggcggatgagagaagattttcagcctgatacagattaaatcagaacgcagaagcggtctgataaaacagaatttgcctggcggcagtagcgcggtggtcccacctgaccccatgccgaactcagaagtgaaacgccgtagcgccgatggtagtgtggggtctccccatgcgagagtagggaactgccaggcatcaaataaaacgaaaggctcagtcgaaagactgggcctttcgttttatctgttgtttgtcggtgaactggatccttactcgagtctagactgcagttgatcgggcacgtaagaggttccaactttcaccataatgaaataagatcactaccgggcgtattttttgagttatcgagattttcaggagctaaggaagctaaaatggagaaaaaaatcactggatataccaccgttgatatatcccaatggcatcgtaaagaacattttgaggcatttcagtcagttgctca
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atgtacctataaccagaccgttcagctggatattacggcctttttaaagaccgtaaagaaaaataagcacaagttttatccggcctttattcacattcttgcccgcctgatgaatgctcatccggaatttcgtatggcaatgaaagacggtgagctggtgatatgggatagtgttcacccttgttacaccgttttccatgagcaaactgaaacgttttcatcgctctggagtgaataccacgacgatttccggcagtttctacacatatattcgcaagatgtggcgtgttacggtgaaaacctggcctatttccctaaagggtttattgagaatatgtttttcgtctcagccaatccctgggtgagtttcaccagttttgatttaaacgtggccaatatggacaacttcttcgcccccgttttcaccatgggcaaatattatacgcaaggcgacaaggtgctgatgccgctggcgattcaggttcatcatgccgtttgtgatggcttccatgtcggcagaatgcttaatgaattacaacagtactgcgatgagtggcagggcggggcgtaatttgatatcgagctcgcttggactcctgttgatagatccagtaatgacctcagaactccatctggatttgttcagaacgctcggttgccgccgggcgttttttattggtgagaatccaagcctccgatcaacgtctcattttcgccaaaagttggcccagggcttcccggtatcaacagggacaccaggatttatttattctgcgaagtgatcttccgtcacaggtatttattcggcgcaaagtgcgtcgggtgatgctgccaacttactgatttagtgtatgatggtgtttttgaggtgctccagtggcttctgtttctatcagctgtccctcctgttcagctactgacggggtggtgcgtaacggcaaaagcaccgccggacatcagcgctagcggagtgtatactggcttactatgttggcactgatgagggtgtcagtgaagtgcttcatgtggcaggagaaaaaaggctgcaccggtgcgtcagcagaatatgtgatacaggatatattccgcttcctcgctcactgactcgctacgctcggtcgttcgactgcggcgagcggaaatggcttacgaacggggcggagatttcctggaagatgccaggaagatacttaacagggaagtgagagggccgcggcaaagccgtttttccataggctccgcccccctgacaagcatcacgaaatctgacgctcaaatcagtggtggcgaaacccgacaggactataaagataccaggcgtttccccctggcggctccctcgtgcgctctcctgttcctgcctttcggtttaccggtgtcattccgctgttatggccgcgtttgtctcattccacgcctgacactcagttccgggtaggcagttcgctccaagctggactgtatgcacgaaccccccgttcagtccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggaaagacatgcaaaagcaccactggcagcagccactggtaattgatttagaggagttagtcttgaagtcatgcgccggttaaggctaaactgaaaggacaagttttggtgactgcgctcctccaagccagttacctcggttcaaagagttggtagctcagagaaccttcgaaaaaccgccctgcaaggcggttttttcgttttcagagcaagagattacgcgcagaccaaaacgatctcaagaagatcatcttattaatcagataaaatatttctagatttcagtgcaatttatctcttcaaatgtagcacctgaagtcagccccatacgatataagttgtaattctcatgtttgacagcttatcatcgataagcttccgatggcgcgccgagaggctttacactttatgcttccggct	JBL	2348	 gene	expression	control	plasmid	
gaattctaaagatctttgacagctagctcagtcctaggtataatactagtgggagaaagaagaagagatgcggaagagagaaatataacacaacaatacgtatatttatatcttccgcaaagaagaggagaggaagaatgaaatatacgagacaacaaacaataaacagcATGagcaaaggagaagaacttttcactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaattttctgtccgtggagagggtgaaggtgatgctacaaacggaaaactcacccttaaatttatttgcactactggaaaactacctgttccgtggccaacacttgtcactactctgacctatggtgttcaatgcttttcccgttatccggatcacatgaaacggcatgactttttcaagagtgccatgcccgaaggttatgtacaggaacgcactatatctttcaaagatgacgggacctacaagacgcgtgctgaagtcaagtttgaaggtgatacccttgttaatcgtatcgagttaaagggtattgattttaaagaagatggaaacattcttggacacaaactcgagtacaactttaactcacacaatgtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaaaattcgccacaacgttgaagatggttccgttcaactagcagaccattatcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtcgacacaatctgtcctttcgaaagatcccaac
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gaaaagcgtgaccacatggtccttcttgagtttgtaactgctgctgggattacacatggcatggatgagctctacaaataaggatcttagcataaccccttggggcctctaaacgggtcttgaggggttttttgtggatccttactcgagtctagactgcagttgatcgggcacgtaagaggttccaactttcaccataatgaaataagatcactaccgggcgtattttttgagttatcgagattttcaggagctaaggaagctaaaatggagaaaaaaatcactggatataccaccgttgatatatcccaatggcatcgtaaagaacattttgaggcatttcagtcagttgctcaatgtacctataaccagaccgttcagctggatattacggcctttttaaagaccgtaaagaaaaataagcacaagttttatccggcctttattcacattcttgcccgcctgatgaatgctcatccggaatttcgtatggcaatgaaagacggtgagctggtgatatgggatagtgttcacccttgttacaccgttttccatgagcaaactgaaacgttttcatcgctctggagtgaataccacgacgatttccggcagtttctacacatatattcgcaagatgtggcgtgttacggtgaaaacctggcctatttccctaaagggtttattgagaatatgtttttcgtctcagccaatccctgggtgagtttcaccagttttgatttaaacgtggccaatatggacaacttcttcgcccccgttttcaccatgggcaaatattatacgcaaggcgacaaggtgctgatgccgctggcgattcaggttcatcatgccgtttgtgatggcttccatgtcggcagaatgcttaatgaattacaacagtactgcgatgagtggcagggcggggcgtaatttgatatcgagctcgcttggactcctgttgatagatccagtaatgacctcagaactccatctggatttgttcagaacgctcggttgccgccgggcgttttttattggtgagaatccaagcctccgatcaacgtctcattttcgccaaaagttggcccagggcttcccggtatcaacagggacaccaggatttatttattctgcgaagtgatcttccgtcacaggtatttattcggcgcaaagtgcgtcgggtgatgctgccaacttactgatttagtgtatgatggtgtttttgaggtgctccagtggcttctgtttctatcagctgtccctcctgttcagctactgacggggtggtgcgtaacggcaaaagcaccgccggacatcagcgctagcggagtgtatactggcttactatgttggcactgatgagggtgtcagtgaagtgcttcatgtggcaggagaaaaaaggctgcaccggtgcgtcagcagaatatgtgatacaggatatattccgcttcctcgctcactgactcgctacgctcggtcgttcgactgcggcgagcggaaatggcttacgaacggggcggagatttcctggaagatgccaggaagatacttaacagggaagtgagagggccgcggcaaagccgtttttccataggctccgcccccctgacaagcatcacgaaatctgacgctcaaatcagtggtggcgaaacccgacaggactataaagataccaggcgtttccccctggcggctccctcgtgcgctctcctgttcctgcctttcggtttaccggtgtcattccgctgttatggccgcgtttgtctcattccacgcctgacactcagttccgggtaggcagttcgctccaagctggactgtatgcacgaaccccccgttcagtccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggaaagacatgcaaaagcaccactggcagcagccactggtaattgatttagaggagttagtcttgaagtcatgcgccggttaaggctaaactgaaaggacaagttttggtgactgcgctcctccaagccagttacctcggttcaaagagttggtagctcagagaaccttcgaaaaaccgccctgcaaggcggttttttcgttttcagagcaagagattacgcgcagaccaaaacgatctcaagaagatcatcttattaatcagataaaatatttctagatttcagtgcaatttatctcttcaaatgtagcacctgaagtcagccccatacgatataagttgtaattctcatgtttgacagcttatcatcgataagcttccgatggcgcgccgagaggctttacactttatgcttccggct		
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D.2	Supplementary	Figures	
	
	
	
	
	
Figure	D.1	Unconstrained	predictions	of	agsA	construct	structure.		Predicted	agsA	variant	structures	at	30	°C	and	42	°C	in	the	absence	of	SHAPE	reactivity	constraints.		Mutations	are	highlighted	in	red.				
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Figure	D.2	agsA	WT	pairing	probability	matrix	at	30	°C	in	vivo.	Pairing	probability	matrix	for	agsA	WT	 5’	 UTR	 as	 predicted	 using	 RNAStructure	 constrained	 by	 in	 vivo	 SHAPE-Seq	probing	data.	 	The	dots	 represent	potential	base	pairs	 that	 form	 in	more	 than	1%	of	 the	structural	ensemble,	and	the	colors	correspond	to	the	pairing	probability.		The	groupings	of	base	pairs	corresponding	to	the	P1	and	P2	helixes	are	labeled.			
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Figure	D.3	agsA	WT	pairing	probability	matrix	at	42	°C	in	vivo.	Pairing	probability	matrix	for	agsA	WT	 5’	 UTR	 as	 predicted	 using	 RNAStructure	 constrained	 by	 in	 vivo	 SHAPE-Seq	probing	data.	 	The	dots	 represent	potential	base	pairs	 that	 form	 in	more	 than	1%	of	 the	structural	ensemble,	and	the	colors	correspond	to	the	pairing	probability.		The	groupings	of	base	pairs	corresponding	to	the	P1	and	P2	helixes	are	labeled.		
P1
P2
1
1
10
10
20
20
30
30
40
40
50
50
61
61
1.000 ≥ Probability > 0.398
0.398 ≥ Probability > 0.158
0.158 ≥ Probability > 0.063
0.063 ≥ Probability > 0.025
0.025 ≥ Probability > 0.010 
	 207	
	
	
Figure	 D.4	 PURExpress	 testing	 of	 agsA	 constructs	 from	 plasmid.	 	 Fluorescence	 traces	demonstrate	successful	thermometer	activation	in	the	context	of	the	PURExpress	cell-free	protein	synthesis	system.				
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Figure	 D.5	 SHAPE-Seq	 characterization	 of	 the	 agsA	 thermometer	 in	 vitro	 in	 buffer.	 (A)	SHAPE-Seq	 normalized	 reactivity	 plots	 for	 agsA	 WT,	 G21C,	 and	 A29C	 variants	 from	triplicate	experiments	 in	vitro	performed	on	mRNAs	equilibrated	at	30	 °C	and	42	 °C.	(B)	Experimentally-derived	RNA	structures	as	predicted	using	the	RNAStructure	program	with	the	reactivity	values	from	(A)	taken	as	pseudoenergy	folding	constraints.		Blue-highlighted	nucleotides	undergo	key	structural	changes	and	correspond	to	the	inset	boxes	in	(A),	while	red	nucleotides	denote	variant	mutations.		
	 209	
	
A
B
G
G
A
C
A
A
G
C
A
A
U
G
C
U
U
G
C
C U U G
A
U
G
U
U
G
A
A
C
U
U
U
U
G
A
A
U
A
G
UG
A
U
U
C
A
G
G
A
GGUU
A
A
U
G
A
U
G
1
10
20
30
40
50
60
G
G
A
C
A
A
G
C
A A
U
G
C
U
U
G
C
C U
U
G
A
U
G
U
U
G
A
A
C
U
U
U
U
G
A
A
U
A
G
UG
A
U
U
C
A
G
G
A
G
G
U
U
A
A
UGA
U
G
1
10
20
30
40
50
60
G
G
A
C
A
A
G
C
A A
U
G
C
U
U
G
C
C
U
U
C
A
U G U U
G
A
A
C
U
U
U
U
G
A
A
U
A
G
U
G
A
U
U
C
A
G
G
A
GG
U
U
A
A
U
G
AUG
1
10
20
30
40
50
60
G
G
A
C
A
A
G
C
A A
U
G
C
U
U
G
C
C U
U
G
A
U
G
U
U
G
A
C
C
U
U
U
U
G
A
A
U
A
G
UG
A
U
U
C
A
G
G
A
G
G
U
U
A
A
UGA
U
G
1
10
20
30
40
50
60
30 °C
30 °C and 42 °C 
42 °C
W
T
G21C
A29C
30 °C and 42 °C 
P1
P2
SD
Start
	 210	
	
Figure	 D.6	The	effect	of	 active	 translation	on	mRNA	reactivity.	AgsA	 construct	 reactivity	comparisons	between	in	vivo	and	in	vitro	in	buffer	at	30	°C	(A)	and	42	°C	(B).		Stars	denote	statistically	significant	reactivity	differences.	
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Figure	D.7	Comparison	between	SHAPE-Seq	reactivities	for	agsA	WT	in	vivo	and	in	vitro	in	PURExpress	with	active	translation.	 	Difference	plot	shows	 in	vitro	with	active	translation	reactivities	minus	 in	vivo	 reactivities,	with	 stars	 corresponding	 to	 statistically	 significant	differences.	
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Figure	D.8	Plasmid	architecture	of	the	agsA	testing	constructs.		The	WT	or	mutant	agsA	5’	UTR	 (purple)	 is	 fused	directly	 after	 the	 J23119	promoter	 (black	 arrow),	 followed	by	 the	fluorescent	reporter	SFGFP	(green)	and	the	TrrnB	intrinsic	terminator	(blue).		The	plasmid	also	 harbors	 the	 chloramphenicol	 resistance	 selection	marker	 (light	 gray)	 and	 the	 p15a	origin	of	replication	(dark	gray).					
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Figure	D.9	Predicted	agsA	WT	construct	structures	for	full	mRNA	sequence	in	vivo.	SHAPE	constraints	 incorporated	 by	 RNAStructure	 covered	 5’	 UTR	 (red	 box)	 and	 SFGFP	 leader	sequence	up	until	the	site	of	reverse	transcription	primer	binding.	
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Figure	 D.10	 Predicted	 agsA	 G21C	 construct	 structures	 for	 full	 mRNA	 sequence	 in	 vivo.	SHAPE	 constraints	 incorporated	 by	 RNAStructure	 covered	 5’	 UTR	 (red	 box)	 and	 SFGFP	leader	sequence	up	until	the	site	of	reverse	transcription	primer	binding.	
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Figure	 D.11	 Predicted	 agsA	 A29C	 construct	 structures	 for	 full	 mRNA	 sequence	 in	 vivo.	SHAPE	 constraints	 incorporated	 by	 RNAStructure	 covered	 5’	 UTR	 (red	 box)	 and	 SFGFP	leader	sequence	up	until	the	site	of	reverse	transcription	primer	binding.	
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Figure	 D.12	 Predicted	agsA	WT	 construct	 structures	 for	 full	mRNA	 sequence	 in	vitro	 in	PURExpress	without	ribosomes.	SHAPE	constraints	incorporated	by	RNAStructure	covered	5’	 UTR	 (red	 box)	 and	 SFGFP	 leader	 sequence	 up	 until	 the	 site	 of	 reverse	 transcription	primer	binding.	
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